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Malgré les grands efforts réalisés pour développer des traitements efficaces, le 
cancer reste une des causes importantes de la mortalité dans le monde. En plus des 
stratégies de lutte classiques contre cette pathologie comme la chirurgie, la 
radiothérapie et la chimiothérapie, l'immunothérapie anti-tumorale est devenue une 
approche prometteuse. En effet, la spécificité du système immunitaire permettrait de 
cibler les cellules cancéreuses sans endommager les cellules normales. Dans ce 
domaine, la vaccination thérapeutique contre des antigènes associés aux tumeurs est 
devenue très attractive. La réponse immune stimulée par cette voie est plus spécifique 
et plus efficace pour empêcher la croissance de la tumeur ou pour éliminer les 
tumeurs résiduelles.  
A L’immunologie du cancer et l’immunothérapie anti-tumorale  
A-I Cancer immunoediting – de l’immunosurveillance à l’échappement tumoral  
Le débat concernant le rôle du système immunitaire au cours de la progression 
tumorale a duré plus d'un siècle. C’est récemment qu’on a expliqué de façon 
appropriée comment le système immunitaire interagit avec les cellules tumorales 
d’une part et comment les tumeurs échappent à l'éradication immunitaire d’autre part. 
L'hypothèse selon laquelle le système immunitaire réprime la croissance des 
carcinomes a été évoquée pour la première fois par Paul Ehrlish en 1909. Burnet et 
Thomas ont proposé la théorie de l'immunosurveillance du cancer en 1957. Selon ce 
concept, les lymphocytes pourraient, en permanence, reconnaître et éliminer les 
cellules cancéreuses (14). Néanmoins, cette théorie a été quelque peu battue en brèche 
par la suite. En effet, Shankaran a démontré en 2001 que le système immunitaire est 
capable de favoriser la formation des tumeurs primaires parce que les cellules 
tumorales ont une immunogénicité réduite. Ces cellules sont capables d'échapper à la 
reconnaissance et la destruction par le système immunitaire. Par conséquent, il a été 
reconnu que le système immunitaire possède une double fonction au cours de la 
progression tumorale. D'une part, le système immunitaire empêche la formation et le 
développement des tumeurs,  c’est la fonction de «immunosurveillance» du cancer. 
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D'autre part, le système immunitaire pourrait modifier la nature intrinsèque de la 
tumeur. Donc, l'immunogénicité de cette dernière change et elle échappe aux actions 
du système immunitaire. Ceci correspond à la fonction appelée «tumor sculpting». En 
se basant sur ces découvertes, une nouvelle théorie décrivant de façon appropriée la 
fonction du système immunitaire lors du développement tumoral a été établie. Elle 
correspond à la théorie de «immunoediting» (18, 22, 23). Selon cette théorie, 
l'interaction entre le système immunitaire et les tumeurs est un processus dynamique 
comprenant trois phases : l'élimination, l'équilibre et l'évasion (Fig. 1) (18). 
A-II le système immunitaire et le cancer 
Il existe plusieurs voies par lesquelles le système immunitaire peut inhiber la 
croissance des tumeurs. Il est bien connu que la voie la plus efficace, in vivo, consiste 
à activer les cellules de la réponse immunitaire. En particulier, les cellules T CD8 + 
sécrétant l'interféron-γ (IFN-γ) et les cellules T-helper 1 (Th1) CD4+ (60). 
Au cours de la formation d’un cancer, la transformation en cellules malignes et la 
perturbation du microenvironnement qui les entoure peut générer des signaux néfastes 
pour les cellules tumorales. Ces signaux induisent fréquemment une inflammation. 
D'une part, cette inflammation active des cellules innées effectrices, telles que les 
NKTs, NKs et les lymphocytes T γδ. Ces cellules peuvent avoir un impact direct sur la 
croissance tumorale. D’autre part, l’inflammation est à l’origine d’une stimulation des 
cellules présentatrices d'antigènes (CPAs), en particulier les cellules dendritiques 
(CDs). Ces dernières peuvent engloutir les antigènes dérivés des tumeurs et activer 
une réponse immunitaire adaptative médiée par les lymphocytes T et B. Cette réponse 
est spécifique des antigènes des tumeurs. 
En absence de la présentation des antigènes, les lymphocytes T ne les 
reconnaissent pas (sauf pour les super-antigènes). Une présentation efficace des 
antigènes par les CPA est cruciale pour le développement d’une réponse spécifique 
médiée par les lymphocytes T. Il existe différents types des CPAs, telles que les 
lymphocytes B, les CDs et les macrophages. Les CDs sont les CPAs les plus 
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puissantes car les molécules du complexe majeur d'histocompatibilité (CMH) et des 
complexes CMH-peptide sont en concentration 10 à 100 fois plus élevées sur les CDs 
que sur les autres CPAs (62). Les lymphocytes T ne reconnaissent que des peptides 
antigéniques situés dans le sillon de liaison peptidique des molécules de MHC. Il 
existe deux classes majeures des molécules du CMH (CMH I et CMH II). Ces 
molécules assurent la présentation des antigènes via différentes voies afin d’activer les 
cellules T CD8 + et les cellules T CD4 + respectivement (63). Outre les voies 
classiques, les CDs peuvent également présenter les antigènes extracellulaires aux 
cellules T CD8+. Ces antigènes proviennent des particules phagocytées ou des 
complexes immunitaires renfermant les molécules du CMH I. Ce phénomène est 
appelé « cross-presentation » (64). Ce processus est nécessaire pour la défense 
immunitaire contre la plupart des tumeurs et les virus qui n'infectent pas les cellules 
présentatrices d'antigènes. Il est également nécessaire pour l'induction de l'immunité 
cytotoxique par la vaccination anti-tumorale (65-67). 
Afin d’expliquer le mécanisme d'activation des lymphocytes T, un modèle appelé 
le modèle des deux signaux « Two-signals » a été établi (Fig. 2) (68). Le premier 
signal est médié par la réorganisation entre les récepteurs des cellules T (TCR) 
exprimés par les lymphocytes T et les CDs avec les peptides présentés dans le 
contexte des molécules du CMH. Le deuxième signal est généré par l'interaction entre 
des membres de la famille B7 (CD80/86) exprimés par les CDs et la molécule CD28 
exprimée par les lymphocytes T; le CD40 exprimé par les CDs et le CD40L exprimé 
par les lymphocytes. Le second signal est aussi appelé co-stimulateur. Il est nécessaire 
pour la division et la différenciation des lymphocytes T en cellules effectrices. Les 
deux signaux sont indispensables pour une réponse immunitaire efficace. Récemment, 
l'existence d’un troisième signal a également été démontrée. La sécrétion ou non de 
facteurs par les CDs, en particulier l'IL-12, est impliquée dans la différenciation 
terminale des cellules T CD4 + en cellules Th1 ou Th2 respectivement (73). 
Le développement et la différenciation de la réponse médiée par les cellules T 
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contre des agents pathogènes infectieux a été considérée comme un processus 
dynamique se composant généralement de quatre phases (89-90) : 1) la phase 
d'expansion : au cours de laquelle les cellules T naïves sont induites et se différencient 
en lymphocytes T effecteurs (CD4 + Th ou CD8 + CTL); 2) la phase de contraction : 
au cours de laquelle la majorité des cellules T effecteurs meurent, laissant 5% -10%  
des cellules de la phase d’expansion comme des cellules mémoires de long terme, 3) 
la phase mémoire : au cours de laquelle le nombre des cellules T mémoires se stabilise. 
Ces cellules sont maintenues pendant des longues périodes de temps, tout au long de 
la vie de la souris et pendant de nombreuses années chez l’homme; 4) Une réponse de 
rappel : rapide et médiée par des cellules T mémoires après une réexposition à l'agent 
pathogène.  
Les cellules T activées de façon adaptative peuvent être divisées en deux 
catégories : les cellules T CD8 + cytotoxiques et les cellules T CD4 + helper. Les 
lymphocytes T CD8+ cytotoxiques (CTLs) sont impliqués dans l’immunité contre les 
virus et la surveillance de la transformation néoplasique. Il a été démontré que les 
CTL détruisent leurs cellules cibles par au moins deux différents mécanismes. L'un est 
médié par la voie perforine / granzyme (81) et l'autre est médié par la voie Fas (82). 
Ces deux mécanismes peuvent spécifiquement et directement induire l'apoptose de 
cellules cibles. 
De nombreuses études ont montré que les CD4 + Th jouent un rôle central dans 
l'amplification et la régulation de la réponse immunitaire. D’une part, à travers leur 
capacité à aider les lymphocytes B à produire des anticorps, d’induire les 
macrophages à développer une forte activité microbicide, de recruter des neutrophiles, 
des éosinophiles et des basophiles au niveau du site d'infection et d'inflammation. 
D’autre part, les les CD4 + Th produisent des cytokines et des chemokines pour 
orchestrer toute la panoplie des réponses immunitaires. Selon leur profil de cytokines, 
les facteurs de transcription caractéristiques et les fonctions, les cellules Th peuvent 
être principalement classées en quatre types : Th1, Th2, Th17 et T régulatrices (Treg). 
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(83-87) 
Les cellules B sont des lymphocytes jouant un rôle important dans la réponse 
immunitaire humorale. Les principales fonctions de ces cellules sont la production des 
anticorps dirigés contre les antigènes. Elles agissent également comme des cellules 
présentatrices d'antigène et éventuellement, elles peuvent se développer en cellules B 
mémoires après activation par l'interaction avec l’antigène. (93) 
Outre la fonction de protection contre les tumeurs qui est assurée par le système 
immunitaire, les interactions entre les cellules tumorales et les cellules immunitaires 
dans le microenvironnement de la tumeur peuvent également créer un réseau 
immunosuppressif. Cette immunosuppression protège les tumeurs de l'attaque 
immunitaire et favorise leur croissance et leur progression. Plusieurs mécanismes ont 
été décrits, par lesquels les tumeurs peuvent supprimer l’action du système 
immunitaire. Parmi ces mécanismes : 1) le profil anormal de cytokines; 2) l’altération 
des molécules co-stimulantes et/ou co-inhibiteurs; 3) des anomalies des 
sous-ensembles des cellules présentatrices d'antigène; 4) la modification du ratio entre 
les Tregs et les lymphocytes T effecteurs, etc. (94-96) 
A-III l’Immunothérapie anti-tumorale (97-103) 
L’immunothérapie anti-tumorale est une classe de traitement contre le cancer. 
Elle a pour le but de moduler le système immunitaire de l'hôte, et/ou utiliser les 
composantes de ce système afin d'induire ou d'augmenter la réponse anti-tumorale. 
L'apparition de ce concept peut remonter à plus de 100 ans. Au cours du siècle dernier, 
des progrès impressionnants ont été réalisés dans le domaine de la biologie et de 
l'immunologie du cancer. La plupart des aspects de la réactivité immunitaire ont été 
clairement énoncés. Les résultats obtenus ont démontré que les attaques 
anti-tumorales déclenchées par le système immunitaire sont plus spécifiques et 
caractérisées par une moindre nocivité pour l'hôte. Par conséquent, l'immunothérapie 
est devenue un traitement de plus en plus prometteur contre le cancer. Pour atteindre 
cet objectif, différentes stratégies ont été testées. Elles peuvent généralement être 
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classées en deux catégories, chacune d'elles consiste en des approches différentes : 
l’immunothérapie anti-tumorale active et l’immunothérapie anti-tumorale passive (ou 
appelée adoptive). 
L’immunothérapie anti-tumorale active comprend les approches qui consistent à 
stimuler la réponse immunitaire intrinsèque de l'hôte contre les tumeurs. Elle peut être 
subdivisée en immunothérapie active non-spécifique et l’immunothérapie active 
spécifique. Le rôle de l'immunothérapie anti-tumorale active non-spécifique est 
l'activation d'une réponse immunitaire générale par l'administration de cytokines ou 
de médiateurs qui pourraient induire la libération des cytokines. L'immunothérapie 
anti-tumorale active et spécifique consiste à activer les réponses immunitaires 
médiées par des cellules et/ou des anticorps ciblant les antigènes spécifiques exprimés 
par les cellules tumorales.  
L’immunothérapie anti-tumorale passive correspond à des approches apportant 
une immunité active extrinsèque plutôt que l'activation de l'immunité intrinsèque. 
Dans ce cas, la réponse immunitaire peut être médiée par des cellules ou des 
anticorps. 
B - Les vaccins anti-cancers 
Le développement des vaccins anti-cancers visant à améliorer la réponse 
immunitaire anti-tumorale est un domaine prometteur de recherche. De nombreux 
résultats encourageants ont été obtenus à partir d’animaux et de nombreux essais 
cliniques de plusieurs vaccins sont en cours. Une vaccination anti-tumorale efficace 
doit être réalisée en se basant sur : l'identification des antigènes spécifiques ou 
associés aux tumeurs, le système de délivrance des antigènes doit être efficace et 
stimuler une réponse immunitaire appropriée et spécifique, et la définition d’une 
formulation optimale du vaccin et les stratégies d’immunisation (110). 
B-I Les antigènes tumoraux 
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L'identification de l'existence des antigènes tumoraux est une découverte cruciale 
pour l'immunothérapie anti-tumorale basée sur l’antigène. Au cours des dernières 
décennies, de nombreux antigènes tumoraux ont été successivement identifiés. En 
général, les antigènes tumoraux peuvent être répartis en deux classes : les 
néo-antigènes (les antigènes spécifiques des tumeurs) et les antigènes de soi (les 
antigènes associés aux tumeurs) (112, 113). Les antigènes spécifiques des tumeurs 
sont exprimés exclusivement par les tumeurs mais pas par les tissus normaux. Les 
antigènes associés aux tumeurs sont exprimés non seulement par les cellules 
tumorales (avec des quantités ou des localisations anormales), mais aussi par les tissus 
normaux. 
B-II Les modalités des vaccins anti-tumoraux 
En général, les vaccins anti-tumoraux peuvent être classés en trois catégories : 
les vaccins basés sur les cellules, les vaccins basés sur les protéines et les vaccins 
basés sur des vecteurs. 
B-II-a Les vaccins anti-tumoraux basés sur les cellules 
Les vaccins anti-tumoraux basés sur les cellules comprennent généralement des 
vaccins basés sur des cellules tumorales entières et des vaccins basés sur les cellules 
dendritiques. Cette classe de vaccins a été largement explorée dans des essais 
précliniques et cliniques. 
Les vaccins basés sur les cellules tumorales entières peuvent être divisés en deux 
sous-ensembles : 1) les vaccins autologues dans lesquels les cellules tumorales 
utilisées proviennent de la même personne à vacciner; 2) les vaccins allogéniques 
dans lesquels les cellules tumorales proviennent d'autres patients, généralement de 
lignées cellulaires tumorales préexistantes (150). Les cellules tumorales, toutes seules, 
sont généralement faiblement immunogènes, donc elles sont habituellement 
administrées avec des adjuvants ou des cytokines (150). En outre, les lysats des 
cellules tumorales peuvent être utilisés comme source d'antigènes et pas uniquement 
les cellules tumorales entières. La méthode usuelle de préparation de lysats des 
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cellules tumorales consiste à faire des cycles répétitifs de congélation-décongélation 
afin d’induire une nécrose des cellules tumorales (154). Récemment, des efforts 
importants ont été effectués pour produire des cellules tumorales autologues ou 
allogéniques génétiquement modifiées. Ces cellules peuvent sécréter des cytokines 
par exemple. En effet, l'administration systémique des cytokines est souvent associée 
à une toxicité profonde pour le patient, surtout lorsque les doses utilisées sont fortes. 
Parmi les cytokines, la transduction des cellules tumorales faiblement immunogènes 
pour qu’elles expriment le GM-CSF ou l'IL2 a été activement étudiée (163-172). 
Les CDs sont considérées comme les cellules présentatrices d’antigène les plus 
puissantes. Elles sont également les stimulateurs les plus forts des cellules T naïves. 
Grâce à cette propriété, la vaccination basée sur les CDs représente une stratégie 
potentiellement puissante pour l'immunothérapie anti-tumorale. Cette stratégie est 
devenue le centre d’intérêt de nombreuses études scientifiques et cliniques. Jusqu'à 
présent, les CDs chargées avec des antigènes associés aux tumeurs et les CDs 
génétiquement modifiées et exprimant des antigènes tumoraux entiers ou des 
cytokines ont été largement testées dans des modèles animaux ainsi que dans des 
essais cliniques (182-186). 
B-II-b Les vaccins anti-tumoraux basés sur les protéines 
Les vaccins anti-tumoraux basés sur les protéines consistent généralement en un 
simple antigène tumoral ou des antigènes tumoraux combinés. Ce genre de vaccins a 
été étudié dans des modèles animaux et des essais cliniques ont été également réalisés. 
Ils sont généralement administrés avec des adjuvants, tels que le GM-CSF, l’IL 2, 
l’IFN-α, le CpG, etc., afin de générer une réponse immunitaire forte et durable 
(217-219). En plus de l'approche basée sur l’antigène tumoral, une famille de 
protéines de choc thermique (HSP) a également été utilisée dans l'immunothérapie 
anti-tumorale actuelle. D'une part, des peptides antigéniques de faible masse 
moléculaire ont été ajoutés à une préparation d’HSPs des cellules tumorales. Ceci 
indique que les interactions peptidiques de certaines HSP sont similaires à celles des 
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protéines du CMH (221-225). D’autre part, et indépendamment des propriétés 
peptidiques, les HSPs ont une propriété d’immunomodulation. Elles induisent une 
réponse immunitaire innée (229). Grâce à ces propriétés d’immunostimulation de 
l'immunité innée et adaptative les HSPs sont maintenant utilisées dans le 
développement de différents vaccins anti-tumoraux. 
Comme les lymphocytes T reçoivent un message antigénique sous forme de 
peptide, l'utilisation de peptides comme agents thérapeutiques a été adoptée dans le 
traitement du cancer. Cependant, l'immunisation avec des séquences natives de 
peptides était souvent insuffisante pour générer une réponse médiée par des 
lymphocytes T au cours d’essais chez les animaux ou d’essais cliniques. Plusieurs 
stratégies ont été développées afin d’améliorer l'immunogénicité et de diriger le 
système immunitaire vers le type de réponses souhaitées. Parmi ces stratégies : la 
modification de la séquence de l’épitope, l'incorporation de cytokines, de chimiokines, 
de molécules costimulantes ou d’immunomodulateurs avec le vaccin peptidique, ou 
encore charger les peptides sur les CDs, etc. (240-253). 
Récemment, la vaccination avec des anticorps anti-idiotype (Id) est apparue 
comme une approche intéressante pour l'immunothérapie anti-tumorale. Cette 
approche est basée sur la théorie du réseau idiotypique de Niels Jerne. Selon ce 
concept (254), un antigène induit la production d’anticorps (Ab1) dont la structure 
sérologique unique (idiotype) peut induire la production des Abs anti-Id (Ab2). 
Certaines de ces molécules Ab2 (Ab2β) sont spécifiques de la région variable d’Ab1 
dédiée à la liaison avec l’antigène. Elles peuvent fonctionner comme une "image 
interne" de l'antigène cible en mimant sa structure tridimensionnelle. La vaccination 
avec ces anticorps Ab2β devrait stimuler la production d'anticorps anti-anti-Id (AB3 
aussi appelé Ab1’) qui reconnaissent l'antigène original. Cette nature cyclique de la 
complémentarité des sites de liaison et des idiotypes représente la base des vaccins 
idiotypiques.  
B-II-c Les vaccins anti-tumoraux basés sur des vecteurs 
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Une expression de l’antigène et un système de délivrance appropriés sont 
importants pour l'efficacité d'un vaccin. Les différents systèmes de délivrance 
d'antigènes peuvent être classés en deux catégories. Les vecteurs non pathogéniques 
comprenant l'ADN plasmidique, les liposomes, les peptides cationiques pénétrants 
(Cell Penetrating Peptides, CPPs) et les vecteurs dérivés de microorganismes. La 
deuxième catégorie correspond aux vecteurs pathogéniques comprenant des vecteurs 
viraux et des vecteurs bactériens. 
 Les vaccins correspondant à l’ADN plasmidique sont basés sur des plasmides 
bactériens modifiés afin d’exprimer l'antigène cible. Ce dernier est sous le contrôle de 
promoteurs actifs dans les cellules de l’hôte. Ils contiennent également un terminateur 
transcriptionnel pour mettre fin à la transcription dans les cellules mammifères et un 
marqueur de sélection pour faciliter la production des plasmides dans des cellules 
bactériennes transformées pour la production du vaccin (261). Les moyens courants 
d'administration de l’ADN plasmidique comprennent : 1) des technologies de 
délivrance physique : l’injection intramusculaire par une aiguille; les ADN 
plasmidiques enrobées avec des particules d'or; l’électroporation après l'injection par 
l’aiguille, etc.; 2) l’application d’adjuvants. 
Les liposomes sont des vésicules sphériques composées d'une ou plusieurs 
bicouches de phospholipide et un centre aqueux interne. Ils sont capables d'encapsuler 
les Ag et les agents immunomodulateurs. Les agents d’intérêt peuvent être véhiculés 
par des liposomes de différentes façons notamment : 1) une encapsulation dans le 
noyau, 2) ancrés dans la bicouche ou 3) adsorbés ou greffés à la surface extérieure 
(271). Les liposomes injectés localement peuvent être capturés avidement par les 
CPAs infiltrant le site d'injection ou ceci dans les vaisseaux lymphatiques (272). En 
outre, les liposomes permettraient de protéger leur contenu d’ADN de l’attaque de 
désoxyribonucléase (273). Ainsi, les liposomes sont considérés comme des vecteurs 
appropriés de vaccin pour délivrer des antigènes ou des ADNs  
Diverse CPPs naturels et/ou synthétiques ont été aussi largement appliqués dans 
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les vaccins. Les CPPs sont des peptides cationiques et/ou amphipathiques de 9-35 
acides aminés qui sont capables d'internaliser et traverser des membranes cellulaires 
(291). Cette capacité de translocation membranaire est possédée non seulement par les 
CPPs seuls, mais aussi par les CPPs attachés avec des cargaisons différentes, comme 
des peptides, des protéines, des oligonucléotides, des ADNs/ARNs, des 
nanoparticules, des liposomes, des bactériophages et des colorants fluorescents (291). 
Deux applications des CPPs déjà validées par des études de vaccins sont les vecteurs 
délivrant des antigènes associés aux tumeurs dans les CPAs et les véhicules 
non-viraux appliqués dans les vaccins ADN (291). 
Les levures ont également été utilisées comme vecteur de délivrance d’antigène 
dans des vaccins anti-tumoraux. Ces organismes peuvent être avidement phagocytés 
par les CPAs et induire par la suite des réponses immunitaires chez les mammifères 
(300, 301). Il a été démontré que les cellules recombinantes de levure sont capables de 
stimuler le système immunitaire pour déclencher des réponses cellulaires très 
spécifiques et puissantes contre les antigènes cibles et ce avec une faible toxicité (302, 
303). 
Les virus sont des petits agents infectieux pouvant se répliquer uniquement à 
l'intérieur des cellules vivantes des organismes. Les virus peuvent infecter tous les 
types d'organismes, animaux, plantes jusqu’aux bactéries (309). Ils ont évolué pour 
avoir des structures et des mécanismes efficaces afin d’infecter les cellules et produire 
des protéines virales en utilisant la machinerie cellulaire (310). Ainsi, les vecteurs 
viraux représentent des véhicules attractifs pour délivrer des antigènes dans un but 
d'immunothérapie anti-tumorale. Ils peuvent mimer une infection naturelle et 
exprimer des signaux de danger. Ici, nous évoquons plusieurs vecteurs viraux 
largement employés dans l'immunothérapie contre le cancer, y compris : des virus 
recombinants de vaccinia, des vecteurs basés sur les adénovirus, des rétrovirus 
recombinants et des virus du type herpès simplex. 
Par ailleurs, plusieurs caractéristiques intrinsèques des bactéries pathogènes, 
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vivantes et atténuées ont permis leur utilisation comme vecteurs de délivrance de 
l'ADN ou d’antigènes protéiques. Ces caractéristiques comprennent : 1) un tropisme 
positif pour les CPAs et 2) la bactérie elle-même est un adjuvant naturel pour le 
vaccin parce que l'infection bactérienne est connue pour induire la libération de 
plusieurs cytokines pro-inflammatoires qui pourraient améliorer les réponses 
immunitaires (318). Nous évoquons en détail plusieurs vecteurs bactériens bien 
caractérisés et largement appliqués dans des vaccins anti-tumoraux, tels que Listeria 
monocytogenes, le genre Salmonella et la délivrance d'antigènes médiée par le 
système de sécrétion de type 3 des bactéries à Gram négative. 
B-III Les récentes stratégies pour l’amélioration des vaccins contre le cancer 
Un défi majeur dans le développement des vaccins anti-tumoraux est la tolérance 
immunitaire vis-à-vis de la tumeur. En fait, beaucoup de TAAs sont des protéines du 
soi et donc souvent n’arrivent pas à induire des réponses antitumorales efficaces 
médiées par des lymphocytes T. En effet, une clef pour développer des vaccins 
anti-tumoraux efficaces consiste à surmonter les mécanismes potentiels de 
suppression immunitaire contre des tumeurs antigéniques mais faiblement 
immunogéniques (409). Pour atteindre cet objectif, plusieurs stratégies ont été 
appliquées afin d’améliorer les performances des vaccins anti-tumoraux. Parmi ces 
stratégies : le ciblage des voies co-inhibitrices, le ciblage des cellules T régulatrices, 
des stratégies utilisant différents protocoles de vaccination par prime-boost et celles 
combinant les vaccins anti-tumoraux et d'autres thérapies, etc. 
C Le système de sécrétion de type III de Pseudomonas aeruginosa 
C I La bactérie P. aeruginosa 
P. aeruginosa est un bacille Gram négatif de l’environnement. Il est non 
fermentaire. C’est un pathogène opportuniste pour l’homme. Il infecte les personnes 
atteintes de la mucoviscidose, les immunodéprimés (en particulier les iatrogènes), les 
personnes avec une ventilation assistée invasive ou atteintes de bronchopathies 
chroniques, les personnes avec des effractions cutanées nosocomiales (chirurgie, …) 
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et les patients porteurs de diverses prothèses en contact avec des surfaces muqueuses 
telle que les lentilles de contact ou les sondes urinaires. En dehors de ces situations, P. 
aeruginosa est incapable de développer une infection à cause des barrières physiques 
(muqueuses, peau, clairance mucociliaire …etc.), de l’immunité innée (macrophages 
pulmonaires …etc.) et de l’immunité acquise. 
C-II Le Système de sécrétion de type 3 (SSTT) 
Le SSTT a été décrit initialement chez Yersinia et Salmonella. Par la suite, il a 
été retrouvé chez la plupart des bacilles à Gram négatif. Le SSTT semble être un 
facteur de virulence majeur jouant un rôle prépondérant au cours de la phase aiguë de 
l'infection par P. aeruginosa. Il peut induire la nécrose ou l'apoptose des différentes 
populations cellulaires et ainsi provoque l'altération de la fonction des phagocytes. 
Les dommages causés par le SSTT sont plus marqués dans l'infection pulmonaire. 
L’appareil de sécrétion du SSTT de P. aeruginosa se compose d’une vingtaine de 
protéines remarquablement conservées. Ces protéines s’assemblent pour former une 
structure qui ressemble à une aiguille. Cette dernière peut traverser les deux 
membranes bactériennes et s’insère dans la membrane des cellules eucaryotes. Cette 
structure constitue un canal continu à travers lequel les toxines bactériennes sont 
directement délivrées dans le cytoplasme des cellules eucaryotes selon un mécanisme 
actif et spécifique. (446-448) 
Quatre toxines sont sécrétées par le SSTT de P. aeruginosa : l'exotoxine (Exo) S, 
ExoT, ExoU et ExoY. En plus de ces toxines, PopB et PopD peuvent également être 
considérées comme des toxines car le pore qu’elles forment au niveau de la 
membrane des cellules eucaryotes peut induire en lui-même une certaine cytotoxicité 
selon le type de cellules. En générale, les exotoxines ont la capacité de modifier les 
fonctions des cellules de l’hôte pour le profit des bactéries. Parmi ces effets, il y a les 
transformations du cytosquelette et par conséquent la modification de la phagocytose 
et le transport des organelles, les altérations de la signalisation intracellulaire 
induisant ainsi l'apoptose des cellules, la diminution de la production des médiateurs, 
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l'induction de la nécrose, etc. 
Le SSTT de P. aeruginosa est régulé au niveau transcriptionnel et 
post-transcriptionnel de façon sophistiquée. Tous les gènes codant pour les protéines 
du SSTT sont régulés par ExsA, un activateur transcriptionnel de type AraC. Il se lie à 
une séquence consensus au niveau du promoteur des gènes (449). Outre la régulation 
dépendante d’ExsA qui est un mécanisme majeur, plusieurs facteurs tels que : les 
facteurs métaboliques, le système du quorum sensing (QS), l'AMP cyclique, Vfr, PtrA, 
etc. peuvent également avoir un impact sur l’activation du SSTT (450). 
C-III Travaux précédemment menés au laboratoire 
Pendant plusieurs années, nous avons étudié le SSTT de P. aeruginosa. En 
utilisant ce système, nous avons essayé de construire des souches bactériennes qui 
délivrent des antigènes. La translocation intracytoplasmique de ces antigènes a été 
réalisée par la fusion des antigènes d'intérêt avec la toxine ExoS du SSTT. Le 
développement et l'utilisation des vecteurs bactériens sont encore en cours. Les 
travaux déjà réalisés concernent la détermination de la séquence minimale d’ExoS qui 
est nécessaire pour la sécrétion d'une protéine de fusion ExoS-antigène (3), le 
développement de différentes souches atténuées (3, 496), le développement d'une 
construction plasmidique dans laquelle ExsA a été inséré sous le contrôle d'un 
promoteur inductible et l'application des vecteurs bactériens atténués dans des 
modèles d’immunothérapie anti-tumorales chez la souris (3, 6, 10). 
D Objectifs du travail 
Dans le but de générer et maintenir une réponse immunitaire acquise efficace, la 
stimulation de l’immunité innée et la délivrance adéquate de l’antigène sont deux 
facteurs cruciaux. Au cours des dernières décennies, l’utilisation de la machinerie de 
sécrétion de type III des bactéries à Gram-negatif telle que Salmonella, Shigella, 
Yersinia et Pseudomonas a séduit énormément grâce à leurs potentiels pour 
développer des vaccins anti-tumoraux. En fait, ces bactéries utilisent cette machinerie 
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pour délivrer les effecteurs bactériens dans les cellules de l’hôte. 
Grâce à une manipulation génétique facile, différentes souches atténuées de P. 
aeruginosa ont été préparées dans notre laboratoire. Leurs potentiels à délivrer des 
vaccins anti-tumorales a été vérifié.   
L’objectif de cette étude est de continuer à développer et améliorer la 
performance de nos souches atténuées utilisées comme vecteur vaccinal pour des 
futures applications cliniques. 
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In spite of great efforts to develop better treatments, cancer remains an important 
cause of mortality in the world. Each year, there are millions of people worldwide 
died from cancer. According to the statistical report published by World Health 
Organization in 2010, cancer is actually the leading cause of death in economically 
developed countries and the second leading cause of death in developing countries 
(1). 
The main cancer treatments include surgery, chemotherapy, radiotherapy, 
immunotherapy and other methods. However, surgery needs to be realized in the early 
stage before the tumor spreads to distant area and required the removal of a wide 
surgical margin; chemotherapy and radiotherapy can not affect tumor cells without 
adverse affects on normal cells, which results in unpleasant side effects. Since several 
decades, the increase in knowledge of the immune system and its regulation have led 
to a great interest in immunologic approaches to target and eliminate cancer, because 
the exquisite specificity of the immune system could be marshaled to precisely target 
cancer cells without harming normal cells.  
Cancer immunotherapy can be either active immunotherapy in which case the 
patient receive a cancer vaccine and his own immune system is trained to recognize 
tumor cells as targets to be destroyed, or passive immunotherapy in which case the 
patient receive either therapeutic antibodies or ex vivo manipulated lymphocytes as 
drugs and his immune system is recruited to destroy tumor cells by the transferred 
effectors. In active immunotherapy, therapeutic vaccination against defined 
tumor-associated antigens (TAAs) for preventing tumor growth or eliminating 
residual tumors is becoming an intense area for medical research, because the immune 
response stimulated by this way is more specific and more efficient. In order to 
generate and maintain efficient acquired cellular immune response, stimulation of the 
innate immune system and adequate antigen delivery are both crucial. In the last 
decades, the use of Gram-negative bacteria, such as Salmonella, Shigella, Yersinia and 
Pseudomonas which use their powerful secretion machinery - type III secretion 
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system (T3SS) to deliver bacterial effectors into the host cell cytoplasm, has attracted 
more and more attention for their potential use for cancer vaccine development (2-5). 
Until now, T3SS based bacteria has been proved as a carrier for cancer vaccines 
which provide the protection against several tumor models like glioma, prostate 
cancer, breast cancer and fibrosarcoma in mice (6-9). 
Due to the ease of genetic manipulation, several attenuated Pseudomonas 
aeruginosa strains have been established in our laboratory and their potential use as 
the carriers for anti-tumor vaccination purpose has also been reported (3, 10, 11). Due 
to previous achievements, I have the honor, during my thesis, to continue developing 
and improving the performance of our attenuated P. aeruginosa strains as vaccine 
vectors for future clinical amplifications purpose. 
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A - Cancer Immunology and Cancer Immunotherapy 
It has been well documented that cancer cell formation and growth is initiated by 
multiple factors. Genetic mutations and physiological changes within normal cells as 
well as within body’s normal defense mechanisms play a crucial role in tumor 
formation and development (12, 13). Mutations in normal cells, such as gain of 
function mutation in oncogenes and loss of function mutation in tumor suppressor 
genes, can induce relative cellular immortality, proliferation, and carcinogenesis. 
During malignant transformation, cells acquire numerous molecular and biochemical 
changes which could be recognized by immune system and provoke interactions 
between the immune system and cancer cells. This last situation is emphasized when 
tumor are induced upon viral infection. 
A-I Cancer Immunoediting – from Immunosurveillance to Tumor Escaping 
Understanding how the immune system affects cancer development and 
progression has long been the biggest challenge question in cancer immunology. The 
exact ways in which the immune system interacts with tumor cells and how tumors 
are able to escape immunological eradication have only recently started to be 
appropriately explained. 
A-I-a Cancer Immunosurveillance and Cancer Immunoediting 
The debate about the role of the immune system during tumor progression has 
undergone for over a century. The hypothesis that the immune system represses the 
growth of carcinomas was first speculated by Paul Ehrlish in 1909. However, during 
the following 50 years, little progress about this idea has been achieved because the 
composition and function of immune system was mainly unknown. With an enhanced 
understanding about transplantation and the demonstration of tumor antigens 
existence, Burnet and Thomas proposed cancer immunosurveillance theory in 1957. 
According to this concept, lymphocytes could continuously recognize and eliminate 
arising, nascent transformed cells (14). Nevertheless, this theory has suffered the 
challenge after that. Studies by Stutman and by Rygaard & Povlsen demonstrated that 
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the susceptibility of immune-competent mice to both spontaneous and 
carcinogen-induced tumors was similar to that of nude mice which had major 
immunodeficiency (15-17). After these experiments, the cancer immunosurveillance 
theory was greatly abandoned. Until the 1990s, interest in cancer immunosurveillance 
was re-incited by two important findings: 1) interferon γ (IFN-γ) can promote 
immunologically induced rejection of transplanted tumor cells and prevent the 
 
Figure 1: The Three Phases of the Cancer Immunoediting Process. 
Normal cells (gray) subject to common oncogenic stimuli ultimately undergo transformation and 
become tumor cells (red) (top). Even at early stages of tumorigenesis, these cells may express 
distinct tumor-specific markers and generate pro-inflammatory “danger” signals that initiate the 
cancer immunoediting process (bottom). In the first phase of elimination, cells and molecules of 
innate and adaptive immunity, which comprise the cancer immunosurveillance network, may 
eradicate the developing tumor and protect the host from tumor formation. However, if this 
process is not successful, the tumor cells may enter the equilibrium phase where they may be 
either maintained chronically or immunologically sculpted by immune “editors” to produce new 
populations of tumor variants. These variants may eventually evade the immune system by a 
variety of mechanisms and become clinically detectable in the escape phase. Reprinted from Dunn 
GP et al. 2004 (18). 
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formation of chemical induced and spontaneous tumors (19); 2) mice lacking either 
IFN-γ responsive ability or adaptive immunity were more susceptible to carcinogen 
induced and spontaneous tumor formation (20, 21). In the same period, other 
experiments demonstrated the similar results and thus the extrinsic tumor suppressor 
function of immune system was proved to indeed exist. However, one growing 
evidence that tumor protection represents only one dimension of the complex 
relationship between the immune system and cancer has emerged (20, 22). The work 
of Shankaran in 2001 revealed that the immune system can also promote the 
formation of primary tumors because the tumor cells have a reduced immunogenicity 
and are capable to escape immune recognition and destruction. Thereby, it is now 
accepted that immune system has dual function during tumor progression. On the one 
hand, immune system prevents tumor formation and development, the function of 
cancer immunosurveillance. On the other hand, the immune system can modify the 
intrinsic nature of tumor which can change the tumor immunogenicity and lead to 
tumor escape, the function of tumor sculpting. Basing on these findings, a new theory 
which can describe more broadly and appropriately the function of immune system 
throughout tumor development was established – immunoediting (18, 22, 23). 
According to immunoediting theory, the interaction between immune system and 
tumors is a dynamic process comprising three phases: elimination, equilibrium and 
escape (Fig. 1, (18)). 
A-I-b Cancer Immunoediting – Elimination 
The elimination phase represents the original concept of cancer 
immunosurveillance. During this phase, both innate and adaptive immune system can 
detect the presence of tumor cells and destroy them so as to prevent tumor 
development. The mechanisms of immunosurveillance initiation have not been fully 
understood. It can be generally considered that accumulated transformed cells can 
express the danger signals to recruit the cells of innate immune system, such as NKT 
(natural killer T) cells, NK (natural killer) cells and γδ T cells, and stimulate them to 
secret IFN-γ (24-26). The early produced IFN-γ can start a cascade of innate immune 
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reactions which result in some tumor death by several mechanisms, such as 
anti-proliferative mechanism (27), apoptotic mechanism (28), chemokines induced 
angiostatic mechanism (29-31). The chemokines produced in this stage can help to 
recruit more NK and macrophages to kill more tumor cells through the mechanisms 
involving tumor necrosis factor-related apoptosis-inducing ligand, perforin and 
reactive oxygen and nitrogen intermediates (32-36). Then, dead tumor cells or tumor 
cell debris can be captured by dendritic cells (DCs) which will migrate to draining 
lymph node to activate tumor antigen specific CD4+ and CD8+ T cells (37-40). After 
that, tumor specific CD4+ and CD8+ T cells can migrate to tumor site to eliminate 
remaining antigen expressing tumor cells (20). If tumor cells are not successfully 
deleted by the elimination process, they may enter the subsequent phase – the 
equilibrium phase. 
A-I-c Cancer Immunoediting – Equilibrium 
Although cancer elimination process can clear away a significant quantity of 
tumor cells, there are still some malignant cells variants that can stand up with the 
pressure exerted by immunosurveillance and enter with immune system into the 
equilibrium stage. During this phase, the host immune system and tumor cells 
maintain a dynamic balance. The analysis in immunodeficient mice model revealed 
that adaptive immunity, but not innate immunity, was responsible for maintaining the 
equilibrium (41). The adaptive immunity could on the one hand restrict tumor 
outgrowth and maintain residual tumor cells in a functional dormant state (42, 43), on 
the other hand shape the intrinsic nature of tumor cells. By reason of genetic 
instabilities in tumor cells, such as nucleotide-excision repair instability, microsatellite 
instability and chromosomal instability (44) , this sculpting effect of immune system 
to tumor cells can results in a large quantity of mutations. These mutations may endue 
tumor cells with the new phenotypes with reduced immunogenicity, which enable 
tumor cells evade the immune system and enter into the escape phase. 
 A-I-d Cancer Immunoediting – Escape 
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During this phase, surviving tumor cells have acquired enough ability to escape 
the recognition and the destruction by immune system, which might result in either 
recurrent primary tumor or distant metastases. Recent studies have documented the 
potential mechanisms of tumor escaping. First of all, the inherent genetic instability in 
tumor cells and selected pressure exerted by immune system can yield numbers of 
mutation in tumor cells. These mutations can lead tumor cells to be poorly 
immunogenic and invisible for immune system through several ways: 1) inducing 
tumor cells lacking rejection antigen expression (45, 46); 2) inducing tumor cells 
lacking responsible molecules for antigen presentation, such as major 
histocompatibility complex (MHC) molecules, β2m (45, 47) and 3) inducing tumor 
cells lacking intra-cellular antigen processing function (48). Moreover, even the 
rejection antigens are correctly expressed and tumor cells can still be detected by 
immune system, they can also develop the means to evade the immune destruction. 
These last mechanism can consist of: 1) the up-regulation of anti-apoptotic molecules, 
such as FLIP (49) and BCL-XL (50); 2) the expression of mutated inactive death 
receptors, such as TRAIL receptor, DR5 and Fas (51, 52); 3) the secretion of 
cytokines which can suppress the function of immune effector cells, such as vascular 
endothelial growth factor (VEGF), transforming growth factor-β (TGF-β), 
indoleamine dioxygenase (IDO), IL10, etc. (53-56); 4) the secretion of cytokines 
which can recruit the regulatory cells, such as regulatory T cells (Treg cells)  and 
myeloid derived suppressor cells (MDSCs) (57-59). 
A-II The Immune System and Cancer 
Advances in cellular and molecular immunology lead to the brilliant insights into 
the nature of the interaction between immune system and tumors. The immune system 
can restrain tumor growth in several ways. However, it is well accepted that the most 
effective way to eradicate a tumor mass in vivo, as well as for the other infectious 
diseases, is to activate the cell mediated immune response, specially the combined 
action of CD8+ and IFN-γ-secreting T-helper 1 (Th1) CD4+ T cells (60). Reflecting 
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current consensus and our own research emphasis, the discussion will focus on the 
cellular branch of anti-tumor immunity. 
During the course of cancer formation, the malignant cell transformation and the 
disruption of surrounding microenvironment can bring out the expression of danger 
signals on tumor cells. These danger signals frequently induce inflammations which 
can on one hand activate innate effector cells, such as NKT, NK and γδ T cells, to 
directly impact tumor growth; on the other hand, stimulate professional 
antigen-presenting cells (APCs), particularly DCs, to engulf tumor-derived antigens 
and to activate antigen-specific, T and B lymphocytes mediated adaptive immune 
response.  
A-II-a Dendritic Cells 
Dendritic cells (DCs) are the most potent APCs that were discovered in 1973 by 
Ralph Steinman. Numerous documented results prove that DCs can present antigens 
to both CD4+ and CD8+ naive T lymphocytes and prime antigen-specific immune 
responses. On the other hand, DCs also participate in the regulation of T cell-mediated 
immune responses including T type 1 helper (Th1) cell- and Th2 cell-responses. Thus, 
DCs are clearly central to the maturation, maintenance the regulation of a cellular 
immune response to cancer.  
Both in mice and humans, DCs consist of distinct subsets (61). In mice, early 
used classification which distinguished DCs as myeloid or lymphoid subset is now 
thought to be inappropriate, whereas these terms are still frequently used in actual 
scientific experiments. Multiple DC subsets have now been defined in mouse 
lymphoid organs on the basis of cell surface marker expression. The expression of 
CD11c and MHC class II (MHC II) in combination with CD4, CD8α, CD11b, and 
CD205 has been used to separate five subsets which are diversely represented in 
spleen, thymus and lymph node. These subsets are myeloid or lymphoid origin and 
differ in the secretion level of certain cytokines and the capacity of migrating to 
secondary lymphoid organ to interact with T lymphocytes. In humans, DCs can be 
Introduction 
45 
classified in three subsets: Langerhans DCs, interstitial DCs and plasmacytoid DCs. 
Similar to mouse DCs, human DCs are defined in terms of the expression of a range 
of cell surface markers, such as CD4 and MHC II combined with CD1a, CD11c, 
CD14 and BDCA, but these might reflect differences in the maturation status rather 
than separate sub-lineage. However, for both species, even certain phenotypic 
differences have been observed among these different DC subsets, cells’ origins, 
maturation stages, and functional differences have not been clearly established. 
DCs residing in peripheral tissues are immature and act as sentinels. Immature 
DCs are characterized by: 1) an enhanced sensibility to chemo-attractors by their 
chemokine receptors (CCR1, CCR2, CCR5 and CXCR1); 2) a high Ag capture 
capacity through endocytosis and phagocytosis; 3) the low expression of MHC II 
molecules and co-stimulatory molecules on their surface. These characters permit the 
recruitment DC precursors, in response to the production of chemokines upon local 
inflammation induced by microbial infections and tissue damages. Then, immature 
DCs can efficiently capture Ag through several pathways: 1) macro-pinocytosis; 2) 
receptor-mediated endocytosis via C-type lectin receptors (mannose receptor, 
DEC-205) or Fcc receptor types I (CD64) and II (CD32) for the uptake of immune 
complexes or opsonized particles; and 3) phagocytosis of particles such as latex beads, 
apoptotic and necrotic cell fragments, viruses, bacteria and intracellular parasites. 
During the recruitment, antigen capturing and immigration processes, immature 
DCs gain the maturation signals which are composed of Toll-liked receptors (TLRs) 
and various agents, such as the inflammatory compounds (TNF-α and IL-1), 
Pathogen-derived compounds (dsRNA, LPS, etc.) and cell-derived compounds (HSP, 
CRT, uric acid, etc.). The DCs maturation process is associated with several 
characters: 1) loss of endocytic and phagocytic receptors; 2) high-level expression of 
MHC II molecules at the cell surface and increased production of co-stimulatory 
molecules including CD40, CD80, and CD86; 3) changes in morphology; 4) 
re-programming of chemokine receptor expression and responsiveness and 5) 
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activation of the Ag-processing machinery (61). The maturation process can 
consequently trigger the migration of DCs from inflamed tissues to T cell-enriched 
draining lymph nodes (DLNs) in response to certain chemokines such as CCR7. Then, 
DCs select rare Ag-specific naive T cells and induce their activation and 
differentiation into effector cells, which thereby initiates primary immune responses. 
A-II-b DCs Mediated Antigen Presentation 
Unlike B cells, T cells fail to recognize antigens (except for super-antigens) in 
the absence of antigen presentation. The effective presentation of antigens by APCs is 
crucial for the development of specific T cell response. Although APCs contain 
different types of cells, such as B cells, DCs and macrophages, DCs are the most 
potent APCs because the MHC molecules (the indispensable components for antigen 
presentation) and MHC-peptide complexes are 10-100 times higher on DCs than on 
the other APCs (62). The T cell is restricted to recognizing antigenic peptides in the 
peptide-binding groove of MHCs molecules. There are two major classes of MHC 
molecules (MHC I and MHC II) that execute the antigen presentation function 
through the different pathways for activating CD8+ and CD4+ T cells, respectively. 
In general, through MHC I pathway, the antigens from self and intracellular 
pathogens (such as viral infection, the presence of intracellular bacteria or cellular 
transformation) can be reported to CD8+ cytotoxic T cells (CTL). First of all, 
antigenic particles will undergo the ubiquitinylation and then the digestion by a 
proteasome complex so as to be transformed into small peptides of 8 to 10 amino 
acids. Then, peptides will be moved by Transporter for Antigen Presentation (TAP) 
molecules to the endoplasmic reticulum (ER). MHC I molecules can be bridged to 
TAP by the transmembrane protein tapasin. By this mean, the antigenic peptides could 
be coupled with MHC Class I molecules and be transferred to the cell surface to 
encounter with CD8+ cytotoxic T cells. (63) 
Through MHC II pathway, the antigens from the extracellular milieu can be 
presented to CD4+ T cells. In contrast to the widespread expression of MHC I 
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molecules, MHC II molecules are restrictedly expressed by professional APCs, 
particularly by DCs. Peripherally resided DCs are immature and express low level of 
MHC II molecules. However, immature DCs have the efficient antigen capturing 
ability. Exogenous pathogens such as bacteria, parasites, and toxins in the tissues can 
be phagocytosed by immature DCs and targeted to MHC II compartments 
(endosomes) where the pathogen-associated proteins can be digested into smaller 
peptides by lysosome-associated enzymes. Meanwhile, immature DCs can migrate to 
T cell-enriched lymph nodes in response to certain chemokines. During migration and 
antigen capturing, immature DCs undergo the maturation process during which stage 
they obtain several new characters including enhanced expression of MHC II 
molecules in MHC II compartments. In result, peptide can be loaded to MHC II 
molecules and then transported to the cell surface where they engage antigen-specific 
CD4+ T cells. (63) 
Besides the standard pathways, dendritic cells can also process and present 
extracellular antigens originated from phagocytosed particulates or immune 
complexes with MHC I molecules to CD8+ T cells. This phenomenon is termed 
cross-presentation (64). This process is necessary for immunity against most tumors 
and against viruses that do not infect antigen-presenting cells (65, 66). It is also 
required for induction of cytotoxic immunity by anti-tumor vaccination (67). 
A-II-c Interaction between DCs and T Cells  
DCs play a central role in T lymphocyte activation and differentiation into Th1, 
Th2 and CTL effectors. After acquiring antigen in the periphery, the DCs migrate to 
the DLNs to encounter and activate both CD4+ and CD8+ T cells. To explain the 
mechanism of T cell activation, “Two-signal” model has been well accepted (Fig. 2) 
(68). Signal 1 is mediated by the reorganization between T-cell receptor (TCR) 
expressed by T cells and DCs with peptide presented in the context of MHC 
molecules. Signal 2 is generated by the interaction between members of the B7 family 
(CD80/86) on DCs and CD28 on T cells; CD40 on DCs and CD40L on lymphocytes.  
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The second signal is also called co-stimulatory which is required to ensure that T cells 
will divide and differentiate into effector cells. Both signals are indispensable for 
production of an effective immune response. Recently, there are also the other 
additional co-stimulatory signals, such as signals mediated through 4-1BBL–4-1BB 
(69, 70), OX40L–OX40 (71, 72) interactions, are documented to be required for 
promoting the survival and proliferative capacity of activated T cells and the 
generation of memory T cells. Recently, the existence of “Signal 3” has also been 
documented. Secretion or non-secretion of factors by DCs, particularly IL-12, are 
proved to be instrumental in the final differentiation of CD4+ T cells into Th1 or Th2 
cells, respectively (73). 
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Figure 2: Two Signals Model for T Cells Activation.  
Two signals are indispensable for T cell activation mediated by dendritic cells. Signal 1: 
reorganization of TCR expressed on T cells by DCs with the appropriate peptide in the context of 
MHC molecules. Signal 2: co-stimulatory mediated by the reorganization between the B7 proteins 
(CD80/CD86) expressed by DCs and their lymphoid ligand CD28. 
Furthermore, it has also been revealed that co-stimulation pathway is quite 
complex, it involves not only activating signals but also inhibitory signals issued from 
the interaction between CD28 and cytotoxic T lymphocyte–associated antigen 4 
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(CTLA-4) molecules (74). CTLA-4 is a co-stimulatory receptor which is only 
expressed by activated T cells. CTLA-4 is structurally similar to CD28 and can bind 
to B7 molecules with an affinity 500 – 2000 folds higher than CD28 (75). However, 
in contrast to CD28, CTLA-4 down-regulates T-cell responses and promotes the 
tolerance. 
On the other hand, while the DC-T cell interaction has been traditionally viewed 
as a one way interaction, recent data suggested that T cells may play an important role 
in activating DCs thus further enhancing the T cell stimulatory capacity of the DCs 
(76, 77). 
A-II-d CD8+ Cytotoxic T Cells Mediated Response (78-80) 
The CTLs mediate immunity against viruses and surveillance against neoplastic 
transformation. CTLs can circulate in organs with various specificities. When CTLs 
encounter their target cells, which means the TCR molecules expressed by CTLs 
recognize their appropriate peptides expressed by target cells in MHC context, CTLs 
can eliminate the target cells through different pathway. 
It has been proved that CTLs destroy their target cells through at least two 
different mechanisms. Both mechanisms can specifically and directionally induce the 
apoptosis of target cells, whereas these processes are totally different. One is 
perforin/granzyme-mediated pathway and the other is Fas-mediated pathway. 
Perforin/granzyme-induced apoptosis is the main pathway used by cytotoxic 
lymphocytes to eliminate virus-infected or transformed cells. When CTLs encounter 
infected/dysfunctional somatic cells, they can release the cytotoxins (perforin, 
granzymes) through exocytosis to the contact region between the killer and target 
cells. Perforin can form via polymerization the aqueous channels in the membrane of 
target cell which can further allow the entry of perforin itself and granzymes. 
Granzymes are serine proteases that cleave at aspartate residues in the substrates and 
can be activated by perforin action in intracellular space. Granzyme B is one serine 
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protease and it can activate numbers of caspases which eventually lead to apoptosis 
(programmed cell death). Granzyme A is the other well-expressed granzyme in CTLs 
and it does not directly process pro-caspases like granzyme B. However, the effection 
of granzyme A has not been clearly defined, some research revealed that granzyme A 
can possibly trigger a novel form of apoptosis associated with DNA single-strand 
breaks (81). 
The second pathway to induce apoptosis is via cell-surface interactions between 
the CTLs and the target cells. Activated CTLs express the surface protein FAS ligand 
(FasL) which can bind to Fas molecules expressed on target cells. Fas molecules 
receptors belong to the TNF receptor family. Engagement of Fas with FasL allows for 
recruitment of the death-induced signaling complex (DISC). Then, the Fas-associated 
death domain (FADD) translocates with the DISC which can activate numbers of 
caspases and result in classical caspase-dependent apoptosis. The main function of the 
FAS–FASL pathway is to eliminate self-reactive lymphoid cells (82). 
.A-II-e CD4+ T Cells Mediated Response (83-87) 
Extensive studies have demonstrated that Th cells play a central role in the 
amplification and regulation of immune response. They do so through their capacity 
to help B cells make antibodies, to induce macrophages to develop enhanced 
microbicidal activity, to recruit neutrophils, eosinophils, and basophiles to sites of 
infection and inflammation, and, through their production of cytokines and 
chemokines, to orchestrate the full panoply of immune responses. Actually, 
stimulation of a CD4+ Th response combining with long lasting CD8+ CTL response 
is appearing more and more important for cancer immunotherapy. According to their 
functions, their unique products, their characteristic transcription factors, and 
cytokines critical for their fate determination, Th cells can be principally classified in 
four types: Th1, Th2, Th17 and regulatory Treg cells (Fig. 3).  
Th 1 cells are mainly generated with the help of IL-12 and are important for the 
eradication of intracellular pathogens, including bacteria, parasites, yeast, and viruses. 
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T-bet and Stat4 are the important transcription factors for Th1 response amplification. 
More and more proofs demonstrated that modulating the Th1 cell response against a 
tumor antigen may lead to effective immune-based therapies. Th1 cells can mainly 
secret IFN-γ, IL-2 and TNF-β. IFN-γ can: 1) sensitize tumor cells to CD8+ T cells by 
upregulating MHC I and other components of the antigen-processing machinery; 2) 
promoting the recruitment of NK cells; 3) activate macrophages, enhancing their 
microbicidal action and 4) providing help to B cells to stimulate the production of 
immunoglobulin (Ig-) G antibodies (IgG1 in human and IgG2 in mice) that are 
involved in opsonization and phagocytosis. TNF-β can stimulate innate and T-cell 
immune responses. IFN-γ and IL-2 can also promote the differentiation of CD8+ 
lymphocytes into cytotoxic cells.  
 
Figure 3: Classification of CD4+ Th Cells. 
Th cells can be classified in four types according to their functions, their unique products, their 
characteristic transcription factors, and cytokines critical for their fate determination. Reprinted 
from Zhu JF et al. 2008 (85). 
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Th2 differentiation is promoted by IL-4 and GATA-3 and signal transducer and 
activator of transcription (STAT) 5 are two important transcription factors for Th2 
differentiation. The Th2 response is often associated with a humoral response and 
mediate host defense against extracellular parasites, such as helminthes. Besides, Th2 
cells are also important in the induction and persistence of asthma and other allergic 
diseases. Th2 cells produce IL-4, IL-5, IL-9, IL-10, IL-13, IL-25, and amphiregulin. 
IL-4 is the inhibitor cytokine for Th2 cell differentiation and is the major mediator of 
IgE class switching in B cells. IL-5 plays a critical role in recruiting eosinophils. IL-9 
can affect mast cells and lymphocytes and also induce mucin production in epithelial 
cells during allergic reactions. IL-10 can suppresses Th1 cell proliferation and also 
suppress dendritic cell function. IL-13 is the effector cytokine in the expulsion of 
helminthes and in the induction of airway hypersensitivity. Amphiregulin is a member 
of the epidermal growth factor (EGF) family. It induces epithelial cell proliferation.  
Th17 cells were recently identified as a distinct Th subset because they exhibit a 
cytokine profile distinct from Th1 and Th2 cells, which was characterized by the 
expression of IL-17A, IL-17F, IL21 and IL-22. The biological activities of IL-17A 
and F are very similar. Both molecules induce multiple pro-inflammatory mediators, 
including IL-6, IL-8, keratinocyte chemo-attractant (KC), granulocyte colony 
stimulating factor (G-CSF), etc. Thus, IL-17A and F play an important role in 
inducing inflammatory responses. IL-21 made by Th17 cells is a stimulatory factor 
for Th17 differentiation and serves as the positive feedback amplifier. The 
development of Th17 subset is depended on IL-6, IL-21, IL-23 and TGF-β. RORγt 
and Stat3 are important in T17 differentiation. Th17 cells can mediate immune 
responses against extracellular bacteria and fungi, but also participate in the 
amplification of autoimmune diseases.  
Treg cells are a highly specialized subset of immune cells capable of suppressing 
auto-reactive cells and thereby maintaining tolerance to self-antigens and preventing 
autoimmunity. On the other hand, Tregs also play an important role in the suppression 
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of immune response to tumors and infection agents and are thought to be the main 
obstacle of successful immunotherapy. Forkhead box P3 (FOXP3) and Stat5 are two 
important transcription factors required for Treg development. Some categories of 
Tregs have been characterized and two subsets are best known: natural Tregs (nTregs) 
and induced Tregs (iTregs). nTregs develop and mature in the thymus and are 
characterized as CD4+CD25+FOXP3+ T cells. They are essential for the induction and 
maintenance of self-tolerance and control of autoimmunity. Various mechanisms 
responding to the suppressive action of nTregs have been identified. nTreg can act 
through (Fig. 4): 1) the secretion of inhibitory cytokines, such as IL-10, TGF-β; 2) the 
down-regulation of DCs function; 3) killing of APCs or responder T cells by means of 
granzyme and perforin; 4) the constitutive expression of high amounts of CTLA4 
molecules which can bind to B7 molecules expressed by DCs and activate 
indoleamine 2,3-IDO pathway. In contrast to nTregs, iTregs do not develop in the 
 
Figure 4: Possible Suppressive Mechanisms of Tumor Environmental Regulatory T Cells. 
Reprinted from Zou W et al 2006 (87). 
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thymus but from peripheral T cells. iTregs can be either FOXP3-positive or negative. 
This cell population is characterized by their cytokine pattern rather than by the 
surface markers. Among Treg cell populations, “T-regulatory 1 cells (TR1 cells)” is 
the term used to represent CD4+IL-10+FOXP3– regulatory T cells that develop under 
the influence of the immunosuppressive cytokine IL-10 and whose suppression 
function is partly mediated by IL-10, this type of iTregs can be induced in response to 
exogenous antigen challenge. “TH3 cells” is the term used to represent the 
CD4+TGFβ+ T cells that are induced in the context of oral tolerance and can 
synthesize TGF-β. In addition, CD8+ Tregs that play an important role in the 
regulation of autoimmune disease have been recently identified. This kind of Treg 
cells only target at the activated T cells and can down-regulate target T cell or APC 
function by cell–cell contact mechanisms or through secreting immunosuppressive 
cytokines, for example, IL10 (87, 88). 
A-II-f T Lymphocytes Differentiation (89, 90) and Memory T Cells (91, 92) 
The development and differentiation of T cell response to infectious pathogen 
has been well studied. It has been identified as a dynamic process and can be 
generally divided into 4 phases (Fig. 5): 1) Expansion phase: T cell immune response 
initiated in the lymphoid tissues. After encountering DCs with antigen in appropriate 
MHC context, naive T cells can be induced to expand and differentiate into effector T 
cells (CD4+ Th cells or CD8+ CTLs) and travel to infection loci. During this stage, 
numerous inflammatory cytokines can be secreted through the combined action of 
CD4+ and CD8+ effector T cells to kill infected cells and a typical acute viral 
infection can be resolved within several days. 2) Contraction phase: Over the weeks 
that follow pathogen clearance, the majority of effector T cells die, leaving behind 
5%–10% of the original burst size as long-lived memory cells. 3) Memory phase: The 
surviving T cells enter the third stage in which the number of memory T cells 
stabilizes, and these cells are maintained for long periods of time, throughout the life 
of the mouse and for many years in humans. 4) The rapid recall response of memory 
T cells following re-exposure to the pathogen.  
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Figure 5: Differentiation of the T Cells Mediated Immune Response. Reprinted from Kaech 
SM et al. 2002 (89) 
It is well accepted that memory T cells play an important role in cancer 
immunotherapy, because these cells have an enhanced ability to control secondary 
exposure to antigen and are very crucial for preventing tumor recurrence. Recently, a 
model of “central memory and effector memory T cells” has been proposed. These 
two memory T populations are characterized by distinct migration capacity and 
effector function. Central memory T cells (TCMs) mediate the reactive memory. This 
T memory subset maintains the similar homing and chemokine receptors and 
recirculation routes as naïve T cells and has little or no effector function. However, 
TCMs have a higher sensitivity to antigenic stimulation and can rapidly proliferate 
and differentiate to effector cells following secondary encounter with antigen. The 
other memory T subset — Effector memory T cells (TEMs) mediate the protective 
memory. Differing from TCM, effector memory T cells (TEM) no longer routinely 
enter lymph nodes and more tend to migrate to inflamed peripheral tissues and display 
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immediate and local effector function. Numerous surface molecules have been 
identified to interpret the distinct homing properties between TCMs and TEMs, 
among which L-selectin (CD62L) and CC-chemokine receptor 7 (CCR7) are two 
lymph-node-homing receptors and have been best defined to discriminate the two 
memory T subsets. CD62L can interact with peripheral-node addressin (PNAd, the 
high endothelial venule (HEV)–specific ligand for L-selectin) and mediate the 
attachment and rolling of lymphocytes to peripheral lymph nodes. CCR7 can bind the 
chemokines CCL19 and CCL21 that are presented on the luminal surface of 
endothelial cells in the lymph nodes, which causes firm arrest and the initiation of 
extravasation. The two molecules are highly expressed by TCMs (CD62LhiCCR7+), 
which lead to their efficient migration to peripheral lymph nodes. For the same reason, 
TEMs (CD62LloCCR7−) demonstrate a reduced potential for homing to lymph nodes 
because of the decreased expression of CD62L and CCR7 by this subset. However, 
TEMs have a greater capacity to migrate to inflamed tissues, which is owned to 
increased expression of chemokine receptors such as CCR5 and CCR2. Besides, the 
different functional proprieties between TCMs and TEMs have also been laid out. 
TCMs can secrete interleukin-2 (IL-2), but little interferon-γ, IL-4 or IL-5. By 
contrast, TEMs rapidly produced these effector cytokines, but produced less IL-2. 
And, only the CD62LloCCR7− subpopulation of CD8+ T cells was found to contain 
intracellular perforin. 
A-II-g B Cells Mediated Response (93) 
B cells are lymphocytes that play an important role in the humoral immune 
response. The principal functions of B cells are to produce antibodies against antigens, 
act as APCs and eventually develop into memory B cells after activation by antigen 
interaction.  
A critical difference between B cells and T cells is how each lymphocyte 
recognizes its antigen. B cells recognize their cognate antigen in its native form. Each 
B cell has a unique receptor protein (B cell receptor, BCR) on its surface that will 
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bind to one particular antigen. In contrast to T cells which recognize their cognate 
antigen in a processed form, which means a peptide fragment presented in MHC 
context by APCs to the T-cell receptor (TCR), B cells recognize free (soluble) antigen 
in the blood or lymph using their BCR without MHC mediation, thereby for which the 
APCs are not necessary.  
B cells don’t produce antibodies until they become fully activated. The activation 
of B cells is frequently T cell-dependent, for which both the signal come from the 
recognition of antigen by BCR and the signal come from co-stimulation provided by a 
CD4+ Th2 cell are indispensable. In this case, B-cell recognition of foreign protein 
via the BCR results in internalization, processing and presentation of peptide to 
cognate CD4+ T-cell which has been primed by the same peptide presented by APCs. 
This interaction can lead Th2 cell to secrete cytokines (IL-4, 5, 6) that activate B cell 
and trigger B cell proliferation and differentiation into plasma cells. 
B-cells are directly implicated in various infectious and autoimmune diseases, 
but seldom participated in anti-tumor therapy. 
A-II-h Tumor Immunosuppressive Environment (94-96) 
The immune system plays a crucial role in detecting and eliminating tumor cells. 
However, the protective function of the immune system against tumors is not always 
efficient, the interactions between tumor cells and the immune cells in tumor 
microenvironment can also create an immunosuppressive network that protects the 
tumors from immune attack and promotes tumors growth and progression.  
Several mechanisms have been described by which tumors can suppress the 
immune system, including: 1) Secretion of cytokines: Series of studies have revealed 
that tumor microenvironment possesses an anomalous cytokine pattern. For a range of 
tumors, cytokines or substances which can suppress DC maturation and function can 
be abundantly expressed in tumor environment, such as VEGF, IL-6, macrophage 
colony-stimulating factor (M-CSF), TGF-β, IL-10, cytochrome c oxidase subunit II 
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(COX2), Prostaglandin E2 (PGE2), gangliosides. However, cytokines which induce 
DC differentiation and maturation, such as granulocyte–macrophage 
colony-stimulating factor (GM-CSF) and IL-4, as well as the Th1-type cytokines 
IL-12 and IFN-γ, are rarely found. As a result, DCs present in the tumor environment 
are either immature or partially differentiated. 2) Co-stimulatory and co-inhibitory 
molecule alterations: Tumor factors present in the local environment can also affect 
the functional capacity of DCs by altering co-stimulatory and co-inhibitory molecules 
expression. In the environment of numerous tumors, B7-H1 and B7-H4, co-inhibitory 
molecules shown to be the negative regulators of T-cell responses in vitro by 
inhibiting T-cell proliferation, cell-cycle progression and cytokine production, might 
be up-regulated; B7-1 and B7-2, co-stimulatory molecules for T cell activation and 
differentiation might be down-regulated. Thereby, DCs present in the tumor 
environment induce either T-cell anergy or suppressive Treg cells. 3) Alterations in 
antigen-presenting cell subsets: Beside the immaturation and dysfunction of DCs, the 
balance between the DCs subsets could also be broken in tumor environment. Tumor 
environments seem to lack angiogenesis-inhibitory myeloid DCs, but present 
abundant angiogenesis-stimulatory DCs, such as plasmacytoid DCs and vascular DCs, 
which could promote tumor vascularization. 4) Altered ratios of Tregs to effector T 
cells. Treg cells are suppressor T cell that inhibits an immune response by influencing 
the activity of another cell type. We have discussed before about the suppressive 
mechanism of Treg. IL-10 and TGF-β produced by tumors favor the induction and 
differentiation of Treg cells. Dysfunctional DCs and tumor-conditioned plasmacytoid 
DCs would directly contribute to Treg cell induction in the tumor microenvironment.  
It is well demonstrated that these mechanisms of immunosuppression can impair 
tumor specific immune responses. 
A-III Cancer Immunotherapy (97-103) 
Cancer immunotherapy is one class of anti-cancer treatment that attempts to 
modulate the host immune system, and/or use the components of immune system in 
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order to induce or augment anticancer response. The appearance of this concept can 
be traced back to more than 100 years ago. In 1890s, William B. Coley observed the 
regression and even the disappearance of tumors following the injection of bacterial 
products in and around tumors. His findings aroused the great enthusiasm for 
exploiting immune reactivity to treat cancer. Over the last century, impressive 
progress has been achieved in tumor biology and tumor immunology, most aspects of 
immune reactivity have been clearly laid out. Results obtained in related trials 
demonstrated that attracts triggered by immune system against tumors are more 
specific and with lower harmfulness to the host. Thereby, immunotherapy is becoming 
the more and more promising approach for cancer treatment today. For this goal, 
many ways have been performed and they can be generally classified into two classes, 
active anti-tumor immunotherapy and passive (or called adoptive) anti-tumor 
immunotherapy. Each of them comprises specific and non specific approaches (Fig. 
6). 
 
Figure 6: Current Segmentations of Cancer Immunotherapy. 
Cancer immunotherapy can be either active or passive. Each subset consists of specific and 
non-specific approaches. 
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A-III-a Active Anti-tumor Immunotherapy 
Active anti-tumor immunotherapy comprises the approaches that attempt to 
stimulate the host's intrinsic immune response to tumors. It can be sub-divided into 
non-specific active immunotherapy and specific active immunotherapy  
Non-specific active anti-tumor immunotherapy refers to the activation of a 
general immune response through the administration of cytokines or the mediators 
which could induce the release of cytokines. The performance of this strategy has 
been first brought out by Coley’s studies in which local injection of bacteria could 
induce tumor remission. The principle mechanism can be explained as following: 
Immune cells expressed Toll-like receptors can recognize Pathogen-associated 
molecular patterns (PAMPs). Thus the local administration of bacteria can provoke 
the recruitment and the activation of innate immune cells, such as macrophage, 
monocytes, and natural killer cells, which can further trigger the release of TNF and 
other pro-inflammatory cytokines to induce tumor shrinkage. Many subsequent 
reports have advocated this approach. For example, BCG (Bacillus Calmette-Guerin), 
a live attenuated form of Mycobacterium tuberculosis, has been applied to boost 
innate immunity to control tumor and now BCG represents the standard treatment for 
certain stages of superficial bladder cancer. However, the limited efficacy and 
significant toxicity of this approach has led to the exploration of the 
immunostimulatory potential of bacterial components or genetically modified bacteria. 
On the other hand, with the discovery of interferons in the mid 1950s, the vast 
research field of inflammatory cytokines has been opened. IFNs, TNFs, ILs and the 
other cytokines were studied with great expectations. Local cytokine administration 
was considered as one possible approach. TNF can arrest proliferation of tumor cells 
and prevent the angiogenesis necessary for tumor growth. IFN can demonstrate direct 
cytotoxic and possibly anti-proliferative properties. It can also enhance MHC 
expression and thereby potentially increase the efficiency of antigen processing and 
recognition. IL-2 is a T-cell growth factor and can stimulate lymphocyte proliferation, 
enhance cytolytic-T-cell activity, induce natural killer cell activity, and induce IFN-γ 
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and TNF. However, in spite of enormous efforts, beneficial responses in clinical trials 
were rare. With the exception of a small subset of patients with advanced renal cell 
carcinoma and malignant melanoma responding to IFN-α or IL-2 treatment, most 
solid tumors, high-risk leukemia and lymphomas are largely resistant to 
administration of cytokines. 
Specific active immunotherapy attempts to induce cell-mediated and/or antibody 
immune responses focused on specific antigens expressed by tumor cells. Even the 
immune system can impact on tumor growth in several ways, it is well accepted that 
the most effective way of eradicating a tumor mass in vivo is through the combined 
action of CD8+ and interferon-γ (IFN-γ)-secreting T-helper 1 (Th1) CD4+ T cells. For 
this purpose, vaccination using either whole cells, proteins, peptides or a wide variety 
of immunizing vectors is the most common and efficient approach applied in specific 
active immunotherapy. However, the performance of anti-tumor vaccines in clinical 
trials is not satisfying; these vaccines have only succeeded in bringing about sporadic 
regressions and temporary stabilization. Effective T cell activation involves two sets 
of signals. One is mediated by MHC molecules performed antigenic peptides 
presentation to TCR; the other is mediated by the interaction of co-stimulators 
expressed on APCs with counter-receptors expressed on T cells. Therefore, the 
efficacy of a cancer vaccine would be improved by identifying highly immunogenic 
TAAs, the effective vaccine adjuvant and the optimal vaccine formulation and 
immunization strategies. We will discuss more in detail in the next chapter about the 
history, the actuality and the perspective of anti-tumor vaccine development. 
A-III-b Passive (or adoptive) Anti-tumor Immunotherapy 
Passive anti-tumor immunotherapy refers to the approaches that supply an active 
extrinsic immunity rather than activating the intrinsic immunity. The transferred 
immune response could be cell mediated or antibody-mediated.  
Adoptive cell transfer (ACT) is a form of immunotherapy by which antitumor 
lymphocytes are induced and expanded ex vivo and then infused to the host. In 
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practice, because of MHC restriction, the lymphocytes manipulated ex vivo are 
normally autologous. Lymphocytes are collected from host, stimulated in vitro and 
finally re-infused to host. This approach has been investigated both in infectious (e.g., 
Epstein-Barr virus (EBV), Human immunodeficiency virus (HIV)) and malignant 
disease (metastatic melanoma). The clinical application of this approach was initially 
performed in 1980s as the activation of lymphocytes of cancer patients through 
non-tumor-specific signals. In several trials, the lymphocytes isolated from patients 
with advanced tumors were stimulated in vitro by IL-2 (lymphokine-activated killer 
cells, LAKs) and then re-infused along with high dose of IL-2. Objective responses 
have been obtained, whereas it was not sure that the responses were due to the 
effection of LAKs or IL-2. So far, some progress has been achieved to improve the 
efficacy of transferred lymphocytes. First, in vitro tumor infiltrating lymphocytes 
(TILs) preparation has been directed to the selection, stimulation and expansion of 
antigen-specific T cells. In general, TILs were screened by cytokine secretion assay 
for recognition of autologous tumor cells or allogeneic tumor cell lines. The TIL 
clones that exhibited specific tumor cell recognition were then expanded with 
irradiated allogeneic feeder cells, T-cell-stimulating antibody OKT3 (anti-CD3) and 
IL-2. Despite the high in vivo frequencies of tumor reactive effector cells achieved, 
only a fraction of patients responded because of the short persistence of these 
transferred cells in vivo. Later experiments revealed that preconditioning 
(lympho-depletion) of patients with cyclophosphamide and fludarabin was necessary 
for the survival and expansion of the infused TILs. Single-arm Phase II studies from 
separate institutions have shown objective response rates of 50% in patients with 
metastatic melanoma who are receiving this treatment. Approximately 10% of 
patients obtained a complete response, which may be durable. In the latest clinical 
trials, individualized and cumbersome micro-culture prepared tumor-reactive T cells 
are being superseded by genetically engineered TCR – transduced T cells for ACT, in 
which genes encoding TCRs with defined antitumor properties are transduced into 
short-term cultured peripheral blood lymphocytes. This therapy is potentially 
accessible to any patient whose tumor possesses the cognate human leukocyte antigen 
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(HLA) allele and expresses the target antigen recognized by the TCR. The first studies 
performed by the national cancer institute (NCI) using HLA-A2–restricted TCRs 
against melanoma antigen MART-1/Melan-A or gp100 leaded to objective responses 
in 20–30% of patients, while objective responses occurred in only 13-19% patients 
received ACT using native TCRs. However, the clinical use of highly avid TCRs has 
been associated with significant collateral destruction of normal tissues sharing the 
target antigen. Thereby, current efforts attempt to optimize gene transfer efficiencies, 
design TCR structural modifications, and identify target antigens, the expression of 
which is highly selective in tumor rather than non-transformed cells. Currently, 
although ACT clinical protocols with altered techniques are still being defined, ACT 
is the most effective treatment for patients with metastatic melanoma. 
The discovery of monoclonal antibodies (mAbs) by Köhler and Milstein was the 
major breakthrough that leaded scientists to exploit the potential approach for tumor 
immunotherapy. mAb can induce tumor cell lysis through the different mechanisms, 
including antibody-depended cellular cytotoxicity, complement-mediated cytotoxicity, 
and enhancement of the adaptive immune response. Rituximab was the first mAb 
applied in clinical trial and approved by the US Food and Drug Administration (FDA). 
It can recognize the B cell antigen CD20 and can mediated complement-depended 
cytotoxicity and antibody-depended cellular cytotoxicity, which can induce the 
apoptosis in CD20+ B cell lymphomas. After that, remarkable progress has been 
achieved in this domain. Until now, a number of mAbs have been approved by FDA 
(98). They can be generally classified into two categories: Naked mAbs and 
Conjugated mAbs. For the second type, radio-labeling or conjugation with toxins 
further improved efficacy of monoclonal antibodies. Furthermore, More than 100 new 
therapeutic antibodies targeting different epitopes and multiple modifications of the 
antibody structure are now in different phases of their preclinical or clinical testing, 
which predict a great prospect for improving antitumor efficacy. 
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B - Cancer Vaccines 
The development of cancer vaccines attempting to enhance the immune response 
against a tumor is a promising area of research. The term of cancer vaccine refers to a 
vaccine that could prevent either infections with cancer causing pathogen or the 
development of cancer in high risk individuals and treat existing cancer (104). 
Advances in molecular immunology and cancer biology have brought out impressive 
progress in this field. Several examples present the great promise of vaccination 
approach in terms of cancer, such as, following a nation-wide hepatitis B vaccination 
program in Taiwan, the incidence of hepatocellular carcinoma substantially declined 
in children (105); also, human papillomavirus-positive cervical cancer can be 
clinically prevented through the vaccination with a recombinant viral capsid protein 
and the Human papillomavirus (HPV) subunit vaccines have been already developed 
(106); moreover, there are also some experimental vaccines which could be hopeful in 
minimizing cancers associated with virus infection, including vaccines against the 
hepatitis C virus (hepatomas) (107), EBV (Burkitt lymphoma, nasopharyngeal 
carcinoma) (108), human T-cell lymphotropic virus type 1 (HTLVI, adult T cell 
leukemia) (109). 
However, despite ongoing efforts to develop effective therapeutic vaccines 
against tumors, little progress has been obtained in clinical applications. It is possibly 
because that the vaccines have not yet adequately simulated critical aspects of a 
curative immune response. The simplest model of immune cell mediated antigen 
specific tumor rejection consists of three elements: appropriate antigen, efficient 
antigen presentation and the generation of potent effector cells. At this level, there are 
many hurdles which limit the development of cancer vaccine, such as: identification 
of antigens that could exploit the exquisite specificity of the immune system against 
cancer cells without harming normal cells; development of methods to induce an 
immune response sufficient to eradicate the tumor, in the face of self-tolerance to 
many tumor antigens; and overcoming the mechanisms by which tumors evade the 
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host immune response. Therefore, the efficacy of a cancer vaccine should be 
improved by identifying highly immunogenic tumor specific or associated antigens, 
using efficient antigen delivery system that stimulate the appropriate specific immune 
response and defining the optimal vaccine formulation and immunization strategies. 
So far, many aggressive strategies have been devised in many laboratories for the 
purpose of producing an effective vaccine (110). A number of therapeutic cancer 
vaccines have been already tested in animals and subsequently in humans (111).  
In this part, we will discuss the progress made in developing cancer vaccines, 
including: 1) the discovery and characterization of tumor antigens used as targets for 
vaccination; 2) cancer vaccine modalities; and 3) recent strategies for cancer vaccines 
improvement. 
B-I Tumor Antigens 
The identification of tumor rejection antigens existence is the crucial 
breakthrough for antigen-based cancer immunotherapy. In the last decades, many 
tumor antigens have been successively identified (112, 113). In general, tumors 
antigens can be divided into two classes: neo-antigens (tumor specific antigens, TSAs) 
and self antigens (TAAs). TSAs are derived from mutated self-proteins (such as 
mutated p53 protein and mutated RAS protein) or oncogenic virus (such as HPV-16 
for cervical cancer or EBV latent phase proteins for nasopharynx cancer) (112). This 
class of antigens is expressed exclusively by tumors but not in normal tissue. Thereby, 
they are foreign and not expressed in the thymus, TSAs activated lymphocyte 
precursors can escape thymic deletion and have a high affinity for the antigens so that 
antigen-specific immune response is strong.   
TAAs are expressed not only by tumor cells with abnormal quantities or 
locations, but also in the normal tissues including the thymus. For these reasons, 
TAAs activated lymphocyte population could either be deleted in the thymus or have 
a low affinity for the antigens which lead to a weak antigen-specific immune response. 
TAAs can be sub-classified in three categories (37, 112): 1) tissue-specific 
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differentiation antigens, such as MART1/MelanA, gp100 and Tyrosinase Related 
Proteins (TRP) for melanoma are melanocyte specific; 2) the proteins that are 
over-expressed in tumor cells and promote cell growth by anti-apoptotic (such as 
survivin) or growth factor (such as HER2/neu) activities; 3) cancer/testis (C/T) 
antigen: the proteins that are more or less specifically expressed in various cancers, 
but almost totally absent in normal tissues, such as the MAGE, GAGE and BAGE 
protein families which are only normally expressed in testis in the adult, but can also 
be expressed in melanoma, mammary adenocarcinomas, the lung carcinoma, bladder 
carcinoma ... 
B-II Cancer Vaccine Modalities 
 
Figure 7: General Cancer Vaccine Modalities.  
Various forms of vaccines can be essentially classified in three types: cell-based vaccine, 
protein-based vaccine and vector-based vaccine. 
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Actually, various forms of vaccines are being implicated for prevention or 
treatment of cancer. Essentially, they can be classified in three types: cell-based 
vaccines, protein-based vaccines and vector based vaccines (Fig. 7). Each of them 
presents the attractive properties as well as the limitations. 
B-II-a Cell-based Vaccines 
Cell-based vaccines generally consist of whole tumor cell-based vaccines and 
dendritic cell-based vaccines. This class of vaccines has been extensively explored 
with different tumor models in both preclinical and clinical trials. Some recent clinical 
applications of cell-based cancer vaccines are summarized in table 1. 
Table 1: Some Cell-based Vaccines Applied in Recent Clinical Trials. 
Cell-based vaccines Tumor model Ref. 
Autologous tumor cell based 
vaccine 
Melanoma 
Glioma 
Leukemia   
Colorectal cancer 
Renal cell carcinomas 
Non small cell lung cancer 
(114-116) 
(117, 118) 
(119) 
(120-122) 
(123, 124) 
(125) 
Allogeneic tumor cell based 
vaccine 
Melanoma 
Renal cancer 
Prostate cancer 
Non small cell lung cancer 
(126, 127) 
(128, 129) 
(130, 131) 
(132) 
DCs based vaccine Melanoma 
Glioma 
Breast cancer 
Renal cell cancer 
Rectal cancer 
Prostate cancer 
Non small cell lung cancer 
(133-135) 
(136-138) 
(139, 140) 
(140-142) 
(143) 
(144-146) 
(147-149) 
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Whole Tumor Cell Vaccines 
In recent decades, even series of TSAs or TAAs have been identified, 
characterized and further applied as targets in anti-tumor immunotherapy, there are 
undoubtedly a large number of antigens remaining undiscovered. Thereby, the appeal 
for using irradiation inactivated whole tumor cells as antigen sources has immerged, 
because a broad range of TSAs or TAAs including the antigens that are not yet known 
could be presented to T cells.  
Whole tumor cell vaccines can be divided into two subsets (150): 1) autologous 
vaccines in which tumor cells used as a vaccine for a patient derive from the same 
person; 2) allogeneic vaccines in which tumor cells derive from other patients, usually 
from pre-existing tumor cell lines.  
For preparing autologous tumor cell vaccines, autologous tumor tissues are 
generally obtained during the surgery and then cultured and processed in vitro. The 
consistency between the antigen source of a vaccine and those expressed by patient’s 
tumor cells is very crucial for vaccine performance. Use of patient’s own tumor cells 
as antigen source can ensure the optimal HLA matching and maximize the 
tumor-specific antigen matching, which is the obvious advantage of this type of 
vaccines. However, with the requirement for in vitro processing or culture, there may 
be a significant delay between surgical treatment and vaccine administration. 
Moreover, individualized manipulation, high cost of production and quality control 
are also required for the preparation of this type of vaccines. These challenges led to 
the limit application of autologous tumor vaccines. (150) 
Allogeneic tumor cell vaccines express a similar load of antigens as autologous 
tumor cell vaccine. As allogeneic tumor cells do not show the perfect HLA matching 
and tumor antigen matching as autologous tumor cells do, allogeneic tumor cell 
vaccines are normally composed of a mixture of several selected allogeneic tumor cell 
lines that express high levels of tumor antigen and present a partial HLA matching to 
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most of the potential patient population. Such pattern can be hoped to give a better 
antigenic spread and generate an effective immunity. Presently, unmodified allogeneic 
cells have been used in clinical trials for melanoma and prostate cancer. The most 
advanced use of unmodified allogeneic cells in clinical trials comes from Donald 
Morton’s group (151-153). A panel of 150 cell lines was tested and three cell lines 
(M10VACC, M24VACC and M101VACC) were selected for the use as vaccine 
(Canvaxin, Cancer Vax Corporation, Carlsbad, CA, USA) that expressed relatively 
high level of melanoma antigens and a spectrum of HLA types with a spatial match 
for approximately 95% of melanoma patients. Canvaxin is now the most thoroughly 
tested allogeneic live whole cell vaccine. Phase II studies demonstrated that 
immunization with Canvaxin resulted in prolonged survival in the treatment group 
compared with a control group receiving no vaccine. In the adjuvant treatment setting, 
the vaccine has also shown promising results. However, the results of phase III trials 
were disappointed, there was an excellent survival for the entire study population and 
no significant difference was found between the treatment group and the BCG control 
group. Beside of this, another vaccine composed of three irradiated prostate cancer 
cell lines (OnyCap23, LnCaP, and P4E6) has also been tested and its efficacy has been 
demonstrated against hormone-resistant prostate cancer in clinical trials (131). 
Compared with autologous tumor cell vaccines, allogeneic tumor cell demonstrate 
several advantages, including: 1) vaccines do not need to be individually prepared; 2) 
vaccines can be industrially prepared in large quantities and can be administrated 
immediately; 3) the quality control of vaccines can be more easily realized.  
Tumor cells alone are generally poorly immunogenic, presumably because of 
low immunogenicity of TAAs, down-regulation of MHC molecules, the lack of 
adequate co-stimulatory molecule expression, secretion of immuno-inhibitory 
cytokines, etc. Thereby, whole tumor cells are usually administered together with 
adjuvants or cytokines. Adjuvants, such as aluminum salts, oil and water emulsions 
and bacterial (BCG, Detox) or viral compounds, can non-specifically stimulate the 
immune system and strengthen the immune responses to the target antigen. Besides, a 
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number of cytokines, such as GM-CSF, IL-2 and IFNs are administered with tumor 
cells to create a pro-inflammatory environment in which antitumor responses will 
arise. Such adjuvants and cytokines can be administrated at the site of vaccination or 
systemically (150). 
Moreover, not only the whole tumor cells, but also the lysates of tumor cells can 
be used as an antigen source. The popular method of preparing tumor cell lysates is by 
repetitive freeze-thaw cycles to induce tumor cell necrosis. Lysates on one hand retain 
the most of the antigen diversity of whole cells; on the other hand, represent several 
advantages compared with whole tumor cells, including: 1) tumor cell’s replication 
incompetence is assured; 2) lysates don’t need the significant care to maintain the 
viability of cells and can be lyophilized or frozen. However, compared to whole tumor 
cells, lysates represent some limits, some epitopes are possibly lost through separation 
of the nuclear fraction and degradation of mRNA, and also more labor will be 
required (154). It has been proved that the antigens contained in tumor cell lysates can 
be taken up by DCs and subsequently be presented in MHC II context to CD4+ T 
cells; and, the antigens can be presented by DCs to CD8+ T cells through 
cross-presentation pathway (155, 156). As the cross-presentation process require 
certain conditions which is more easier to be achieved in vitro, current lysates based 
vaccine strategies generally apply lysates to DCs first in vitro and then administer the 
loaded cells as vaccine. Until now, lysates-based vaccines have been investigated in 
patients with different types of cancer, such as hepatocellular carcinoma (157), colon 
carcinoma (158), breast cancer (159), renal cell carcinoma (160), thyroid carcinoma 
(161), leukemia (162), etc. 
Genetically Modified Tumor Cell Vaccines  
Although systemically administered cytokines have been used to treat advanced 
cancers with some success, treatment with cytokines is often associated with profound 
toxicity for the patient, especially when used in high doses. Thereby, great efforts 
have been performed to generate genetically modified autologous or allogeneic tumor 
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cells which can secret the cytokines themselves. Among the cytokines, transduction of 
weakly immunogenic tumor cells to express GM-CSF or IL-2 has been actively 
investigated. GM-CSF can lead to the recruitment and differentiation of DCs. In 
animal studies, it has been shown that immunization with tumor cells expressing 
GM-CSF led to a long lasting systemic antitumor immunity (163, 164). In clinical 
trials, it has been tested in different cancer models, such as prostate cancer (165), 
metastatic malignant melanoma (166) and non-small cell lung cancer (167). IL-2 is a 
growth factor for lymphocytes and has been shown to restore responsiveness in 
anergic or unresponsive T cells. In animal studies, immunization with the engineered 
tumor cells secreting IL-2 resulted in a reduced tumorigenicity and a long lasting 
protective immunity (168, 169). Tumor cell vaccines transferred with IL-2 gene have 
also been investigated in clinical trials, largely in melanoma model (170-172). 
Besides, there are also other cytokines that have been investigated using this strategy, 
such as IL-4, IL-6, IL-7, IL-12, IFN-γ, etc. 
Moreover, as the poor immunogenicity of tumor cells is partly due to the absence 
of co-stimulation, some studies have also focused genetically induced co-stimulator 
expression on tumor cells. Co-stimulation is normally provided by APCs that take up 
and present antigens to T cells. Engineered tumor cells expressing co-stimulator 
molecules could behave more like the APCs and probably prime efficient antitumor 
immune responses. B7-1 and B7-2 molecules have been largely studied in both 
animal and clinical trials. In murine model, it has been shown that B7-transfected 
tumor cells can elicit CTL responses (173) and can protect against tumor challenge in 
curative models (174, 175). B7-1 gene modified tumor cell vaccine has also been 
tested in clinical trials against different cancer models (176-178). Similarly, there are 
also some other co-stimulatory molecules, such as CD40L (179, 180), intracellular 
adhesion molecule (ICAM-1), lymphocyte function-associated antigen (LFA)-3 (181), 
etc. have been transduced to tumor cells to prime and strengthen antigen tumor 
response.  
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DCs Vaccines 
DCs are considered as the most potent antigen presenting cells and the most 
powerful stimulators of naïve T cells. Due to this endowed property, DC-based 
vaccination represents a potentially powerful strategy for cancer immunotherapy and 
has become the focus of a vast array of scientific and clinical studies. Beside the 
classic MHC I and II antigen presentation pathway that DCs profit to present antigen 
to CD8+ and CD4+ T lymphocytes, respectively, DCs are also capable of 
cross-presenting exogenous Ags in MHC I context to generate antigen specific CTLs. 
This specialized capacity made DCs become one of the focal points of anti-tumor 
immunotherapy.  
DCs can be exogenously loaded with TAAs through numerous approaches, 
including: 1) pulsed with synthetic peptides; 2) pulsed with protein; 3) pulsed with 
tumor lysates or apoptotic tumor cells; 4) fused to tumor cells; 5) transfected with 
cDNA or RNA encoding known TAAs; 6) infected with a viral vector. Up to now, 
TAAs loaded DCs vaccines have been widely tested in animal models as well as in 
clinical trials without any dose-limiting toxicity (182-186). In particular, one of 
autologous-DCs based therapeutic cancer vaccines for the treatment of advanced 
prostate cancer – Provenge (APC8015, also called Sipuleucel-T) has been recently 
approved by the USA Food and Drug Administration (FDA). Provenge is 
manufactured by Dendreon Corporation and is the only FDA-approved autologous 
cellular immunotherapy indicated for the treatment of asymptomatic or minimally 
symptomatic metastatic castrate resistant prostate cancer (CRPC) (187). Provenge is 
designed to train patient's immune system to seek and attack prostate cancer cells. 
One course of Provenge treatment consists of three basic steps (Fig. 8). Firstly, 
patient’s autologous peripheral blood mononuclear cells are extracted in a 
leukapheresis procedure. Then, the blood product is sent to the factory for the 
preparation of Provenge which involves enrichment for antigen-presenting cells from 
the leukapheresis product and activation ex vivo through incubation with a fusion 
protein (PA2024). PA2024 consists of two parts: one is the antigen prostatic acid 
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phosphatase (PAP) which is present in 95% of prostate cancer cells; the other one is 
GM-CSF that helps the APCs to mature. Finally, the activated blood product is 
re-infused into the patient to cause an immune response against cancer cells carrying 
the PAP antigen. Until now, Provenge showed overall survival (OS) benefit to patients 
in three double-blind randomized phase III clinical trials, D9901 (144), D9902 (145) 
and IMPACT (146). Presently, Dendreon Corporation continues to investigate this 
individual approach to treat cancer in other tumor types. 
 
Figure 8: Diagram Explanation of PROVENGE Action Mechanism. Reprinted from 
www.provenge.com. 
Although clinical trials have demonstrated immunological responses after 
vaccination with DCs loaded with tumor specific peptides, peptide-based vaccines are 
limited in their application because the use of specific TAAs depends on the 
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identification of relevant TAAs, but not all tumor cells have well defined TAAs. 
Moreover, both MHC I and MHC II epitopes are required for efficient T cell priming, 
while a number of MHC-I restricted peptides have been identified, fewer MHC II 
epitopes are known. However, loading DCs with tumor lysates or apoptotic tumor 
cells and fusing DCs with whole tumor cells could overcome these limits. Through 
these approaches, a broad spectrum of tumor-associated antigens, including those 
known and unidentified, are processed and presented on MHC I and MHC II 
molecules in the context of DCs-derived co-stimulatory signals to stimulate CD8+ 
and CD4+ T-cells. In animal models, tumor cell pulsed or tumor cell fused DCs could 
promote significant protective immunity against parental tumors (188-192). In the 
clinical trials, clinical and immunological responses were observed in patients with 
advanced stage of malignant tumors after being vaccinated with tumor cell-pulsed 
DCs or DC/tumor fusion cells, although the antitumor effect is not as vigorous as in 
the animal tumor models (135, 193-196). 
Besides pulsing approaches, genetic modifications of DCs with genes encoding 
whole tumor antigens, widely mediated by adenoviral vectors (AdVs), recombinant 
poxviruses (rPs), and mRNA electroporation, have been investigated against a broad 
range of tumor models (197). In animal experiments, TAA-transduced DCs 
vaccinations have elicited stronger immune responses and led to obvious tumor 
protection (198-201). In clinical trials, this kind of vaccines has primed effective TAA 
specific T cell responses and contributed to promising clinical outcome (202-207). 
Compared to peptides or proteins loading methods, this pattern represents several 
advantages, including: 1) be capable of enhancing T cell priming potential via antigen 
presentation; 2) can avoid limitations associated with pulsing of DCs with defined 
TAAs, such as TAA identification requirement: modification of DCs with entire 
cancer cell-derived genetic material may enable them to present defined and 
uncharacterized TAAs to immune cells and to stimulate polyclonal cancer specific 
CTLs; 3) allow long lasting expression of introduced genes; 4) matching of MHC 
molecules is not required, the same gene construct may be inserted into DCs derived 
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from different patients. (97, 208) 
In addition to loading DCs with TAAs, genetic approaches have also been used 
to introduce cytokine production (such as GM-CSF, IL-12, IL-2, IL-10, IFN-γ, etc.) or 
co-stimulatory molecules expression (such as CD40L, B7-1, etc.) on DCs to enhance 
their abilities. For example, GM-CSF is a key cytokine for the generation and 
stimulation of DCs, DCs transfected with GM-CSF demonstrated increased antigen 
presentation, better migration capacity and a prolonged lifespan, which contributed to 
an enhanced anti-tumor immune response in vitro and in vivo (209, 210). In a similar 
way, CD40L is usually expressed by CD4+ T cells, recent studies suggested that 
stimuli from CD4+ T-helper cells via the CD40/CD40L interaction could increase DC 
immune-stimulation with up-regulation of CD80/CD86- and interleukin-12 (IL-12) 
expression, which is the essential state of DCs for triggering antigen-specific T-cell 
responses (211-213), therefore numerous studies have focused on genetically 
expressing of CD40L on DCs to enhance the efficacy of DCs based the cancer 
vaccines (214-216).    
B-II-b Protein-based Vaccines 
Protein Vaccines 
Protein vaccines generally consist of single or combined tumor antigens. This 
kind of vaccines has been investigated in both animal and clinical trials and is usually 
administered with adjuvant, such as GM-CSF, IL-2, IFN-α, CpG, etc., to produce a 
strong and long-lasting immune response (217-219).  
In addition to tumor antigen based approach, a family of heat shock proteins 
(HSPs) has also been intensively studied and applied in actual cancer immunotherapy. 
HSPs are molecular chaperones that exist in almost all the sub-cellular compartments 
of eukaryotes and prokaryotes. Under normal condition, many of HSPs are chaperons 
that help protein folding and intracellular transport of peptides. HSPs can be 
unregulated by a variety of environmental stress, such as heat shock, fever, oxidative 
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stress, inflammation, etc., as well as by internal stresses, like malignant cell 
transformation. In 1980s, Srivastava et al. first proposed that certain HSPs purified 
from a particular tumor can elicit specific immune responses against that tumor. 
Afterwards, great amount of work has focused on the characterization of HSPs and 
their application in cancer immunotherapy (220). 
Biochemical studies reported that the low molecular weight antigenic peptides 
were associated with HSPs preparation from tumor cells (221, 222), which proposed 
that certain HSPs perform the peptide-binding properties similar to that of MHC 
proteins. To confirm this theory, a number of studies revealed the existence of 
peptide-binding pocket frame in HSPs molecules, which provided the structural 
support (223-225). Then, immunological studies demonstrated that the HSP-peptide 
complexes can elicit a potent antigen specific adaptive cellular response. HSP-peptide 
complexes can be untaken and endocytosed by APCs through specialized receptors, 
such as CD91 and LOX-1. Once be internalized, the antigenic peptides carried by 
HSPs can be channeled into the endogenous presentation pathway and presented in 
MHC I context to activate CD8+ T cells (called cross-priming) (226, 227). In a 
variety of murine cancer models, vaccinations with certain HSPs induced anti-tumor 
activity via the generation of tumor reactive CTLs (228).  
In the other hand, some studies also demonstrated that independent of their 
bound peptides, HSPs are endowed also the immunomodulator property to prime an 
innate immune responses. HSPs released by dead or dying cells can be regarded by 
immune system as danger signal and be acquired by APCs through specialized 
receptor. HSP–APC interaction leads to up-regulation of co-stimulatory molecules on 
APCs and secretion of pro-inflammatory cytokines or chemokines. TLR 2/4 and the 
downstream MyD88/NF-kB pathway have been proposed to mediate the 
HSP-triggered APCs activation (229). Therefore, HSPs are also considered as natural 
adjuvants. 
These specialized immune-stimulatory properties of innate and adaptive 
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immunity lead HSPs to be widely utilized in various cancer vaccines design. Up to 
now, different types of HSPs based cancer vaccines have been developed, including: 1) 
autologous tumor-derived HSP vaccine; 2) reconstituted HSP–peptide complex, in 
which multiple peptides from different tumor antigens can be selected to create a 
polyvalent vaccine to generate a more vigorous immune response; 3) HSP–antigen 
fusion gene, which uses HSPs in a form of chimerical DNA through linkage of a 
known antigen gene to the HSP gene; 4) recombinant HSP–antigen fusion proteins; 5) 
ex vivo expanded HSP pulsed DC vaccine; 6) genetically modified HSP 
over-expressing tumor cells vaccines (230). The efficacy of HSPs based vaccines has 
been evaluated in animal models (231-234) as well as in clinical trials against 
different tumor models; promising results have been obtained in human tests 
(235-237).  
Peptide Vaccines 
Peptides derived from tumor-associated antigens and recognized by patient T 
cells have been firstly defined in the early of 1990's. The observation that short 
peptide segments (8–10 amino acids) fit into a groove in MHC molecules, combined 
with knowledge of the amino acid sequences of tumor epitopes, prompted the use of 
peptides as therapeutic agents in the treatment of cancer. 
The use of peptides as immunogens demonstrates several advantages, such as: 1) 
this approach has been shown to facilitate the breaking of tolerance to self, for 
example in the case of Her-2/neu (238); 2) it can minimize the potential for inducing 
autoimmunity when compared to the use of a whole protein, which might share 
fragments with normal cellular proteins; 3) peptides can be modified to increase their 
immunogenicity and the affinity for the relevant MHC molecules; 4) synthetic 
peptides are chemically stable and free of bacterial/viral contaminating substances and 
are devoid of oncogenic potential; 5) the preparation of peptides is relatively easy and 
inexpensive (239). 
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It has been widely found that immunization with native peptide sequences was 
often insufficient to generate reactive T cell response in both animal and clinical trials, 
which is probably because of the poor immunogenicity of peptides, the lack of CD4+ 
helper-T-cell activation and the escape of tumor cells. Several strategies have been 
developed both to improve immunogenicity and to steer the immune system toward 
desired types of responses. First, the epitopes applied into the peptides vaccines can 
be improved by sequence modification, a strategy called epitope enhancement. This 
strategy can be used: 1) to increase the binding ability of peptides to MHC molecules 
and the binding stability between peptides and MHC molecules, which has been 
applied to tumor antigens like p53, gp100, PSA, MUC 1 (240-243); 2) to increase the 
affinity of peptide-MHC complex to TCRs, which has been applied to, for example, 
carcinoembryonic antigen (CEA) and p53 (244, 245); 3) to inhibit the proteolysis of 
peptides by serum peptidases (246). Second, incorporation of cytokines, chemokines, 
co-stimulatory molecules or other immunomodulators with peptide vaccines can 
enhance the immune response. In this category, a series of adjuvants have been 
applied alone or in combination, such as GM-CSF which can provoke the recruitment 
and differentiation of DC, CD40L or agonistic anti-CD40 which can induce DCs 
maturation, IL12 and IL15 which are Th1/CTL-supporting cytokines, 
CpG-oligodeoxynucleotide which are shown to elicit a broad range of immune 
responses (247-250). Moreover, as CD4+ Th cells activation is necessary for inducing 
an efficient CTL response, inclusion of helper T cell epitopes has also been tried to 
enhance the efficacy of peptides vaccines. Some papers reported that using peptides 
with broad MHC II binding, such as pan-HLA-DR-binding peptide (PADRE), 
endogenous helper epitopes or enhanced helper epitopes, to stimulate CD4+ Th 
responses also resulted in increased CD8+ CTL responses (251-253). Also, peptides 
can be loaded onto DCs or other APCs, which will be used as autologous cellular 
vaccines. The significant advantages of this approach are that DCs are the most potent 
APCs that could effectively activate naïve T cells and thereby can serve as the natural 
adjuvant; the loading of peptides and the induction of DCs maturation in vitro can be 
easily achieved. 
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Despite impressive results in animal models, the application of peptide vaccines 
in humans has met with only limited success, their efficacy remains to be ultimately 
proven. Moreover, individual peptides will be useful only in patients with appropriate 
HLA molecules capable of presenting that peptide, which might be also a potential 
restriction for this vaccine model. 
Anti-idiotype Antibodies 
Immunization with anti-idiotype (Id) antibodies (Abs) represents an attractive 
approach for tumor immunotherapy. This approach is based on Niels Jerne's idiotypic 
network theory. According to the network concept (254), an antigen generates 
antibodies (Ab1) whose serologically unique structure (idiotype) can induce the 
production of anti-Id Abs (Ab2). Some of these Ab2 molecules (Ab2β) are specific for 
the variable antigen-binding region of Ab1, and can function as an “internal image” of 
the target antigen by mimicking its three-dimensional structure. Immunization using 
these Ab2β antibodies should stimulate the production of anti-anti-Id antibodies (Ab3 
also called Ab1’) that recognize the original Ag. This cyclic nature of complementary 
binding sites and idiotype is the basis for the approach to idiotype vaccines. 
The administration of Ab2β as surrogate tumor-associated antigens represents a 
potential application of the idiotype vaccine concept and exhibit several advantages. 
The anti-idiotype hybridoma route of making surrogate antigens could alleviate the 
problem of preparing large amounts of purified antigens associated with a given tumor. 
Also, the internal antigens which are expressed in a different molecular environment 
may be able to overcome the immunosuppression and break the tolerance in the host 
by stimulating “silent” clones, or by activating T cell help, making the overall 
immune response stronger than the nominal antigen is capable to do. In addition, by 
virtue of being proteins, anti-idiotype antibodies can be easily manipulated and 
coupled to potential immunogenic carrier molecules to make them T cell dependent 
antigens which can receive full T help. Furthermore, idiotype-based tumor antigens 
used for immunotherapy are free of the potential danger of transmitting tumor viruses. 
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(255) 
This strategy has been applied in different cancer models, such as B cell 
lymphoma, melanoma, colorectal cancer, ovarian cancers, and breast cancer 
(reviewed in Ref. (256)). Active immunization with tumor-specific anti-Id vaccines 
has been shown to inhibit the growth of tumors and cure mice with established tumors 
in animal models (257). Results obtained in human trials were promising, using, some 
experience using anti-Id to stimulate immunity against tumors has shown that 
immunization with true anti-Id reagents (Ab2β) can induce both cellular and humoral 
immunity (258-260). 
The main problem for this strategy is that the Id is not only tumor-specific but 
also patient-specific. And also, large-scale feasibility remains still questionable for 
this moment. 
B-II-c Vector-based Vaccines 
The effectiveness of a vaccine depends upon optimal therapeutic gene expression, 
an appropriate DNA delivery method and the presentation of antigen to lymphocytes. 
Actually, the design of efficient vectors for cancer vaccine development is an area of 
intensive research. They should be able to deliver in vivo heterologous antigens into 
the antigen-processing pathways to stimulate MHC class I-restricted CTL responses 
as well as Th response. The different antigen delivery systems can be essentially 
classified in two categories, non pathogenic based vectors, such as DNA plasmid, 
liposome, cationic peptides (cell-penetrating peptides, CPPs) and yeast vectors; and 
pathogenic based vectors including viral and bacterial vectors. 
Plasmid DNA 
Plasmid DNAs are simple antigen delivery vehicles that can be easily designed 
and produced in vitro. Plasmid DNA vaccines are based on bacterial plasmids that 
have been engineered to express the target antigen using promoter elements that are 
active in mammalian cells. They also contain a transcriptional terminator to terminate 
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transcription in mammalian cells and a selectable marker to facilitate production of 
the plasmids in transformed bacterial cells. After administration, the role of plasmid 
DNA vaccines is duplex. On one hand, the antigen encoded by the plasmid is 
produced in host cells, either in professional antigen presenting cells (APCs) leading 
to direct priming of immune responses or in non-professional cells from where the 
antigen can be transferred to APCs leading to cross-priming. On the other hand, 
because DNA plasmids are derived from bacteria DNA, they stimulate the innate 
immune system by interacting with specific Toll-like receptors. This non-specific 
immune response increases the antigen-specific immune response (261).  
Initial studies focused on the application of naked plasmid DNA vaccines. In 
general, naked plasmid DNA vaccines were administered trough intramuscular way. 
The action of DNA vaccines relies on the ability of myocytes to engulf the plasmid. 
Plasmid secreted by the myocytes or as such can also be taken up by APCs infiltrating 
the injected site. Meanwhile, some of the DNA might also be endocytosed by APCs 
infiltrating the site of injection or in the lymph nodes following its migration to the 
lymphatics (262). Studies in animal models have demonstrated the feasibility of 
utilizing plasmid DNAs to induce both specific humoral and cell-mediated immune 
responses and elicit protective antitumor immune responses. (263, 264). Besides of 
this, the use of plasmid DNA demonstrated also some advantages, including that: they 
are easy and inexpensive to generate and can be tested rapidly; they do not require 
special handling or storage conditions; multiple or multi-gene vectors encoding 
several antigens and immune-modulatory molecules can be delivered as single 
administration; plasmid DNA vaccination will not generate anti-vector immune 
responses, thereby there is no preexisting immune responses that might interfere with 
the ability of the plasmid to be used or reused (265). 
However, plasmid DNA vaccines were less efficient when tested in clinical trials. 
The inability of plasmid DNA vaccines to induce potent immune responses in humans 
may be mainly related to their low immunogenicity and associated with the fact that 
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high doses of plasmid DNA were needed to induce a sufficient cell-mediated 
immunity (CMI) (reviewed in ref (266)). 
A variety of strategies are being followed to increase the immunologic potency 
of DNA based genetic immunization. In general, they could be classified in to 3 types: 
1) physical delivery technologies: forcing the plasmid DNAs into cells of either the 
skin or muscle through intramuscular needle injection (267); application by 
bombardment using DNA-coated gold particles (268), electroporation following 
needle injection (269), jet injection (270) or topical exposure to mucosal sites; 2) 
application of adjuvants; 3) formation with different delivery system to target APCs. 
Most application methods were shown to induce more or less strong protective 
immune responses in a series of experimental animal models  
Liposomes 
In recent years, the use of liposomes as potential antigen carriers for cancer 
vaccines has been extensively explored.  
Liposomes are spherical vesicles composed of one or more phospholipid 
bi-layers and an internal aqueous center and they are capable of encapsulating both 
Ag and immunomodulator agents (271). The target agents can be carried by liposome 
in different patterns, including: 1) encapsulated in the core, 2) embedded in the 
bi-layer or 3) adsorbed or engrafted to the outer surface. 
It has been reported that locally injected liposomes can be taken up avidly by 
APCs infiltrating the site of injection or in the lymphatics, an event that has been 
implicated in their immune-adjuvant activity (272). And also, liposomes would 
protect their DNA content from deoxyribonuclease attack (273). Thus, liposomes are 
regarded as suitable antigen or DNA delivery structures for the development of potent 
cancer vaccines. 
Many variations of liposomes have been studied with respect to their vaccine 
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potential. It has been revealed that vaccination with liposome based vaccine can elicit 
cell mediated immune response as well as humoral immune response (274). For this 
attractive property, some studies suggested that small liposomes can be delivered to 
the cytoplasm of cells by the process of endocytosis or pinocytosis. These different 
routes of uptake could result in either the partial or complete degradation of the 
antigen and consequently the antigen has the potential to enter different processing 
compartments such as the endosomes, the lysosomes or the cytosol (275). Thereby, 
liposome mediated antigen delivery could allow antigen to gain access to both MHC I 
and MHC II pathway in APCs. In addition to antigenic stimuli, liposomes can also be 
designed to carry adjuvants which will enhance anti-tumor immunity (276-278).  
Besides their capacity of inducing a large spectrum of immune responses, the use 
of liposome as vaccine vector demonstrated also several advantages (279). For 
example, there were no granulomas at the site of injection (280); no hypersensitivity 
reactions were observed in pre-immunized animals when the antigen was given in the 
entrapped form (281); also, liposomes composed of the appropriate phospholipid do 
not develop antibodies against their phospholipid component (282) nor have they 
produced any side effects in repeatedly injected patients (283). 
One well-recognized limitation of liposomes is their low entrapment efficiencies 
for water-soluble antigens. In such cases, in order to improve entrapment efficiencies, 
attentions were generally focused on optimizing the manufacturing method and/or 
altering the antigen properties, without affecting antigenicity (274). 
In many animal experiments, tumor protection was achieved by immunization 
with a relevant antigen entrapped in liposome. And currently, liposome based 
vaccines have been carried to clinical trials, in which the delivery of tumor antigens 
using liposomes holds great promise as a safe and non-immunogenic approach to 
cancer immunotherapy (284, 285) 
Cell-penetrating Peptides 
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Presently, various natural and/or synthetic cell-penetrating peptides (CPPs) have 
been widely used in vaccine design.  
CPPs are cationic and/or amphipathic peptides containing 9-35 amino acids that 
are capable of internalizing across cell membranes. In fact, the cell membrane is 
impermeable and possesses an effective barrier for most hydrophilic substances. It 
was first discovered in 1980s that a natural poly-cationic protein, the trans-acting 
activator of transcription of the human immunodeficiency virus (HIV-TAT), contains 
the domain capable of cell membrane translocation (286, 287). Following this 
discovery, additional poly-cationic peptides of natural origin, such as herpes simplex 
virus (HSV-1) protein VP22 (288) and penetratin (Antp) derived from the 
homeodomain of Antennapedia (289); or of synthetic origin, like transportan (290), 
have also been identified to facilitate cellular uptake and translocation. The 
mechanism of cellular uptake and subsequent processing still remains controversial. It 
has been suggested that CPP mediate intracellular delivery via both endocytic and 
non-endocytic pathways (291).  
This cell membrane translocation ability is processed not only by the CPPs alone 
but also by the CPPs attached with cargos. Different cargos, such as drugs, 
peptide/protein, oligonucleotide/DNA/RNA, nanoparticles, liposomes, bacteriophages, 
fluorescent dyes and quantum dots, have been linked to CPPs for intracellular 
delivery with possible use in future vaccine design (291). Cellular delivery using 
CPPs has several advantages over conventional techniques because it is efficient for a 
range of cell types, can be applied to cells en masse, and has a potential therapeutic 
application (292). 
Two applications of CPPs already validated in vaccine studies are the delivery of 
tumor-associated antigens into APCs and the use as a non-viral gene delivery vehicle 
in DNA vaccines (291). The major drawback with CPPs is their lack of specific 
delivery, which is a highly desirable property for cancer treatment. This limitation can 
be overcome by addition of a receptor-targeting domain. Through this way, 
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polypeptides will recognize and bind to cell surface receptors that are unique to target 
cells and deliver cargos into the cells through receptor mediated endocytosis (293). 
Until now, the ability of CPPs to induce a superior broad anti-tumor immune response 
via enhanced delivery and presentation has been demonstrated in different murine 
tumor models, like cervical cancer (294-296), colorectal cancer (297), breast cancer 
(298), lymphoma (299). Research is now being extended to in vitro human systems. 
Yeast Vectors 
Saccharomyces cerevisiae is a unicellular eukaryotic microorganism mainly used 
in the making of beer and bread.   
Although be nonpathogenic, S. cerevisiae can be avidly phagocytosed by APCs 
and subsequently induce immunologic responses in mammals (300, 301). The 
phagocytosis of yeast by DCs is driven by the immunogenicity of yeast cell-wall 
components, such as β-1, 3-D-glucan and mannan, which can transmit ‘danger 
signals’ normally associated with microbial infection. These components have strong 
adjuvant properties and can be detected by Toll-like receptors and mannan receptors 
on DCs (302). Once inside in APCs, yeast can be degraded in proteasomes, antigens 
contained by yeast can be presented in MHC I context to be recognized by CD8+ 
CTLs. On the other hand, yeast can also be degraded in endosomes and antigens will 
be presented to MHC II molecules and be recognized by CD4+ T helper cells. 
Thereby, the use of yeast-based vaccines can lead to the recruitment and specific 
activation of both CD4+ and CD8+ T cells (303).  
Due to this particular property, yeast has also been exploited as cancer vaccine 
vector for antigen delivery. It has been shown that recombinant yeast cells are capable 
of stimulating the immune system to produce highly specific and potent cellular 
responses against target protein antigens with little toxicity. Stubbs et al. demonstrated 
that whole recombinant S. cerevisiae expressing foreign antigens can activate DCs, 
elicit robust antigen-specific CTL responses, and confer protective immunity against 
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tumor challenge in mice (300). Lu et al. reported that whole recombinant yeast 
vaccines expressing mammalian mutant Ras proteins contributed complete regression 
of established Ras mutation-bearing lung tumors in mice in a dose-dependent, 
antigen-specific manner (304). It has been demonstrated that recombinant yeast 
expressing a tumor antigen could induce the activation and maturation of DCs in vitro 
and elicit immune and antitumor responses in different mice models, such as 
melanoma, pancreatic carcinoma and lung carcinoma (305-308). Following these 
encouraging pre-clinical experiments, recombinant yeast vaccines are currently 
investigated in clinical trials. 
Viral Vectors 
Viruses are small infectious agents that can replicate only inside the living cells 
of organisms. Viruses can infect all types of organisms, from animals and plants to 
bacteria (309). They have evolved highly efficient structures and mechanisms for 
infecting cells and utilizing the cellular machinery for production of virally encoded 
proteins (310). Thereby, viral vectors represent the attractive antigen delivery vehicles 
for cancer immunotherapy since they can mimic a natural infection and express potent 
danger signals.  
A large number of viruses have been engineered as attenuated replication 
deficient vaccines. The first recombinant vaccinia viruses were constructed in 1982, 
since then several other viruses have also been developed as recombinant viral vectors. 
In the field of cancer immunotherapy, a variety of recombinant viruses has been used 
to deliver immune modulators (such as cytokine and co-stimulatory molecules) or 
tumor antigens. Generally, these virus vectors can be applied in two ways: 1) be 
directly administered for either the local administration of cytokines, co-stimulatory 
molecules and therapeutic genes, or systemic administration of viral vectors serving 
for delivery carriers of tumor antigen; 2) be used to modify cells ex vivo for the 
development of different cell mediated vaccines.  
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Within the last decade, many such recombinant vectors have made the transition 
from pre-clinical research to clinical development. Each viral vector system 
demonstrates some attractive properties that make it suitable for cancer vaccine 
application. Meanwhile, each system shows also some instinctive shortcomings. Next, 
we talk about several widely investigated viral vectors in cancer immunotherapy.  
Recombinant vaccinia viruses were among the first vectors developed for 
vaccination purpose and have been widely utilized in clinical trials. Advantage of 
using vaccinia as a vector include the ease with which recombinant vectors can be 
formed and isolated; the large capacity of Pox viruses for foreign DNA; the relatively 
high level of transgene expression, and the wide host range. However, their efficacy 
for immunization has been shown to be limited by pre-existing anti-vaccinia 
immunity in the general population. Given the vaccination history of many individual, 
its application in the clinic is likely to be limited (311).  
Adenovirus based vectors, are generally considered to be one of most potent 
vectors for vaccine development. Adenoviruses process several attractive features for 
vaccine use, for example, infection of a large variety of cells, expression of 
heterologous protein in both dividing and non-dividing cells, high levels of transgene 
expression, ability to grow to high titers in vitro, lack of integration in the host 
genome, and physical and genetic stability (312). Particularly, it has been reported 
adenoviruses can infect dendritic cells, up-regulate co-stimulatory molecules, and 
elicit cytokine and chemokine responses, thus effectively elicit immune responses and 
provide potent tumor protection (313). However, the use of adenoviruses is limited by 
several obstacles. They do not integrate into the host chromosomes, which results in a 
short-term expression of the transduced gene. There exist a widespread pre-existing 
anti-vector immunity in targeted populations and there is the novel generation of 
immunodominant immune responses against adenovirus Ags following vector 
delivery; and immunological responses to adenoviruses may also reduce the duration 
of expression therapeutic gene expression (311). Thereby, the clinical application of 
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recombinant adenoviral vectors for the treatment of tumor is shown with limited 
progress.  
Cancer immunotherapy has also profited from the development of recombinant 
retroviruses. Because retroviruses are capable of integrating into the host genome and 
this property permits the long-term expression of the foreign gene (314). Also, this 
type of virus is not able to replicate in non-dividing cells, which displays a high 
degree of safety, whereas demonstrates also a low transfection efficacy (315). 
However, little clinical data support the development of recombinant retrovirus 
vectors in cancer immunotherapy. The main concerns in using recombinant 
retroviruses are accidentally random integration into the host chromosome resulting in 
deleterious effects such as the activation of certain proto-oncogenes by insertional 
mutagenesis, or suppression of other tumor suppressor genes. Furthermore, the 
requirement of cell division for the provirus integration limited their application. One 
solution to this problem is using lentivirus because this subset of adenovirus is 
capable of integrating into non-dividing cells (311).  
HSV is also a promising vector for the delivery of tumor antigens due to its 
ability to infect a broad range of cells including both dividing and non-dividing host 
cells, its ability to accept large DNA inserts and its good safety profile (316). This 
vector has been shown to have a good clinical bio-safety profile due to the fact that 
following infection of the target cells there is no further replication (317). Major 
problems associated with the use of HSV vectors are the difficulty in completely 
eliminating lytic viral gene expression; vector induced cytotoxicity, and the transient 
nature of gene expression (311). 
Bacterial Vectors 
Due to several intrinsic features, live, attenuated pathogenic bacteria are being 
explored as vectors for protein antigen and DNA delivery, including: 1) they have a 
positive tropism for professional APCs; and 2) the bacteria itself is a natural adjuvant 
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for the vaccine because bacterial infection has been well known to induce the release 
of several pro-inflammatory cytokines which could enhance the immune responses. 
Numerous preclinical and clinical studies have investigated the potential for 
bacterial delivery of therapies for cancer. The major problems of using bacteria as 
cancer vaccine vector are their toxicity at the dose required for therapeutic efficacy 
and the diminished efficacy at reduced dose. 
As this work has been achieved in dependence of live, attenuated bacterial 
vectors, we will discuss next in more details the application of this type of delivery 
system for cancer immunotherapy. 
B-III Bacteria-based Antigen Delivery Vehicles in Cancer Immunotherapy 
Originally, bacteria were developed as live vaccines against bacterial infections. 
Induction of humoral and/or cellular immune response can be achieved by 
administration of attenuated strains derived from pathogenic bacteria, which leads to 
protection of the host against a subsequent challenge with the respective wild-type 
strain. In addition to be used to confer protection against self-antigens, live attenuated 
bacteria are also thought as promising carriers to deliver antigenic message in vivo for 
induction of a broad immune response against heterologous pathogens (reviewed in 
(318, 319)).  
Presently, attenuated bacterial strains have been exploited as potential vaccine 
vectors for cancer immunotherapy. For this purpose, bacteria based vaccines function 
majorly through two mechanisms: bacteria mediated DNA delivery and bacteria 
mediated antigen delivery. 
Numerous bacterial strains, majorly belonging to Salmonella genus, has been 
explored as DNA delivery vectors for inducing protective responses against a variety 
of tumor antigens (table 2). In this pattern, tumor antigen encoding plasmids carried 
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Table 2: Live Attenuated Bacteria-mediated DNA Delivery Applied for 
Anti-tumor Immunotherapy in Animal Models. 
Cancer model Vaccine antigen Animal model Vaccination strain Ref 
Melanoma 
 
 
 
Breast carcinoma  
 
 
 
Lung carcinoma 
 
 
Colon carcinoma 
 
Neuroblastoma 
 
Prostate carcinoma 
Gastric carcinoma 
Cervical 
carcinoma 
GP100 
flk1 
hTERT/ TRAIL 
TRP2/GP100 
MTDH/AEG-1 
Endoglin (CD105) 
Legumain 
flk1 
flk1  
hTERT/ TRAIL 
CEA 
flk1 
CEA 
Survivin 
tyrosine hydroxylase (TH) 
PSA 
MG7-Ag 
HPV 16-E7 
C57 BL/6 mice 
C57 BL/6 mice 
BALB/c & C57BL/6 mice 
C57BL/6J 
BALB/c mice 
BALB/c mice 
BALB/c mice 
BALB/c mice 
C57 BL/6 mice 
BALB/c & C57BL/6 mice 
C57 BL/6 mice 
BALB/c mice 
C57 BL/6 mice 
A/J mice 
A/J mice 
C57 BL/6 mice 
C57BL/6J 
C57BL/6J 
S. typhimurium SL7207 
S. typhimurium SL7207 
S. typhimurium SL3261 
S. typhimurium SL7207 
S. typhimurium RE88 
S. typhimurium RE88 
S. typhimurium RE88 
S. typhimurium RE88 
S. typhimurium SL3261 
S. typhimurium SL3261 
S. typhimurium SL7207 
S. typhimurium SL3261 
S. typhimurium SL7207 
S. typhimurium SL7207 
S. typhimurium SL7207 
S. typhimurium SL7207 
S. typhimurium SL3261 
L. monocytogenes-LLO 
(320) 
(321) 
(322) 
(323) 
(324) 
(325) 
(326) 
(8) 
(327) 
(322) 
(328) 
(329) 
(330) 
(331) 
(332) 
(333) 
(334) 
(335) 
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by bacterial vectors will be expressed in the eukaryotic cells after transfection. With a 
few exceptions, most of the bacterial strains utilized in vivo for the delivery of vaccine 
plasmids are intestinal pathogens of humans and some other mammalian. The use of 
live attenuated enteric bacteria based vaccines permit colonic mucosa infections 
following oral administration. After crossing the intestinal mucosal barrier, mainly via 
M cells, a large fraction of bacterial carriers can be taken up by APCs, either in local 
lymphoid tissues or after systemic spread, in spleen, liver and lymph nodes (336). 
After being phagocytosed by the APCs, these bacteria either enter the cytosol of these 
cells, like Listeria, shigella; or remain in the phagosomal compartment, such as 
Salmonella, through which antigen could be expressed, processed and further 
presented on MHC class I and II molecules to T cells, respectively. 
Besides, bacteria can also be used as vaccine vectors for antigen delivery. This 
pattern refers to the mechanism by which antigens are not produced by host cells but 
by the bacteria in situ and in addition bacteria act as adjuvants. More examples will be 
presented in following sections for individual bacteria species. In this model, 
heterologous antigens can be expressed either through chromosomal integration of 
antigen coding cassettes or by plasmid-based antigen expression systems. 
Chromosomal expression of antigens demonstrates several advantages, including 
genetic stability and the possibility of integrating and expressing multiple antigen 
genes. Meanwhile, this strategy shows an inherent drawback that generally one copy 
of the antigen gene will be expressed per bacterial cell, which might result in 
insufficient antigen expression and thereby the inefficient protection. However, 
expressing the antigen from a plasmid can circumvent this limitation. The quantity 
and location of antigen expression can be regulated by using a plasmid-based system. 
The amount of antigen expressed can be controlled by using either high-copy or 
low-copy plasmid backbones as well as inducible systems that produce large 
quantities of antigen upon addition of the induction agent. Furthermore, the location 
of antigen expression can be controlled in vivo to give the maximal antigen dosage 
depending on sub-cellular localization (337). Constant antigen synthesis can result in 
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decreased bacterial vector fitness and decreased immunogenicity; therefore, using in 
vivo inducible promoters to control antigen expression in a plasmid can improve 
immune responses (337). For bacteria-mediated antigen delivery, besides endocytosis 
/phagocytosis pathway, the in situ translocation of heterologous antigens that are 
locally produced by bacteria and engaged by their type III secretion system (T3SS) 
has been widely investigated. This will be discussed below. 
Bacteria based protein/DNA delivery vectors offer multiple advantages: (1) there 
exist a variety of well-characterized virulence attenuating mutations; (2) the quantity 
and in vivo location of antigen expression can be regulated; (3) multiple vaccine 
delivery routes are possible; (4) they are potent innate and adaptive immune system 
stimulators; and 5) the others, like low batch preparation costs, facilitated technology 
transfer following development of the prototype, increased shelf-life and stability in 
the field respect to other formulations (e.g. subunit vaccines), easy administration and 
low delivery costs (337).  
Bacterial vaccine delivery has demonstrated in vivo efficacy in several 
experimental animal models of infectious diseases and tumors and has been further 
evaluated in humans. However, despite these promising results, the development of 
bacterial vaccines for cancer treatment faces a number of technical and biological 
challenges. Bacteria are unable to carry out a variety of post-translational protein 
modifications observed in mammalian cells and do not readily fold proteins with great 
molecular weight. In addition, the necessity to secrete protein antigens expressed by 
bacteria limits the number of proteins that can be targeted by this approach. Also, high 
levels of antigen expression can sometimes lead to toxicity in host cells and 
consequently to the loss of its normal delivery function (338). Moreover, some other 
factors, including the reversion to virulent state, stability of the recombinant 
phenotype, pre-existing immunity, etc., should also be taken into consideration (319). 
Furthermore, to be applied as vaccine in vivo, wild-type bacteria should be first 
attenuated. This process is in order to generate strains that can be well tolerated by the 
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immune system and reduce vector induced inflammatory responses. With a greater 
understanding of bacterial virulence and recombinant DNA technology, numerous 
genetically defined attenuated bacterial strains have been developed. One of the most 
widely studied classes of attenuated bacteria is auxotroph. Generally, this type of 
mutants will undergo limited replication and can be eliminated from host tissues 
within a short time (339). Salmonella strains with a deletion in the aroA gene of the 
aromatic amino acid (aro) biosynthetic pathway are immunogenic and less virulent in 
mice and can protect against a subsequent challenge with homologous Salmonella 
(340). Similarly, aroA mutants of S. flexneri (341), Y. enterocolitica (342), L. 
Monocytogenes (343), etc., have also been constitued. In our laboratory, we have also 
estabilished one mutant of P. aeruginosa-CHA-OAL in which the aroA gene is 
deleted and of which the lethal dose is significant enhanced than wild type strain (10). 
Next, we will talk about several well characterized and widely applied bacterial 
vectors for cancer vaccine design. 
Listeria Monocytogenes 
L. monocytogenes is a gram-positive facultative intracellular bacterium that can 
cause listeriosis in both animals and humans. Its natural route of infection is oral, and 
translocation occurs across the gut epithelium prior to systemic dissemination.  
L. monocytogenes is able to infect both phagocytic and non-phagocytic cells. L. 
monocytogenes invades cells either through direct phagocytosis or by binding to host 
cells via virulence factors called internalins. Once inside the phagosome, the majority 
of the bacteria could be killed and degraded lysozomal compartment. Meanwhile, 
there is still a small fraction of bacteria that can escape degradation and enter the cell 
cytosol. This phagosomal escape is mainly mediated by the action of one virulence 
factors - listeriolysin O (LLO). This enzyme can degrade the phagosomal membrane 
and allow the release of bacteria into the cytoplasm where they undergo cell division.  
At the same times, in the cytoplasm, the expression of ActA, an actin polymerase, 
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allows L. monocytogenes to polymerize host cell actin monomers to become motile. 
Ultimately, motile bacteria move to the periphery of the cell where they form 
pseudopod-like structures that are recognized and internalized by neighboring 
adjacent cells where the cycle is subsequently repeated. Through the direct cell-to-cell 
transfer mechanism, L. monocytogenes can spread without leaving the intracellular 
compartment. Due to the dual intracellular location, antigens secreted by L. 
monocytogenes can be targeted for both MHC class I and II presentation on the cell 
surface (344). 
In addition to heterologous antigen delivery, L. monocytogenes, as the other 
bacterial vector, is endowed the ability to stimulate robust innate immune responses.  
L. monocytogenes can efficiently induce the functional maturation of DCs, and L. 
monocytogenes infection can trigger cascades of pro-inflammatory cytokine and 
chemokine production and promote the cellular recruitment to infectious loci, which 
are crucial for priming an antigen-specific CTL responses. The inherent 
immunostimulatory properties of L. monocytogenes vectors stimulate optimal 
antigenpresenting DCs in vivo (345). 
Moreover, L. monocytogenes demonstrated several particular biological and 
immunological characteristics that make it an ideal vaccine vector, including: 1) it is 
capable of infecting a wide variety of different cell types inside the host (346); 2) as a 
Gram-positive bacterium, it does not express LPS and thereby is less likely to induce 
an LPS mediated septic shock in contrast to Gram-negative bacteria (347); 3) the 
complete genome sequences of two L. monocytogenes strains have been determined 
(348), which makes it possible to obtain virulence-attenuated strains through genetic 
modification; 4) the virulence attenuation or pre-existing anti-listeria immunity will 
not affect its ability of eliciting effective immune responses against heterologous 
antigens, which has been reported by several groups in a murine model (349-351); 4) 
it can be easily cultivated to large numbers in simple growth media, which renders the 
feasibility of producing a larger quantities of vaccine strains in an industrial setting. 
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In the past decades, the unique biological and immunological characteristics of L. 
monocytogenes prompted ones to examine the ability of these bacteria to act as 
vaccine vectors. It has been first reported in 1992 that L. monocytogenes could deliver 
heterologous antigens to the immune system with the induction of CTL responses 
(352). Since then, L. monocytogenes has been successfully explored as a vaccine 
vector for the delivery of antigens and antigen encoding plasmid (353) in diverse 
models (for recent reviews see ref (354-356). Nearly almost pre-clinical studies using 
L. monocytogenes to deliver tumor antigens as proteins in mouse models of cancer 
can be found in recent reviews (357, 358). Currently, the applications of L. 
monocytogenes as cancer vaccine carriers for human disease have entered phase I 
clinical trials. For example, a L. monocytogenes vaccine that secreted an LLO-E7 
fusion product was the first bacteria vaccine evaluated in clinical trials. The results of 
this study showed that that a live-attenuated L. monocytogenes immunotherapeutic is 
safe to be administered to late stage invasive cancer patients (359). 
During constructing and testing L. monocytogenes based immunotherapeutics, 
some interesting advantages have been revealed. For example, the delivery of the 
whole proteins can induce the immune responses against immuno-subdominant 
epitopes not previously identified (360); also expression of a chimerical product 
composed of multiple immunodominant regions can avoid the weak immune 
responses caused by the loss of CTL epitopes in tumors (361). However, some 
obstacles have also been observed, such as the difficulty of secreting large and 
hydrophobic molecules (362).  
Some applications of L. monocytogenes as antigen delivery carrier for anti-tumor 
immunotherapy in animal models are summarized in Table 3. 
Salmonella Genus 
Salmonella is a gram-negative bacterium and the causal agent for salmonellosis. 
Based on antigenic determinants of LPS, flagellar and capsular antigens, over 2500 
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Table 3: Live Attenuated Listeria-mediated Antigen Delivery Applied for 
Anti-tumor Immunotherapy in Animal Models. 
Cancer model Vaccine antigen Animal model Ref 
Cervical 
carcinoma 
 
Breast carcinoma 
 
 
 
Melanoma 
 
Colon carcinoma 
Prostate cancer 
HPV16-E7 
HPV16-L1 1–258 
Her2/neu 
VEGFR2 
Endoglin 
MAGE-b 
ISG15 
TRP2 
HMW-MAA 
GP70, AH1epitope 
PSA 
C57BL/6 mice 
C57BL/6 mice 
C57BL/6 & FVB/N mice 
FVB/N mice 
FVB/N & Balb/c mice 
Balb/c mice 
FVB/N & Balb/c mice 
C57Bl/6 mice 
C57BL/6, BALB/c & FVB/N mice 
C57Bl/6 mice 
C57BL/6 mice 
(363-366) 
(367) 
(362, 368, 369) 
(370) 
(371) 
(372) 
(373) 
(374) 
(359) 
(375) 
(376) 
 
serotypes of Salmonella are defined (377). And, around 50 serovars are recognized as 
human or animal pathogens. Some of them, such as S. typhi, are host-restricted; and 
the others, like S. typhimurium, can infect a wide range of hosts (378) Generally, 
Salmonella infects humans and animals by the oral-faecal route.  
Once inside the host, Salmonella can invade the intestinal mucosa and 
subsequently be captured by phagocytes. In contrast to L. monocytogenes, Salmonella 
lacks a phagosomal escape mechanism. After invasion into mammalian cells, it 
remains and divides within phagosomes (379). In order to survive in compartment, 
Salmonella can express several virulence factors encoded in the phoP locus and these 
molecules can induce the formation of spacious vacuoles from phagosomes that allow 
bacterial persistence and growth in these organelles (380). Proteins secreted by 
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Salmonella are degraded in the phagosome and are treated as exogenous antigens and 
presented by MHC II molecules resulting predominantly in Th2 type immune 
responses. Meanwhile, it has also been reported that the vaccination of mice with one 
attenuated S. typhimurium vaccine induced protective T cell response. It remains 
unclear how such antigens are released by Salmonella and target the MHC I antigen 
processing pathway. One hypothesis is that infection with Salmonella possibly causes 
leakage of the phago-lysosome (381).  
Recently, vast progress has been acquired in Salmonella studies. First, the high 
level of homology in the genome between Salmonella and Escherichia (382) allows 
the extension of the enormous knowledge on the genetics of E. coli to the study of 
Salmonella and the genetic manipulation of the bacteria, which leads to the 
construction of a large number of attenuated mutants as well as chromosomal 
insertions of heterologous antigen-coding genes (383). And, a wide variety of 
plasmid-based strategies are available to realize the expression of heterologous 
antigens in Salmonella during infection of a host (384). Also, due to de expression of 
PAMPs and LPS, Salmonella can trigger a wide range of innate immune responses 
(344). Moreover, the growth of this bacterium can be easily achieved in laboratory 
conditions; it can be administered either systemically (intraperitoneally (i.p.) or 
intravenously (i.v.)) or orally and stimulate local and systemic immune responses; its 
biology and the interaction mechanisms with the host has been well studied. All these 
futures have turned Salmonella an attractive delivery carrier for tumor antigens. 
Two Salmonella serovars, S. Typhi and S. Typhimurium, have been extensively 
assessed as live vectors for antigen delivery for the design and development of new 
vaccines for human diseases (reviewed in ref (384)). One major limitation in the use 
of Salmonella as a vaccine platform has been its inefficiency at stimulating MHC 
I-restricted CD8+ T-cell responses. This limitation is most likely due to the intrinsic 
properties of intracellular lifestyle of Salmonella (385). In order to overcome this 
limitation and strengthen the performances of Salmonella as cancer vaccine, 
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numerous efforts have been consumed to promote antigen secretion by the bacterium. 
For example, one modified Salmonella was created to carry a construct encoding for 
listeriolysin (hly) from L. monocytogenes, which was shown to facilitate escape from 
phagosomes (381); the hemolysin (HlyA) secretion system of E. coli, the prototype of 
type I secretion systems, was employed in Salmonella to ensure secretion of the tumor 
antigen (386); Heterologous antigen was fused to cholera toxin subunit B (a potent 
mucosal adjuvant), which was shown to enhance antigen secretion and uptake by 
APCs and consequently induce a protective cell-mediated immunity (7). Moreover, 
one more abstract strategy, exploiting the T3SS of Salmonella, has been applied to 
improve antigen delivery and tumor specificity of Salmonella-based vaccines, about 
which we will talk in following section.  
As cancer vaccine carriers, Salmonella genus has been widely used for DNA 
vaccine plasmids delivery (table 2) and tumor antigen delivery (majorly through T3SS, 
table 4). Furthermore, due to its tumor targeting capacity inherent antitumor activity, 
Salmonella genus, itself, has great potential as cancer therapeutics. Some cases have 
been reported in clinical trials. The clinical Phase I applications of an attenuated S. 
Typhimurium strain administered i.v. or intra-tumorally to an heterogeneous group of 
cancer patients resulted in tumor colonization and mild side effects (387-389). 
T3SS Mediated Antigen Delivery 
This secretion machinery is used by a broad spectrum of Gram negative 
pathogenic bacteria (Salmonella, Shigella, Yersinia and Pseudomonas, etc.) to deliver 
effector proteins to membrane or into cytoplasm of host cells, which alter the function 
of the host cell to promote the survival of the bacterium (390). The activation of T3SS 
can be induced in vivo via bacteria - host cells contact. Before that moment, most of 
the effector proteins are expressed and stored within bacteria (391). As the protection 
against tumor is highly dependent on the triggering of MHC class I-restricted cellular 
immune response, this distinctive intracellular protein-translocation machinery of 
T3SS has being widely applied for improving the performance of bacteria based 
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cancer vaccines (table 4).  
Table 4: T3SS Mediated Antigen Delivery Applied for Anti-tumor 
Immunotherapy in Animal Models. 
Cancer model Vaccine antigen Animal model bacterial carrier strain Ref. 
Melanoma B16F10 
Colon carcinoma 
 
Hepatocellular carcinoma 
Fibrosarcoma  
 
Sarcoma  
 
Glioblastoma 
 
 
 
TRP2153-417+HSP70 
Survivin 
 
Hepatitis B virus x (HBx) 
p60 
p60130-477 
NY-ESO-1 
 
survivn 
 
TRP2L125-376 
 
C57BL ⁄ 6J mice 
BALB/c mice 
 
C57BL ⁄ 6J mice 
BALB/c mice 
BALB/c mice 
BALB/c mice 
 
BALB/c mice 
 
C57BL ⁄ 6J mice 
 
S. typhimurium (SL3261) 
S. typhimurium, MvP728 
(ΔpurD/ΔhtrA) 
S. typhimurium (SL3261) 
S. typhimurium (SB824) 
S. typhimurium (SB824) 
S. typhimurium(ΔphoP 
ΔphoQ) 
S. typhimurium, MvP728 
(ΔpurD/ΔhtrA) 
P. aeruginosa(ΔexoS 
ΔexoT 
(392) 
(393) 
 
(394) 
(395) 
(396) 
(397) 
 
(393) 
 
(6) 
 
 
As mentioned before, attenuated Salmonella bacterium is considered as a 
promising candidate for antigen delivery. However, after invading host cells, 
Salmonella is confined within vacuole compartment, which prevents the delivery of 
heterologous antigens to the host cell cytosol. Several strategies have been established 
to overcome this problem, among which an innovative approach using the T3SS of 
Salmonella has been investigated with the aim to promote the cytosolic delivery of Ag 
and their subsequent engagement by MHC I pathway for the generation of CTL 
response. In Salmonella, there are two types of T3SSs that are encoded by Salmonella 
Pathogenicity Island-1 (SPI-1) and Salmonella Pathogenicity Island-2 (SPI-2), 
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respectively. In early stages of infections, the T3SS encoded by SPI1 mediates 
bacterial invasion into the host cell. In contrast, the T3SS encoded by SPI2 is 
activated under intracellular conditions and is required for the intracellular survival 
and proliferation of the bacterium (398).  
It has been demonstrated in several infectious models that when peptide 
fragments from pathogenic viruses or bacteria were fused to Salmonella T3SS effector 
proteins, such as SopE and SptP of SPI-1 T3SS (385, 399, 400); SspH2 and SseF of 
SPI-2 T3SS (401, 402), they could be engaged by the T3SS and delivered to the host 
cell cytosol, resulting in the priming of a protective class I-restricted immune 
response. Similarly, Salmonella has also been engineered deliver tumor antigens to 
the cytosol of antigen-presenting cells via T3SS. Through this way, significant T-cell 
priming and anti-tumor protection have been observed (396-398).  
Besides, T3SS mediated antigen delivery has also been applied in other live 
attenuated bacterial strains. In our laboratory, we have developed cancer vaccines on 
profiting the T3SS of P. aeruginosa. Different to the other bacteria vectors being 
investigated, P. aeruginosa is extracellular pathogen and thereby reacts with the 
immune system in a different way; moreover, it is not intestinal bacteria so that it 
might allow alternative vaccine administration ways. About the characters of T3SS of 
P. aeruginosa and the work already achieved in our laboratory, we will discuss in 
more details below (see in section C). 
Also, Yersinia genus can also secret antigens through T3SS machinery. Even no 
study about the application of Yersinia T3SS in cancer vaccine design has been 
reported until now, the vaccine potential of recombinant Yersinia enterocolitica strain 
has been already investigated in different infectious models. Several studies have 
demonstrated the potential of the Yersinia outer protein E (YopE) to function as a 
carrier molecule for heterologous antigen delivery (403, 404). Fusion of these 
antigens to the first 138 amino acids of YopE can lead to the translocation of hybrid 
proteins into the cytosol of host cells and thereby elicit protective CD8+ T cell 
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responses (405-407). Furthermore, it was revealed recently that Yersinia T3SS is 
capable of delivering heterologous Ag with high molecular weight and complex 
structures, such as E. histolytica 170 kDa cysteine-rich proteins, to induce 
antigen-specific type 1 immune responses as well as promote the significant 
protection against invasive amoebiasis (408).  
These current investigations highlight the potential use of the T3SS of bacteria 
for cancer vaccine development. Then, it should translate such proof of concept to 
effective therapeutics in humans.  
B-IV Recent Strategies for Cancer Vaccine Improvement 
One major challenge in the development of cancer vaccines is the 
immune-tolerance of tumor. In fact, many defined TAAs are self-proteins and 
therefore generally fail to prime efficient antitumor T cell responses. Thus, a 
bottleneck for developing successful cancer vaccines is to overcome potential 
mechanisms of immune suppression against antigenic but weakly immunogenic 
tumors (409). For this purpose, several strategies have been applied for improving the 
performances of cancer vaccines. 
B-IV a Target of Co-inhibitory Pathway 
A number of co-inhibitory molecules expressed on the surface of immune cells, 
cancer cells, and stromal cells play a role in decreasing immune responses to cancer. 
Thus, one strategy to enhance the outcome of an antitumor immune approach is to 
eliminate negative signals imparted to T-cells by co-inhibitory molecules, two of 
which, B7- H1, and CTLA- 4, have been widely investigated.  
 B7-H1 is the major ligand for programmed death 1 (PD-1) mediated 
immunosuppression. It is constitutively expressed on APCs and can be broadly 
induced on cells in both lymphoid tissues and non-lymphoid peripheral tissues 
following cellular activation (410). B7-H1 has been shown to promote evasion of 
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tumor immunity by promoting apoptosis of activated effector T-cells (411) and tumor 
resistance to T cell mediated lysis (412). Several studies in mouse models revealed 
that blockade of B7-H1 by mAb could enhance T cell responses and dramatically 
improves the efficacy of tumor vaccines (413, 414). Currently, anti-B7-H1 human 
mAbs are under clinical development and Phase I trial results showed that the 
blockade of B7-H1 by mAb was safe, well-tolerated, and induced a low rate of 
autoimmune-type side effects (415). 
CTLA-4 is a co-inhibitory receptor expressed by activated T cells and Tregs. 
CTLA-4 is homolog of CD28 and can also bind to B7 on the surface of the APC with 
an even higher affinity than CD28. Binding of CTLA-4 to B7 initiates a negative 
signal cascade that leads to down-regulation of the T-cell response (416). Thereby, the 
blockade of CTLA-4 has been explored in cancer vaccine researches. Treatment with 
an anti-CTLA-4 mAb in murine models has been shown to improve tumor 
immunosurveillance and amplify the effects if cancer vaccines (416, 417). These 
preclinical results led to the ongoing clinical investigations of anti-CTLA-4 
humanized mAbs, in which antiCTLA-4 has been used alone or in combination with 
other immune-mediated anticancer modalities, like cancer vaccines (418). 
B-IV b Target of Regulatory T Cells 
Treg cells are actively involved in an important mechanism of peripheral T-cell 
tolerance through their inhibition of self-reactive effector T-cells (419). As many 
define TAAs are antigens, Tregs mediated regulation is also a main reason for the 
decrease of antitumor immunity. In fact, the quantity of Treg cells has been seen 
increased in the tumors and peripheral blood of cancer patients (420, 421). Therefore, 
it is expected that depletion of these regulatory T cells would enhance antitumor 
immune responses.  
Several studies in murine models showed that blockade or elimination of Treg 
cells by anti-CD25 mAbs strengthened antigen-specific T-cell responses, enhanced 
antitumor immunity and improve efficacy of antitumor vaccines, which leaded to the 
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tumor rejection (422, 423). However, a potential disadvantage of this approach is that 
effector T-cells also transiently up-regulate the expression of CD25 on their cell 
surface and therefore being at risk of depletion. One of the alternative choices for 
Treg cells deletion is denileukin diftitox (ONTAK(®), DAB(389) IL-2). Denileukin 
diftitox is a recombinant fusion protein of IL-2 and diphtheria toxin and capable of 
depleting cells that express high-affinity IL-2 receptor (424). In clinical trials, the 
application of denileukin diftitox has been shown to reduce Treg cells, enhance 
tumor-specific T-cell responses and improve the efficacy of vaccines in patients with 
different tumors (318, 425, 426). 
B-IV c Diversified Prime-boost Vaccination Protocols  
In recent years, it has been believed that the most effective immunization could 
be achieved through the association of different antigen delivery platforms.   
Indeed, there exist a variety of vaccination vectors, but the action mode of each 
is not identical. Some pattern target cell mediated immune responses, while other 
modality aim at humoral immune responses. Some methodologies may be more 
effective in priming naive cells, while others may be more effective in enhancing 
memory cell function. But, even each antigen delivery pattern presents attractive 
properties, they also involve some limitations. For example, naked plasmid DNAs 
vaccines are safe and will not activate anti-vector immune response, however the 
DNA transfection efficacy via this approach is not high enough to prime efficient 
immune responses. Some of the most effective methods of immunization, like the use 
of some recombinant virus or bacteria, can be applied only a limited number of times 
because of host anti-vector responses, and also there are always the concerns of 
safety.  
Thereby, combination of various antigen presentation systems would prime 
broad immune responses and achieve the best performance. The cooperation between 
different platforms, as part of prime-boost protocols, appears to be appropriate for 
therapeutic vaccinations against cancer. Numerous preclinical studies demonstrate the 
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advantages of diversified prime and boost protocols (427-430). 
B-IV d Combination of Cancer Vaccines with Other Therapeutics 
Antitumor effects induced by cancer vaccines may be difficult to obtain with 
large tumor masses for a variety of reasons, including (1) large tumor masses are 
difficult to penetrate by T cells; (2) the quantity of T cells generated by the host 
immune system would be far outnumbered by the cells in a large tumor mass; and (3) 
tumor cells produce immunoregulatory molecules that have the ability to suppress or 
inhibit T-cell function (431). Thereby, cancer vaccines might represent greatest 
performance in combination with other therapies, including radiotherapy, 
chemotherapy and cytokines. 
Radiation is the standard of care for many types of cancer because of its direct 
cytotoxic effect on the tumor or its palliative effects on the patient. It has been 
recently reported that local irradiation of tumors with doses insufficient to induce 
tumor cell death could result in changes on the phenotype of the tumor cells that 
include the up-regulation of MHC, Fas, ICAM-1, and various tumor associated 
antigens (432-434). As a result of these changes, irradiated tumor cells are more 
susceptible to T cell mediated immune attack. In the clinical setting, the approach has 
been investigated in a phase II clinical trial in patients with localized prostate cancer, 
randomized to receive a PSA based poxviral vaccine plus radiotherapy versus 
radiotherapy alone (435). 
Like radiotherapy, the use of various types of chemotherapy in combination with 
vaccines has resulted in enhanced antitumor immune responses. Although the 
mechanisms involved vary among the various types of cytotoxic drugs employed, in 
general, drugs can: (a) induce “immunogenic death” of tumor cells, leading to 
activation of DCs followed by antigen presentation to T cells (436, 437) or (b) 
modulate the phenotype of the tumor cells making them more susceptible to 
immune-mediated killing. For example, it has been shown that treatment of human 
colon carcinoma cell lines with 5-fluorouracil or cisplatin enhances their lytic 
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sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes, by inducing expression 
of ICAM-1 and Fas (438). 
Cytokines can promote the differentiation, activation, or recruitment of APC, 
therefore enhance antigen presentation and activation of antigen-specific T-cell 
responses, such as GMC-SF; or promote T-cell proliferation, activation, and effector 
function, like IL-2 (439), IL-7 (440), IL-12 (441) and IL-15 (442). These cytokines 
have been investigated in combination to cancer vaccine, significant enhanced 
antitumor immune responses have been observed. 
C Type III Secretion System of Pseudomonas aeruginosa 
C-I P. aeruginosa Bacteria 
P. aeruginosa is a common environmental gram-negative bacillus. It acts as an 
opportunistic pathogen to humans under several particular circumstances, including: 
cystic fibrosis, immunosuppression (especially in iatrogenic cases), invasive 
mechanical ventilation, chronic bronchial diseases, nosocomial skin-piercing 
procedures (like surgery), and patients bearing various prostheses at mucosal interface 
(such as contact lenses or urinary catheters). Outside of these situations, due to the 
protection by physical barriers (mucous membranes, skin, mucociliary clearance, etc.), 
innate immunity (NKs, macrophages, etc.) and acquired immunity, P. aeruginosa is 
incapable of developing an infection.  
In above mentioned situations, P. aeruginosa can be a pathogen. The 
implementation of its virulent factors are associated with direct cytotoxicity and local 
inflammatory reaction, which are often deleterious and can lead to poor functional 
outcome (for example, keratitis, destruction of lung parenchyma, etc.) or even vital 
prognosis (pneumonia, septic shock, etc). Many studies have suggested that the T3SS 
was probably the factor that contributed most to the virulence of this germ. 
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C-II T3SS 
Gram-negative bacteria dominate six types of protein secretion systems: 1) type I 
secretion system, which transports proteins to the extracellular space through two 
bacterial membranes due to two pore-forming proteins that are linked between them 
by a periplasmic protein; 2) type II secretion system, which transports proteins from 
the periplasmic space to extracellular space via a protein embedded in the outer 
membrane; 3) T3SS, of which the secretion device traverses not only bacterial cell 
wall but also the membrane of a eukaryotic cell being in touch with the bacteria, and 
through which the toxins will be directly delivered into the cytoplasm of the 
eukaryotic cell; 4) and the system of type IV secretion, which delivers different types 
of substrates (DNA, proteins ...) in the extra-bacterial medium by a system similar to 
that used during the combination, and is not described in P. aeruginosa; (443) 5) type 
V secretion system (T5SS), which transports proteins from interior of a bacterial cell 
to its exterior by two steps: first, proteins can cross the inner membrane using the Sec 
system; then, beta-barrel domain of proteins will form a channel in the outer 
membrane, which allow the passenger protein to be secreted (444); 6) type VI 
secretion system (T6SS), which has been recently identified by the group of John 
Mekalanos in 2006 (445). The Type VI secretion system gene clusters contain from 15 
to more than 20 genes. Hcp and VgrG have been shown to be nearly universally 
secreted substrates of the system. The secretion mechanism of this system has not yet 
been clearly identified. 
The T3SS was originally described in Yersinia and Salmonella. Up now, T3SS 
has been found in the most Gram-negative bacilli and usually plays a dominant role 
for the virulence of these germs. The secretion apparatus of T3SS consists of about 
twenty remarkably preserved proteins, which, after assembling into a syringe-like 
pattern, can traverse the two bacterial membranes, insert into the membrane of a 
eukaryotic cell and allow the intra-cytoplasmic delivery of toxins. Generally, these 
transported toxins can modify the functions of target cell in the interest of bacteria, for 
example, the transformations of cytoskeleton and consequent modification of 
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phagocytosis and organelles transport; alterations of intracellular signaling for 
inducing apoptosis; decreasing of mediators production, induction of necrosis, etc. 
As T3SS was introduced as an essential part to achieve this work, we describe 
later in more details the T3SS of P. aeruginosa and the progresses obtained in our 
laboratory in this field before this work. 
C-II-a The Structure of T3SS 
 
Figure 9: Type III Secretion System of P. aeruginosa ( Adapted from Frank DW et al. (446)). 
The secretion apparatus is embedded in bacterial membranes and continues with a needle-like 
structure that inserts terminally into the membrane of a eukaryotic cell, which allows the 
intracellular translocation of effectors. 
The T3SS (Fig. 9) can be disassembled into two structures: 1) the secretion 
apparatus, which is a protein complex embedded in two bacterial membranes and the 
organization of which is very similar to that of the base of flagellate; 2) the 
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translocation apparatus, which is continuum to the secretion apparatus and can 
inserted into the membrane of a eukaryotic cell. The structural organization of this 
assembling complex as well as the involved proteins are quite retained from one 
bacterial genus to another so that the information collected in one genus 
(crystallography, protein-protein interaction, polymerization ...) could be  transposed, 
at least in one part, to others. Thereby, the understandings of T3SS obtained from S. 
typhimurium, Y. pseudotuberculosis, S. flexnerii and P. syringae permit the deduction 
of T3SS structure in P. aeruginosa. 
The part inserted into the inner membrane of the bacterial cell wall has a ring 
structure composed of proteins PscD, PscR, PscS, PscT, PscU and PscV. The part 
inserted into the outer membrane of the bacteria is a pore formed by the 
oligomerization of PscC. The two parts are connected by the protein PscJ, all of which 
form a pipe with the diameter of 50 Å (447). 
Following the part crossing two bacterial membranes, there is a duct composed 
of a polymer of PscF protein and the end of this duct is the PcrV protein. Then, at the 
contact interface with a eukaryotic cell, two other proteins, PopB and PopD, will be 
transported by T3SS from the interior of bacteria to the cell membrane where they 
will insert and form a pore, after which T3SS is suitable for the intracellular 
translocation of effectors. During the translocation channel formation process, PcrV 
probably act as the chaperone which allows the oligomerization of PopB and PopD 
(446, 448). The role of PcrV has been proved by the application of anti-PcrV 
antibodies during the infections with P. aeruginosa (449). 
C-II-b Effectors Delivered Through T3SS 
Four toxins are secreted through the T3SS of P. aeruginosa: exotoxin (Exo) S, 
ExoT, ExoU and ExoY. Apart from these, PopB and PopD are also regarded as toxins, 
because their T3SS terminal pore forming activity was shown to be deleterious for the 
cells. 
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ExoS and ExoT 
ExoS is a protein of 49 kDa and Exo T is a protein of 53 kDa. ExoS and ExoT 
share 76% amino acid identity, and are bifunctional effectors with N-terminal 
RhoGAP domains and C-terminal ADP-ribosyltransferase (ADPRT) domains. The 
GAP domains of either enzyme target small Rho-like GTPases, and can stimulate the 
reorganization of the actin cytoskeleton by inhibition of Rac and Cdc42 and stimulate 
actin stress fiber formation by inhibition of Rho (450-453), which probably allows 
bacteria to escape phagocytosis.  
Activation of ADPRT activity needs a soluble eukaryotic protein, FAS (factor 
activating exoenzyme S) (454), which belongs to a highly conserved, widely 
distributed eukaryotic protein family, collectively designated as 14-3-3 proteins (455). 
Though both ExoS and ExoT have ADPRT activity, they ADP-ribosylate different 
substrates. ExoS has poly-substrate specificity and preferentially targets Ras 
superfamily proteins that are integral to cell signaling pathways (456), whereas ExoT 
has a more restricted host proteins and specially targets CrkI and CrkII, two host 
kinases that regulate focal adhesion and phagocytosis (457). ExoS ADPRT activity 
has effects on cell growth (DNA synthesis), morphology (cell rounding) and cellular 
adherence (458), whereas ExoS GAP activity plays an antiphagocytic role (459). The 
C-terminal part of Exo S possesses an ADP-ribosylation activity (ADPR) to the small 
G proteins of the Ras family. This ADPR activity inhibits transduction signal 
mediated by Ras, which could induce cell death.  
 Some studies have shown that proteins secreted through the T3SS of Yersinia 
express the secretion signal in N-terminal (460). In P. aeruginosa, the expression of a 
domain contained six amino acid in N-terminal in various toxins secreted by the T3SS 
(461) suggests that this is a secretion signal, but no work has so far confirmed this 
opinion. The group of D. Frank (462) deduced from their results that the secretion 
signal is contained in the first 99 amino acids of ExoS, however the proof was not so 
convincing. Our previous work has defined that the first 54 N-terminal amino acids of 
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ExoS form the ideal sequence allowing the secretion of the toxin via T3SS (3). 
 The exoS gene was found in 11-60% of the clinically obtained strains 
(especially in strains isolated from acute pneumonia, bacteremia and infection of 
burning). And, the exoT gene is expressed by nearly all strains. 
ExoU 
ExoU, parallely identified as PepA, is a protein of 72 kDa. ExoU is the most 
cytotoxic (461) and possesses lipase activity similar to patatin, human calcium 
independent phospholipase A2 (iPLA2) and cytosolic phospholipase A2 (cPLA2) 
(463). 
ExoU is found in about one-third of clinical isolates, and these ExoU-expressing 
strains in 90% of cases are associated with severe disease (464). ExoU has been 
shown to cause fatality in a mouse model of lung infection (461), and expression of 
ExoU in P. aeruginosa strains lacking it increases virulence in a mouse model of 
acute pneumonia 
Curiously, most strains of P. aeruginosa possess either the gene coding ExoS or 
the gene coding ExoU, but not both (465). The P. aeruginosa strain-CHA used as 
vector in our laboratory does not express ExoU. 
ExoY 
 ExoY is an adenylate cyclase of 40 kDa and expressed by about 90 % P. 
aeruginosa strains. Active ExoY results in an elevation of intracellular cAMP and 
cell-morphology changes. And, ExoY only intoxicates host cells at sites of 
colonization due to the delivery mechanism of T3SS. Recently, studies showed that 
ExoY could inhibit P. aeruginosa invasion of epithelial cells coinciding with 
adenylate cyclase-mediated cytoskeleton disruption (466). However, ExoY does not 
seem to be important for infection (467). 
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PopB and PopD 
The status of these two proteins is still ambiguous. Recent studies suggested that 
on one hand, they participate in the structure of the T3SS and are essential for the 
translocation of the toxins described above; on the other hand, the induction of T3SS 
by calcium depletion (see below) leads to their release into the environment as 
exotoxins likewise and endues them the role of pore-forming toxin (468). 
Chaperones of T3SS Toxins 
Chaperones are proteins that associate transiently with one or several substrates 
to prevent premature or incorrect intra-molecular or inter-molecular interactions. In 
T3SSs, before being secreted, some proteins are stored in the cytoplasm, which is not 
their final destination. These proteins need to be stabilized, separated from other 
interaction partners, and maintained in a secretion competent state with the help of 
chaperones (469). Thereby, T3SS chaperones have been suggested to i) act as 
anti-aggregation and stabilizing factors; ii) be secretion signal and set a secretion 
hierarchy; iii) function as anti-folding factors; iv) participate in the regulation of the 
T3SS (470). 
In P. aeruginosa, several chaperones have been identified. SpcU has been 
defined as the specific P. aeruginosa chaperone for ExoU (471). In our previous work, 
ORF1 or SpsC has been suggested as the chaperone for ExoS (472). 
C-II-c The Role of T3SS in P. aeruginosa Virulence 
The T3SS appears to be predominant virulence factor during the acute phase of P. 
aeruginosa infection. It can induce the necrosis and apoptosis of various cell 
populations and lead to the impairment of phagocytes function. The damage caused 
by T3SS is more notable in lung infection.  
T3SS can target a variety of cell populations, like dendritic cells, macrophages, 
neutrophils but also epithelial cells. The contact between these cells and the bacterium 
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can activate T3SS and subsequently either bring out cellular structure changes or 
induce apoptosis or necrosis of these cells. Different cellular damages induced by P. 
aeruginosa infection have been observed in several in vitro experiments. For example, 
some ExoS+ strains as well as Exo U+ strains could develop cytotoxicity against 
macrophages and the cytotoxicity was T3SS-dependent (464); cytotoxicity against 
polymorphonuclear neutrophils, which can lead to rapid necrosis of the latter, is also 
T3SS-dependent dependent but ExoU-independent (473); moreover, the structure 
change in epithelial cells induced by the interaction with P. aeruginosa is still 
dependent on T3SS, and the presence of ExoU is crucial under this situation (474). 
In animal models, the presence of T3SS is necessary for intra-pulmonary 
multiplication (474) and extra-pulmonary dissemination (467). Numbers of studies 
defined the roles of T3SS toxins. The experiments comparing a ExoU-ExoS+ strain 
and a ExoU-ExoS- strain demonstrated the decisive effection of ExoS relative to 
ExoT and ExoY; the comparison between a ExoU+ExoS-strain and a ExoU-ExoS+ 
strain revealed a decisive role of the two toxins in the intrapulmonary multiplication 
and a predominant role of ExoU in the dissemination extra-pulmonary (475). In some 
models, Exotic and ExoY haven’t play particular roles for P. aeruginosa virulence, 
and ExoT even presented a protective effect (474). 
Clinical observations reported that the activation of T3SS during P. aeruginosa 
infection and the secretion of T3SS toxins were associated with poor clinical 
outcomes (476). 
C-II-d Regulation of T3SS of P. aeruginosa 
P. aeruginosa can be resistant to different environments that exert stresses to its 
metabolic resources or its physicochemical properties and expose potential dangerous 
elements to this germ. An important part of the genome of P. aeruginosa is dominated 
by regulatory genes, which could explain the powerful adaptability of P. aeruginosa. 
The T3SS plays an important role in the resistant ability of P. aeruginosa and it can be 
activated by at least three environmental signals (477, 478): i) in vivo contact with 
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eukaryotic host cells; ii) in vitro removal of calcium from medium; iii) the presence of 
serum (due to the existence of type III secretion factors, which were recently 
identified as albumin and casein (479).  
T3SS of P. aeruginosa is tightly transcriptionally and post-transcriptionally 
regulated. All T3SS genes are coordinately regulated by ExsA, an AraC-like master 
transcriptional activator, which binds to a consensus sequence in the promoter region 
of these genes (480). Besides the major Exs-A dependent regulatory mechanism, 
several factors, including metabolic factors, quorum sensing (QS) systems, cyclic 
AMP with Vfr, PtrA, etc. (481) can also impact T3SS activation. However, their 
action approaches have not yet been perfectly understood. 
ExsA-dependent Regulation 
The regulator genes involved in this mechanism are exsA, exsB, exsC, exsE 
(assembled in exsCEBA operon) and exsD (locating in exsD-pscBL operon). 
ExsA is a member of the AraC family of transcriptional regulators. ExsA 
functions as a central transcriptional regulator of T3SS because it is required for the 
expression of all T3SS genes, including itself, by binding to the consensus sequence 
TXAAAAXA, which is located approximately 51 or 52 bp upstream of the 
transcriptional start site of four operons (pscN-U, popNpcr1234DR, pcrGVHpopBD, 
exsDpscB-L) encoding the T3SS apparatus and translocation machinery, the operon 
exsCEBA, and the effector proteins (480). 
exsB is not translated. Untranslated exsB region mediates either the stability or 
the translation of exsA (482). 
ExsC, a type three secretion chaperone of ExsE, functions as an 
anti-anti-activator due to the fact that ExsC binds to and sequesters the anti-activator, 
ExsD, under T3SS-inducing conditions, thus freeing ExsA to activate the expression 
of T3SS genes (483). 
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ExsE is a secreted regulator of T3SS in P. aeruginosa (484). When the secretion 
channel is closed, ExsE is complexed with its chaperone (ExsC) in the cytoplasm, and 
transcription of the T3SS is repressed by sequestration of ExsA by ExsD. On the 
contrary, when the secretion channel is opened, ExsE is secreted, leaving ExsC free to 
interact with ExsD and releasing ExsA, thereby allowing liberated ExsA to activate 
transcription of the T3SS genes (see more details in later paragraph). 
ExsD was identified as the first negative regulator of P. aeruginosa T3SS (485). 
Bacterial two-hybrid data indicated that ExsD interacts with the ExsA and functions 
as an antiactivator to regulate the expression of T3SS genes. ExsD is essential to 
prevent inappropriate expression of T3SS genes in conditions such as in the absence 
of the appropriate environmental cue for secretion or in mutants lacking a functional 
TTSA. 
 
Figure 10: A Model for the Induction of the Type III Secretion Regulation. 
In calcium depletion or cell contact situations, ExsE can be secreted trough T3SS, which can 
subsequently release ExsC and the inhibition of ExsA by ExsD. And finally, T3SS is activated. All 
proteins except ExsE (E) and PcrV (V) are indicated by name.  Reprinted from Rietsch et al., 
2005 (484) and Urbanowski et al., 2005 (486). 
Introduction 
115 
This complex regulatory network can be explained by figure 10 (484, 486). The 
first gene of the exsD-pscBL operon encodes ExsD which can inhibit ExsA activity by 
forming an inactive complex. ExsC is encoded by the first gene of the exsCEBA 
operon, Fixation of ExsD to ExsA can be prevented by the interaction between ExsC 
and ExsD. And, ExsE, encoded in the exsCEBA operon, can interact with ExsC and 
prevents it to bind with ExsD. Upon T3SS activation by calcium depletion or cell 
contact, ExsE is secreted through it, thus releasing ExsC and the inhibition of ExsA by 
ExsD. 
ExsA-independent Regulation 
The influences mediated by metabolic signals/stresses to T3SS can be 
demonstrated by several examples. Mutants lacking pyruvate dehydrogenase (aceA or 
aceB), or a glucose transport regulator (gltR) fail to induce the T3SS expression (487, 
488). In the presence of histidine in the medium, excessive uptake and degradation of 
histidine due to the overexpression of histidine utilization genes, for instance hutT, 
abolishes the ability to induce exoS expression and rends the bacteria non-cytotoxic 
(489). A dose-dependent upregulation of T3SS gene expression is seen with 
increasing NaCl concentrations (478). 
QS has been demonstrated to be crucial in the pathogenesis of P. aeruginosa 
infections and controls virulence factor gene expression (490, 491). Mutants lacking 
the rhl quorum sensing system show increased expression of T3SS genes and 
secretion of ExoS at an earlier stage during exponential growth (492, 493). Analysis 
of 5 rhl QS-deficient clinical isolates showed that, only one isolate produced normal 
T3SS effector proteins ExoS and ExoT, two isolates produced ExoT only, and two 
isolates produced no effector proteins (494). 
Moreover, a membrane-associated adenylcyclase (CyaB), responsible for cAMP 
synthesis, and a cAMP-binding CRP homologue called Vfr are shown to be required 
for the expression of T3SS genes (488). Modulation of intracellular cAMP seems to 
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be an important mechanism controlling T3SS expression.  
truA, gene encoding pseudouridinase enzyme, is required for the expression of 
type III secretory genes. Pseudouridination of tRNAs is proposed to be critical for the 
translation of T3SS genes or their regulators (495). 
dsbA, gene encoding a periplasmic thiol/disulphide oxidoreductase affects 
expression of multiple virulence factors, including T3SS genes. This is probably a 
non-specific effect resulting from abnormal protein folding caused by the lack of 
disulphide bonds (496). 
C-III Previously Achieved Work in Our Laboratory 
We have been studying the T3SS of P. aeruginosa and trying to construct T3SS 
based antigen delivering bacterial strains for several years. The intracytoplasmic 
antigen delivery was carried out through the fusion of interest antigens with T3SS 
toxin ExoS. The development and application of bacterial vectors are still on going 
further. Previously achieved work focused on the determination of the necessary 
minimal sequence of ExoS for the secretion of an ExoS-antigen fusion protein, the 
development of different attenuated strains, the development of a plasmid construct in 
which ExsA was inserted in the dependence of an inducible promoter, and the 
application of attenuated bacterial vectors in anti-tumor vaccinations. 
C-III-a Attenuation of Bacterial Strain 
Firstly, two T3SS toxin genes (exoS and exoT) were deleted in CHA strain 
according to our published Cre-lox system (497) and this attenuated strain is called 
CHA-OST. In vitro experiments showed that the cytotoxicity of CHA-OST strain 
against bone-marrow-derived myeloid DCs from C57BL/6 mice the PLB985 cell line 
has been reduced to 50% of that of the parental strain (3). An international patent 
about this bacterium used as interest protein delivery vector has been applied in 2005 
(WO 2005/049644). 
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Afterwards, other genes, aroA and two genes participating in the QS system (lasI 
and rhlI), have been targeted for further virulence attenuation. aroA-encoded 
3-phosphoshikimate 1-carboxyvinyltransferase is a key enzyme in aromatic amino 
acid synthesis; the aroA deletion confers auxotrophy for aromatic amino acids and has 
been successfully used to elaborate attenuated P. aeruginosa strains for the purpose of 
anti-Pseudomonas vaccination. lasI and rhlI encode the two enzymes producing QS 
homoserine lactones 3-oxo-C12-HSL and C4-HSL, respectively; P. aeruginosa QS 
inactivation has been associated with virulence attenuation in various animal models 
for injury or illness, including those for pneumonia, burns, and pyelonephritis. 
Thereby, basing on Cre-lox system, CHA-OA (ΔexoS ΔexoT ΔaroA), CHA-OAL 
(ΔexoS ΔexoT ΔaroA ΔlasI), and CHA-ORL (ΔexoS ΔexoT ΔrhlI ΔlasI) have been 
constructed, of which the cytotoxicity has been significantly reduced (10). 
C-III-b Construct of Inducible ExsA Containing Plasmid 
 
Figure 11: Inducible Protein Expression System.  
The addition of IPTG can suppress the quiescent effect imparted by LacIQ to ptac, which can 
initiate exsA transcription and permit the expression of T3SS genes. 
The sequence of the transcriptional activator-ExsA was cloned in a plasmid 
pEsxAind in dependence of the ptac promoter. This plasmid contains the sequence 
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encoding the repressor of ptac, LacIQ. In non-induced situation, ptac is coupled with 
LacIQ and the transcription of ExsA is inhibited. With the presence of a ligand of 
LacIQ (lactose, isopropyl-β-D thiogalactopyranoside (IPTG)), the quiescent effect 
imparted by LacIQ to ptac can be eliminated, consequently ExsA gene will be 
transcribed and T3SS genes will be expressed (Fig. 11). 
Studies realized in the laboratory shown that the addition of IPTG to the culture 
medium of one pExsAind transformed CHA strain effectively induced the 
transcription of the entire regulon in dependence of ExsA. And, the high-level protein 
secretion was only depended upon calcium depletion in vitro or contact with target 
cells in vivo.  
C-III-c Determination of the Necessary Minimal Sequence for Protein Secretion 
(3) 
In order to determine the region of the P. aeruginosa T3SS toxin ExoS required 
for the secretion and translocation of an ExoS-fused antigen, a series of fusion 
proteins containing different sequences of ExoS (the N-terminal 129, 96, 54, or 17aa 
of ExoS) and three reporter proteins that are not normally secreted by the T3SS (P. 
aeruginosa inhibitor of vertebrate lysozyme (IVY), P. putida catechol 
2,3-dioxygenase (CDO), and green fluorescent protein (GFP)) were generated, 
respectively. The different fusion protein coding plasmids were transferred into P. 
aeruginosa strain CHA and the secretion of the fusion proteins was assessed after 
T3SS induction mediated by calcium depletion, a condition known to trigger T3SS. 
It was observed that with the N terminal ExoS fragments of 129 or 96 aa, only 
IVY was efficiently secreted but not CDO or GFP. All reporter proteins fused with the 
N terminal 17 aa of ExoS were secreted only at low levels. However, high secretion 
levels when each of the reporter proteins was fused with the N terminal 54 aa of ExoS. 
Thereby, the first 54aa of Exo S is considered as the most optimal sequence for the 
secretion of fusion protein via T3SS. 
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C-III-d Application of Antigen Delivering Bacterial Vectors in Anti-tumor 
Vaccination 
The antigen delivery efficiency and anti-tumor immunity activation ability of 
these attenuated T3SS based bacterial vectors have been evaluated not only in vitro 
but also in murine models and their performance has been confirmed; 
Using OVA as model antigen, CHA-OST strain can provide 100% prophylactic 
protection against B16OVA tumor; CHA-ORL, CHA-OA, CHA-OAL can be applied 
in vivo at high dose but with the reduced anti-tumor efficiency (3, 10).  
Moreover, our platform technology has been also demonstrated so efficient to 
break tolerance against self antigens. In murin glioblastoma model, CHA-OST-TRP2 
strain can significant delay the tumor formation in prophylactic assay (6). 
However, in different therapeutic experiments, the results were not so satisfied, 
maybe because of the non-optimized vaccination regime. 
D The Objectives of This Work 
Due to the endowed effective ability to deliver antigen to cytoplasm of APCs in 
vivo, T3SS based attenuated bacterial vectors, such as Yersinia, Salmonella, Shigella, 
attracted more and more attention for their potential interest in cancer vaccine 
development.  
Basing on the studies of our laboratory during the last years, a great amount of 
characterizations of P. aeruginosa has been identified. In particular, T3SS antigen 
delivery induced immune response is MHC I restricted, CD8+ T cell mediated 
response. On the other hand, as the genome of P. aeruginosa has been identified and 
mapped, the attenuation of this germ through genetic manipulations has become 
realistic. Due to these progresses, we have developed live attenuated P. aeruginosa 
T3SS based vectors and applied them as antigen carriers for cancer vaccine design.  
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The ultimate objective of all cancer researches is that the results of these 
researches can be applied in human cancer treatment, which is also the important 
consideration for us. For this purpose, efficacy, safety (virulence attenuation), and the 
production process of bacterial vector complying with current good manufacturing 
practices grade are essential. 
To respond to these requirements, in this study, we attempted to: 1) further 
enhance the performance of bacterial vectors; 2) validate bacterial vaccines efficacy in 
therapeutic vaccination mode; 3) generate safe, efficient vaccine candidate for clinical 
application on following good manufacturing practices; 4) evaluate bacterial vector in 
a humanized animal model; and 5) investigate a general issue for all bacterial/viral 
vaccine: pre-existing anti-vector immunity. 
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A Bacterial Strains and Plasmids 
Table 5: Bacterial Strains Used in This Study 
Strains Description Source 
E.coli 
DH5α used for plasmid transformation Invitrogen 
S17-1 used for mating constructs into P. aeruginosa Simon et al. 
1983 
P.aeruginosa 
CHA-OST Mutant of CHA strain (a mucoid strain isolated 
from the lungs of a cystic fibrosis patient (498)) 
with the deletion of ExoS & ExoT encoding 
genes (CHAΔexoSΔexoT) 
(497) 
CHA-OST S54-P-OVA CHA-OST strain transformed with the plasmid 
pEAI S54-Padre-OVA248-376 
This study 
CHA-OST S54-P-TRP2L CHA-OST strain transformed with the plasmid 
pEAI S54-Padre-TRP2125-376 
This study 
CHA-OST S54-TRP2L-P CHA-OST strain transformed with the plasmid 
pEAI S54- TRP2125-376-Padre 
This study 
CHA-OST S54-P-TRP2S CHA-OST strain transformed with the plasmid 
pEAI S54-Padre-TRP2291-376 
This study 
CHA-OST S54-TRP2S-P CHA-OST strain transformed with the plasmid 
pEAI S54- TRP2291-376-Padre 
This study 
CHA-OST S54-P-GP100 CHA-OST strain transformed with the plasmid 
pEAI S54-Padre-GP10021-150 
This study 
CHA-OST- S54-P-HER2 CHA-OST strain transformed with the plasmid 
pEAI S54-Padre- HER2340-507 
This study 
CHA-OST S54-P-OVA 
         S54-P-TRP2L 
CHA-OST strain transformed with the plasmid 
pEAI S54-Padre-OVA248-376 S54-Padre- 
TRP2125-376 
This study 
CHA-OST S54-P-TRP2L 
         S54-P-OVA 
CHA-OST strain transformed with the plasmid 
pEAI S54-Padre- TRP2125-376 
S54-Padre-OVA248-376  
This study 
CHA-OST S54-P-TRP2L 
         S54-P-GP100 
CHA-OST strain transformed with the plasmid 
pEAI S54-Padre- TRP2125-376 S54-Padre- 
GP10021-150 
This study 
CHA-OST AroA LasI 
(CHA-OAL) 
Mutant of CHA strain with the deletion of ExoS, 
ExoT, AroA & LasI encoding genes 
(CHAΔexoSΔexoTΔaroAΔlasI) 
(10) 
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CHA-OAL S54-P-OVA CHA-OAL strain transformed with the plasmid 
pEAI S54-Padre-OVA248-376 
This study 
CHA-CLIN1 CHA-OAL strain adapted in one chemically 
defined medium 
This study 
CHA-CLIN1 S54-P-OVA CHA-CLIN1 strain transformed with the plasmid 
pEAI S54-Padre-OVA248-376 
This study 
CHA-OST-ΔBD Mutant of CHA strain with the deletion of ExoS, 
ExoT, PopB & PopD encoding genes 
(CHAΔexoSΔexoTΔpopBΔpopD) 
This study 
CHA-OST-ΔBD S54-P-OVA CHA-OST-ΔBD strain transformed with the 
plasmid pEAI S54-Padre-OVA248-376 
This study 
 
Table 6: Plasmids Used in This Study 
Plasmids Description Source 
pExsAind pUCP20 (Escherichia-Pseudomonas shuttle 
vector; Apr(Cbr) (499))-derived vector 
containing IPTG-inducible exsA; Apr(Cbr) 
(500) 
pEAI-S54-OVA248-376 Cloning of orf1 sequence and 
exoS54-ova248-376 fusion sequence in 
pExsAind plasmid 
(3) 
pEAI S54-Padre OVA248-376 Derived from pEAI-S54-OVACter in which 
exoS54-ova248-376 fusion sequence was 
replaced by exoS54-padre-ova248-376 fusion 
sequence. 
This study 
pEAI S54-Padre-TRP2125-376 Idem; exoS54-padre-trp2125-376 fusion 
sequence. 
This study 
pEAI S54-TRP2125-376-Padre Idem; exoS54-trp2125-376-padre fusion 
sequence 
This study 
pEAI S54-Padre-TRP2291-376 Idem; exoS54-padre-trp2291-376 fusion 
sequence 
This study 
pEAI S54 -TRP2291-376-Padre Idem; exoS54-trp2291-376 -padre fusion 
sequence 
This study 
pEAI S54-Padre-GP10021-150 Idem; exoS54-padre-gp10021-150 fusion 
sequence 
This study 
pEAI-S54-PADRE-HER2340-507 Idem; exoS54-padre-her2340-507 fusion 
sequence 
This study 
pEAI S54-Padre-OVA248-376 
S54-Padre- TRP2125-376 
Idem ; whereas two independent fusion 
sequences, exoS54-padre-ova248-376 and 
exoS54-padre-trp2125-376, were sequentially 
cloned in pExsAind plasmid 
This study 
pEAI S54-Padre-TRP2125-376 Idem; exoS54-padre-trp2125-376 fusion This study 
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S54-Padre-OVA248-376 sequence and exoS54-padre-ova248-376 fusion 
sequence, sequentially. 
pEAI S54-Padre-TRP2125-376 
S54-Padre- GP10021-150 
Idem; exoS54-padre-trp2125-376 fusion 
sequence and exoS54-padre-gp10021-150 fusion 
sequence, sequentially. 
This study 
pEX100T mut popBpopD pEX100Tlink-derived vector containing up- 
and downstream region of PopB-PopD and 
Gmlox; Apr, Gmr 
Madiha 
Derouazi, 
2005 
 
B Manipulations of Bacteria 
B-I Manipulations of Escherichia Coli 
B-I-a Bacterial Media 
Luria Broth (LB) medium: Luria Broth Base (Miller) powder (Sigma): 25 g/L 
                      H2O QSP 
Luria Broth (LB) plate: Luria Broth Base (Miller) powder: 25 g/L 
                   Agar (Invitrogen): 10 g/L 
                   H2O QSP 
Antibiotics (identical in liquid and solid media): Ampicillin (Sigma): 100 μg/mL 
                                       Gentamycin (Sigma): 10 μg/mL 
B-I-b Transformation of E.Coli Strains with Plasmids 
a) Thaw competent bacteria cells on ice; 
b) Add 1-10 ng of plasmid DNA to 50 uL of competent cells and mix well. 
Incubate mixture on ice for 30 minutes; 
c) Heat shock the cells for 30 seconds at 37C; 
d) Place back on ice for 2 minutes; 
e) Add 450 μL of pre-warmed SOC medium and shake at 250 rpm at 37°C for 1 
hour to express the antibiotic resistance gene; 
f) Spread 100 mL and 400 mL of transformed cells onto the pre-warmed LB 
plates containing appropriate antibiotic.  
g) Incubate plates overnight at 37°C. 
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B-II Manipulations of P. aeruginosa 
B-II-a Bacterial Media 
Luria Broth (LB) medium: Luria Broth Base (Miller) powder: 25 g/L 
                      H2O QSP 
Luria Broth (LB) plate: Luria Broth Base (Miller) powder: 25 g/L 
                   Agar: 10 g/L 
                   H2O QSP 
Pseudomonas Isolation Agar (PIA) plate: Difco Pseudomonas Isolation Agar: 45 g/L  
                                      (Becton Dickinson) 
                                    Glycerol (VWR): 20 mL/L 
H2O QSP 
   Antibiotics: Carbecillin: 300 μg/mL in liquid medium, 600 μg/mL in solid medium 
Gentamycin: 200 μg/mL in liquid medium, 400 μg/mL in solid medium 
B-II-b Transformation of P. aeruginosa with Plasmids by Electroporation  
a) Transfer 1 mL pre-cultured P. aeruginosa to a 1.5 mL micro-centrifuge tube 
and centrifuge at 13 000 rpm for 3 min.  
b) Remove the supernatant, resuspend the cells in 500 μL cold sucrose (300 mM) 
and centrifuge at 13 000 rpm for 3 min. 
c) Repeat the step 2 for 2 times. 
d) Add 1-3 mL plasmid (10-30 ng) and mix well with the cell. Incubate on ice 
for 30 minutes. 
e) Add the mixture in the cold electroporation cuvette (-20°C for 30 minutes) 
and pulse the cuvette at 1800 V, 5 ms (ElectroCell Manipulator ECM399 BTX 
system, Genetronic Inc, San Diego, CA).  
f) Add immediately 450 mL of pre-warmed SOC medium and shake at 37°C 
for 1 hour. 
g) Spread 100 mL and 400 mL of transformed cells onto the pre-warmed PIA 
plates containing appropriate antibiotic. 
h) Incubate at 37°C overnight. 
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B-II-c P. aeruginosa T3SS Analysis  
The T3SS of P. aeruginosa can be induced through the calcium depletion in the 
culture medium. We believe that this condition can artificially open the secretion 
channel of the T3SS, leading to 1) a transcriptional activation of all T3SS genes in 
dependence of ExsA; and 2) the secretion of toxins or toxin-protein fusion fragments. 
This calcium depletion can be achieved by incorporating a calcium chelator, EGTA 
(ethylene glycol bis (b-aminoethyl ether) N,N,N’,N’-tetraacetic acid) of 5 mM, into 
culture medium. Moreover, we added also 20 mM MgCl2 to the culture medium so 
that the bacteria have enough divalent cations. The detailed protocol is described as 
following. 
After an overnight pre-culture in LB containing 300 µg/mL carbenicillin, the 
bacteria were resuspended at 0.2 OD600 in LB containing 300 µg/mL carbenicillin, 
0.5 mM IPTG, 5 mM EGTA and 20 mM MgCl2 until the OD600 reaches a value 
between 1.5 and 2. Then, bacterial cultures were centrifuged at 13000 g for 10 min 
and the supernatant was recovered. The production of toxins or toxin-protein fusion 
fragments can be analyzed through an appropriated method (SDS-page, etc.). 
B-III Adaptations of CHA-OAL Strain in One Chemically Defined Medium 
At beginning, we compounded CHA-OAL strain adaptation medium basing M9 
medium and Debell MR compounded medium (501). But the growth rate of bacteria 
was not high enough. After that, we further modified adaption medium by 
supplementing it with Mg2+ and Ca2+ and the composition of final CHA-OAL 
adaptation medium (M9-TheREx) is shown in table 7. 
For CHA-OAL strain adaptation, the bacterial culture was begun in LB broth and 
the replacement of LB broth by modified M9 (M9-TheREx) broth for bacterial culture 
was progressive (100% LB —> 50% LB-M9-TheREx —> 20% LB-M9-TheREx —> 
5% LB-M9-TheREx —> 2% LB-M9-TheREx —> 100% M9-TheREx). For each step, 
at least two days of adaptation was realized, finally OAL strain proliferate stably in 
100% M9-TheREx medium. Except the culture medium, the manipulation protocols 
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for OAL strains are the same as that described in the section of Manipulations of P. 
aeruginosa. 
Table 7: The Composition of Modified M9 (M9-TheREx) Medium 
Extract of synthetic yeast……………..  4 g/L 
Tryptophan ……………………………  1 mmol/L ( 0,2 g/L) 
Glucose…………………………………  14 mmol/L (2,5 g/L) 
Glycerol………………………………...  1% 
FeSO4…………………………………..  0.4 g/L 
Citric acid………………………………  2 mmol/L (0,36g/L) 
M9 Salts Medium 5X ( Sigma) approximate composition per 
liter 
Na2PO3 anhydre....................  33.9 g 
KPO3.......................................  15.0 g 
NaCl .......................................  2.5 g 
NH4Cl......................................  5.0 g 
MgSO4…… ……………………………  1mmol/L (50mg/L) 
CaSo4…. ……………………………….  1mmol/L (50mg/L) 
H2O……………………………………..   qsp 1L 
 
B-IV Constitution of CHA-OST-∆BD Mutant Strain 
1. Preparation of E.coli S17-1 containing plasmid pKO-PopB & PopD: transform 
E.coli S17-1with pEX100T mut popBpopD (described before, B-I-b). 
2. Mating between CHA-OST and E.coli S17-1- pKO-POP B & POP D 
a) Mix at 1:1 of 50 µL exponential phase (OD600≈0.5) CHA-OST and E.coli 
S17-1- pEX100T mut popBpopD. Deposit the mixture on the surface of LB agar 
without salt. Incubate the plate overnight in the incubator at 37°C. 
b) Transfer the bacteria into a micro-centrifuge tube containing 1 ml of LB. 
c) Spread 100 µL bacteria (OD600 is from 1 to 2) on the PIA (Gm400) at 37°C, 
overnight.  
d) Incubate 50 colonies on the PIA containing 5% sucrose at 37°C, overnight. In 
theory, only mutants with double combination could survive in the presence of 5% 
sucrose, but in fact all mutants survive after overnight’s incubation (with different 
size of the colonies).  
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e) Re-incubate these 50 colonies on the PIA (Gm400) as well as PIA (Cb600) at 
37°C, overnight.  
f) Select colonies growing on the PIA (Gm400) but not on the PIA (Cb600) for 
further verification by PCR 
B-V Bacterial Vaccines Culture 
Principally, P. aeruginosa vaccine strains were grown overnight at 37°C with 
shaking at 250 rpm in bacteria culture medium containing 300 µg/mL carbenicillin 
(Euromedex, France). Next morning, the bacteria were resuspended in fresh culture 
medium at OD600 of 0.2 in LB containing 300 µg/mL carbenicillin and 0.5 mM IPTG 
until the OD600 reaches value between 1.5 and 2. Finally, bacteria cells were washed 
and resuspended in PBS, pH 7.2 for mice injection. 
The culture medium for CHA-OST and CHA-OALstrains was LB, and for 
adapted CHA-OAL (CHA-CLIN1) strains was M9-TheREx. 
C Molecular Biology 
C-I PCR 
Polymerase chain reaction (PCR) is a common method of creating copies of 
specific fragments of DNA. PCR rapidly amplifies a single DNA molecule into many 
billions of molecules. In this study, PCR has been used for either synthesizing DNA 
fragments for cloning or detecting the presence of one sequence. All the PCRs have 
been achieved as follows:  
C-I-a Materials 
a) Template DNA. The template can be a fragment of DNA, a preparation of 
genomic DNA or a plasmid. Up to 10 ng of DNA has been utilized per reaction, 
b) Forward primer and reverse primer. Each primer should be 20-30 nucleotides 
in length, G+C content should be between 40 and 60%, with a balanced 
distribution of all four bases along the length of the primer and a low propensity to 
form stable secondary structures. Restriction sites can be added to the 5’ termini of 
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the primer and these primer-specific restriction sites are transferred to the termini 
of the target DNA during amplification. All primers used in this work were 
synthesized by Metabion, Germany and are shown in table 8. 
Table 8: Primer Sequences Used in This Study 
 Oligonucleotide Sequence 
Primers used for cloning antigen in uni-antigen vector 
PADRE(Nter) forward 5’-gatcggccaagttcgtcgccgcctggaccctgaaggccgccgccggatccaaagcatg-3’ 
PADRE(Nter) reverse 5’-ctttggatccggcggcggccttcagggtccaggcggcgacgaacttggcc-3’ 
PADRE(Cter) forward 5’-gatccaaagcatgcgccaagttcgtcgccgcctggaccctgaaggccgccgccccatgwere-3’ 
PADRE(Cter) reverse 5’-gggcggcggccttcagggtccaggcggcgacgaacttggcgcatgctttg-3’ 
TRP2125-376 forward (BamH I) 5’-aaggatccagacggaatatccattccctgact-3’ 
TRP2125-376 reverse (Sph I) 5’-catgggcatgcttacttgcggaaggagtgagc-3’ 
TRP2125-376 reverse (Bgl II) 5’-ggaagatctttacttgcggaaggagtgagccaag-3’ 
TRP2291-376 forward (BamH I) 5’-aaggatccgactacaaccgccgggtcaca-3’ 
TRP2291-376 reverse (Sph I) 5’-aagcatgccttgcggaaggagtgagccaagttatgaag-3’ 
OVA248-376 forward (BamH I) 5’-gccggatccgatgaagtctcaggccttgag-3’ 
OVA248-376 reverse (Sph I) 5’-catgggcatgcttaggcgttggttgcgatgt-3’ 
OVA248-376 reverse (Bgl II) 5’-ggaagatctttaggcgttggttgcgatgt-3’ 
GP10021-150 forward (BamH I) 5’-aaggatcccctagaaggatccaggaatcaggac-3’ 
GP10021-150 reverse (Sph I) 5’-aagcatgcttaagatgggcagggtccaccgt-3’ 
HER2340-507 forward (BamH I) 5’-cgggatcccgagtgtgctatggtctgggc-3’ 
HER2340-507 reverse (Sph I) 5’-acatgcatgcatgttactcgcccacacactcgtcct-3’ 
Primers used for cloning antigen in the second position in bi-antigen vector 
Universal forward primer (Bgl II) 5’-gaagatctcaggagaaggcaaccatcat-3’ 
S54-PADRE-OVA248-376 reverse (Sph I) 5’-catgggcatgcttaggcgttggttgcgatgt-3’ 
S54-PADRE-TRP2125-376 reverse (Sph I) 5’-catgggcatgcttacttgcggaaggagtgagc-3’ 
S54-PADRE-GP10021-150 reverse (Sph I) 5’-catgggcatgctcttaagatgggcagggtccaccgt-3’ 
 
c) Thermostable DNA polymerase. The thermostable DNA polymerase used in 
this work was principally PfuUltra™ HF DNA polymerase, Stratagene, USA, 
which can synthesize PCR fragments with high fidelity due to its proofreading 
capacity. Using Pfu polymerase, the elongation rate is about 500 bp / min. 
d) PfuUltra™ HF reaction buffer (Stratagene). 
e) dNTP solution containing all four dNTPs (Invitrogen). 
f) Thermal cycler (MJ MiniCyclerTM, watertown, USA). 
g) In summary, standard PCR reaction compositions are as following: 
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Template DNA…………………………………1-10 ng 
5 mM solution of four dNTPs…………………...2.5 µL 
30 mM (pmol ml-1) forward primer…………….0.5 µL 
30 mM (pmol ml-1) reverse primer......................0.5 µL 
PfuUltra™ HF DNA polymerase (2.5 U/μl)……0.5 µL 
10X PfuUltra™ HF reaction buffer....................... 5 mL 
H2O………………………………………...OSP 50 µL 
C-I-b PCR Programming 
PCR is an iterative process, consisting of three elements: denaturation of the 
template by heat, annealing of the oligonucleotide primers to the single-stranded 
target sequence(s), and extension of the annealed primers by a thermostable 
polymerase. 
a) The denaturation step at 95 °C (usually 30-60s) is required for obtaining 
single-stranded DNA molecules to which the primers will bind. In the first cycle of 
PCR, denaturation is sometimes carried out for 5 minutes to increase the 
probability that long molecules of template DNA are fully denatured. 
b) The annealing step (usually 45 - 60 s) allows primers to hybridize with the 
matrix. Annealing is generally carried out 5°C lower than the melting temperature 
at which the oligonucleotide primers dissociate from their templates. The melting 
temperature (Tm) of oligonucleotide primers can be calculated using the following 
formula: Tm (°C) = 2(A+T) + 4(G+C), where (A+T) is the sum of the A and T 
residues in the oligonucleotide and (G+C) is the sum of G and C residues in the 
oligonucleotide.  
c) The extension step permits DNA synthesis catalyzed by the thermostable 
polymerase. This step is carried out at 72°C in the case of Pfu DNA polymerase 
and the duration of this step is depended on the length of the amplifying sequence. 
For the last cycle of PCR, an extension time is generally longer than in the 
previous cycles, which is used to allow completion of all amplified products. 
d) The number of cycles required for amplification depends on the number of 
copies of template DNA present at the beginning of the reaction and the efficiency 
of primer extension and amplification. In this study, PCR reactions generally 
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include more than thirty cycles which were carried out by incubating the tubes in 
Minicycler device (MJ Research, Watertown, MA). 
e) One example of PCR amplification using PfuUltra™ HF DNA polymerase: 
 95°C  5 min 
 95°C  1 min 
 63°C  1 min 
 72°C  2 min (for 1 kb of length of the target DNA) 
 Repeat steps 2-4 for another 34 cycles 
 72°C  10 min 
 4°C   up to overnight 
 
C-II Agarose Gel Electrophoresis 
DNA is an anion. Due to this electric charge, DNA fragments can be migrated in 
an electric field. Electrophoresis through agarose gel is one simple, rapidly performed 
technique that has been used to identify, separate and purify DNA fragments in this 
study. 
C-II-a Materials 
 Agarose Ultrapure (Invitrogen) 
 Electrophoresis buffer: 50 x TAE Solution, Euromedex (2 M Tris-Amino, 1 
M Acetate, 50 mM EDTA, pH 8) 
 Ethidium bromide: 10 mg/mL (20,000 X) (Sigma) 
 Gel-loading buffer: Blue/Orange 6 X loading buffer (Promega) 
 Molecular weight marker: 1 kb DNA ladder (100 ng/µL)( Promega) 
 Gel-sealing tape 
 Electrophoresis apparatus with chamber and comb (Embi Tec, San Diego, 
CA, USA) 
 Electrophoresis power supply device (Apelex, Massy, France) 
 UV device (Bioblock Scientific, Illkirch, France) 
 Imaging device 
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C-II-b Methods 
a) Prepare a solution of agarose in 1 X TAE buffer at an appropriate 
concentration (in general, 1% for the fragment of length more than 500 pb; 2% for 
the fragment of length less than 500 pb).  
b) Heat the slurry in a microwave oven until the agarose dissolves. Add EB to 
the mixture to a final concentration of 0.5 µg/mL. 
c) Shape gel in one mold containing an appropriate comb for forming the 
sample slots. 
d) Mount the gel in the electrophoresis tank and add 1 X TAE buffer to cover 
the gel; 
e) Mix the DNA samples with 6 ´ gel-loading buffer. Load the DNA marker and 
the sample mixture into the slots of the submerged gel. 
f) Carry out the migration under 50-100 voltage. 
g) Examine the gel by UV device or photograph the gel using the imaging 
device. 
C-II-c Recovery of DNA from Agarose Gel 
After the migration within agarose gel, the different DNA fragments can be 
recovered from gel by using the commercial gel extraction kit (QIAquick Gel 
Extraction kit (Qiagen, Courtaboeuf, France)). All procedures were performed 
according to the instructions of manufacturer. 
C-III Cloning 
In principle, closed circular plasmid DNA is cleaved with one or two restriction 
enzymes and ligated in vitro to foreign DNA bearing compatible termini. The 
products of the ligation reaction are then used to transform an appropriate strain of E. 
coli (DH 5α). The resulting transformed colonies are screened by PCR or by digestion 
with restriction enzymes to identify those that carry the desired DNA sequences. 
Finally, positive clones can be confirmed by commercial DNA sequencing. 
C-III-a Plasmid Vectors Preparation 
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Purified plasmid DNA can be developed from bacteria, which generally involve 
three steps: growth of the bacterial culture, harvesting and lysis of the bacteria and 
purification of the plasmid DNA. In this work, generally 2-3 mL of bacteria were 
cultivated during 12-16 hours for DNA plasmid expression. Then, the extraction of 
plasmid was achieved by using commercial Kit (QIAprep Spin Miniprep kit (Qiagen, 
Courtaboeuf, France)). All procedures were performed according to the instructions of 
the manual of the kit. 
C-III-b Restriction Enzyme Digestion  
a) Materials: 
– Restriction enzymes (Roche, Meylan, France or Invitrogen, Cergy 
pontoise, France) 
– 10 X buffer for Restriction enzymes (Roche or Invitrogen) 
– Plasmids 
– Thermomixer (Eppendorf, Hamburg, Germany) or a water bath preset to 
37°C 
b) Standard recipe:  Plasmid……………………………... 0.1-0.5 µg (1-5 µL) 
                    Restriction enzymes (10 U ml-1).......................... 0.5 mL 
                    10 X buffer for restriction enzymes…………………1µL 
                    H2O..................................................................QSP 10 µL 
c) Method: Incubate the reaction mixture at 37°C for 1-3 hours. At the end, 
digestion can be checked by agarose gel electrophoresis (see C-II section). 
C-III-c DNA Ligation  
The ligation between digested plasmid vector and insert DNA has been achieved 
by using the commercial Kit (Rapid DNA ligation Kit, Roche, Meylan, France). All 
procedures were performed according to the instructions of the manual of the kit. 
C-III-d Transformation 
It was performed as described in Materials and Methods B-I-b and B-II-b. 
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C-III-e DNA Sequencing 
It was performed at AGOWA, Germany by delivering 1 µg of plasmid (generally 
10 µl of Miniprep) with appropriated sequencing primer. 
D Protein Analysis 
D-I Protein Precipitation 
For precipitation of proteins, perchloric acid was added to supernatant at a final 
concentration of 15% and incubated at 4°C, overnight. The next day, precipitated 
proteins were centrifuged at 17000 g, 4°C for 30 min; proteins were washed two times 
with acetone (17000 g, 15 min), dried at room temperature.  
D-II Protein Denaturation  
Washed and dried proteins were resuspended in 60 µL denaturation buffer (0.5 M 
Tris-HCL, 0.6 M dithiothreitol, 10% SDS, 0.012% bromophenol blue, 30% glycerol). 
SDS is an anionic detergent which denatures secondary and non–disulfide–linked 
tertiary structures, and applies a negative charge to each protein in proportion to its 
mass. DTT is frequently used to reduce the disulfide bonds of proteins. This method 
allows the protein to preferentially migrate according to its mass but not its structure. 
Dissolved in the denaturation buffer, protein can be analyzed immediately or 
conserved at -20°C. Before polyacrylamide gel migration, a further denaturation step 
was generally carried out by exposing the protein at 95°C for 5 min. 
D-III SDS-PAGE (SDS-PolyAcrylamide Gel Electrophoresis) 
In principle, the SDS-PAGE is realized in a vertically migrated gel composed of 
two parts. The upper part, also called stacking gel, is of thinner acrylamide (5%). The 
migration in this part allows all proteins to migrate at the same level after applying an 
electric field. The bottom part, also called resolving gel, is of concentrated acrylamide. 
The migration in this part permits the separation of the different proteins according to 
their molecular weight. The acrylamide concentration of the resolving gel can be 
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varied, generally in the range from 5% to 25%. Lower percentage gels are better for 
resolving high molecular weight proteins, while much higher percentages are needed 
to resolve smaller proteins. In this study, we usually used the gel of 12% or 15% 
acrylamide, we suggested that protein of molecular weight between 20 and 30 kDa are 
better visualized in a 15% acrylamide gel, and proteins of 30 to 40 kDa are better 
visualized in a 12% acrylamide gel.  
D-III-a Materials 
 Acrylamide (Purity 99.9%) / Bis-Acrylamide 40% Solution    Sigma 
 Stacking Gel Buffer, 0,5 M Tris-HCL, pH 6,8               Biorad 
 Resolving Gel Buffer, 1,5 M Tris-HCL, pH 8,8              Biorad 
 SDS                                                Sigma 
 Ammonium persulfate                                  Sigma 
 TEMED (N,N,N',N'-Tetramethylethylenediamine)            Sigma 
 Migaration buffer: (Tris-HCl 25 mM pH 8, glycine 200 mM, SDS 0,1%) 
D-III-b SDS-Page Gel Compositions 
 Stacking Gel Resolving Gel 
Acrylamide 5% 12% or 15% 
SDS 1% 
Tris 0,5 M pH 6,8 25%  
Tris 1,5 M pH 8,8  25% 
Ammonium persulfate 10% (w/v) 1% 
TEMED 1‰ 
H2O QSP 
 
D-III-c Migration 
Apply a voltage of 8 V/cm to the stacking gel and then increase the voltage to 15 
V/cm to the resolving gel. Run it until the bromophenol blue reaches the bottom of the 
gel. 
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D-III-d Staining of SDS-Polyacrylamide Gels 
In this study, we have stained SDS-polyacrylamides gels either through standard 
Coomassie Brilliant Blue staining methods or using a commercial rapid 
stainingsolution. 
a) Standard Coomassie Brilliant Blue Staining: Coomassie Brilliant Blue binds 
nonspecifically to proteins but not to the gel, thereby allowing visualization of the 
proteins as discreet blue bands. 
 Immerse the gel in the 0.25% Coomassie Brilliant Blue R 250 (Merck, 
Darmstadt, Germany) solution. 
 Rotate slowly for a minimum of 1 hour at room temperature. 
 Remove the staining solution destain the gel by soaking it in the methanol: 
glacial acetic acid: H2O (5:1:4, v/v/v) on a slowly rocking platform for 
4-8 hours.  
 Changing the destaining solution several times (Use methanol: glacial 
acetic acid: H2O 3:1:6, v/vv, for a more rapid destaining). 
 Store indefinitely the fixed gel in H2O containing 20 % glycerol before 
drying. 
b) Rapid Staining Using One Commercial Staining Solution: PageBlue™ 
Protein Staining Solution, Euromedex. All procedures were performed according 
to the instructions of the manual of product. 
 
E Immune response Monitoring 
E-I CTLs Cytotoxicity Detection Assay 
E-I-a In Vitro CTL Induction  
a) Mice that have been vaccinated on day –14 and day –7 were sacrificed on 
day 0, and their spleens were removed and processed individually.  
b) Prepare single cell suspension by grinding spleen and filtering the tissue 
through a cell strainer (70 µm; Becton Dickinson, Franklin Lakes, NJ). 
c) Add splenocytes to ficoll solution (GE Healthcare/Amersham) and 
centrifuged at 800g for 20 minutes to obtain lymphocytes fraction.  
d) Wash cells and resuspend lymphocytes in RPMI containing 10% FBS, 100 
U/ml penicillin, 100 µg/mL streptomycin, IL-2 30 U/mL. 
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e) Seat lymphocytes in a 6-well plate and incubate with mitomycin-C-treated 
tumor cells at the ration of 40:1 (L/T).  
f) On day 3, add IL-2 to culture solution at 30 U/mL.  
g) On day 6, non-adherent T lymphocytes were harvested for cytolytic assays. 
E-I-b Cytotoxicity Assay  
Inducted T lymphocytes were plated with target tumor cells (GL26) at different 
effector/target ratios (ranging from 10/1 to 60/1). The cytolytic activity of T cells was 
determined by measuring lactate dehydrogenase (LDH) release. The percentage of 
lysis was calculated using the following formula: 
 
                          Exp. Value – Negative control        
 Positive control – Negative control 
   - Positive control: target cells 100% lysed 
   - Negative control: only target cells 
 
LDH release was measured according to the protocol of “Cytotoxicity Detection 
Kit (LDH)” (Roche, Indianapolis, In, USA). In general, tumor cells and CTL cells 
were co-incubated at 37°C, 5% CO2 in 200µl RPMI, 1% FBS during 4 hours, then 
100 µL supernatant of each sample was transferred to an optically clear 96-well 
microplate and 100 µL detect reagent was added to each well. After that, the plate was 
incubated at room temperature for 30 min in the dark and the absorbance of samples 
was measured by an ELISA reader at 492 nm. For the 100% lysis control, tumor cells 
were treated with 100 µL Triton X-100 solution (2% in assay medium) during 4 
hours. 
E-II Treg Cells Detection through Flow Cytometry Analysis 
a) Mice that have been vaccinated on day –14 and day –7 were sacrificed on 
day 0, and draining lymph nodes (DLN) in vaccination area were removed and 
Cytotoxicity (%) = * 100 
Materials and Methods 
139 
processed individually, and grinded to obtain the single cell suspension.  
b) Incubate DLN lymphocytes with FITC-conjugated anti-CD4 Ab, 
PE-conjugated anti-CD25 Ab and APC conjugated anti-FoxP3 Ab on following the 
protocol of Miltenyi Biotec (Germany).  
E-III IFN-γ Enzyme-Linked Immunosorbent Spot (ELISpot) Assay  
a) Immunized mice were sacrificed and splenocytes were harvested as 
described before (E-I-a).  
b) Splenocytes were washed and resuspended in RPMI containing 10% FBS at 
8*106 cells/mL. 
c) Seat 50 µL/well of splenocytes to an IFN-γ capture ELISpot plate 
(MultiScreen HTS filter plates, Millipore, Danvers, MA). 
d) Add 50 µL/well of 10 µg/mL OVA(SIINFEKL) peptide to plate and incubate 
at 37°C, 5%CO2 for 18-20 hours. As positive control, splenocytes were incubated 
with 4 µg/mL Con A (Sigma); and as negative control, splenocytes were incubated 
with only medium (RPMI containing 10% FBS). 
e) The next day, IFN-γ spots were developed according the manufacturer’s 
protocol (Diaclone, France) and counted by an automated counter (Bioreader 4000 
Pro, Biosys., Germany).  
f) Results are reported as the number of spot-forming cells (SFC) per 4×106 
splenocytes plus or minus the SD of triplicate animals. 
E-IV Enzyme-Linked Immunosorbent Assay (ELISA)  
The first day: 
1. Coating: Dilute protein (OVA, Sigma) in 1X PBS buffer at concentration of 2.5 
µg/ml. Distribute 100 µL/well of solution to 96-well polystyrene plate (BD, UK). 
Cover plate with plastic lid and incubate at 4°C overnight. 
The second day: 
1. Washing: Discard protein solution and wash plate three times with 0.05% tween - 
PBS. 
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2. Saturation: Distribute 300 µL of Tween 2% - BSA 2% - PAS buffer to each well 
and incubate 1 hour at R.T. with agitation. 
3. Washing: same as previously. 
4. Incubation of samples:  
i) Preparation of samples: Dilute each sample at 1/1000 in Tween 0.05% - BSA 1% 
- PBS buffer. 
ii) Distribute 100 µL of diluted pool samples in triple wells to plate and incubate 
plate at R.T. for 1h with agitation. 
5. Washing: same as previously. 
6. Incubation of secondary antibody: (Anti-Mouse IgG (whole molecule) − Biotin 
antibody produced in rabbit - IgG fraction of antiserum, buffered aqueous solution 
(Sigma B8520-1ML)).  
Dilute secondary antibody at 1/1500 in Tween 0.05% - BSA 1% - SVF 1% - PBS 
buffer and distribute 100 µL to each well. Incubate the plate 1h at R.T. with agitation. 
7. Washing: same as previously. 
8. Incubation of avidin: (Avidin–Alkaline Phosphatase buffered aqueous solution 
(Sigma A7294-1ML)) 
Dilute avidin at 1/3000 in Tween 0.05% - BSA 1% - SVF 1% - PBS buffer and 
distribute 100 µL to each well. Incubate the plate 1 hour at R.T. with agitation. 
9. Addition of substrate and dynamical detection: (4-Nitrophenyl phosphate 
disodium salt hexahydrate - tablet (Sigma N9389-50TAB)) 
i) Extemporaneous preparation: Dilute pNPP tablet in diethanolamine buffer 
(Diethanolamine reagent grade, ≥  98.0% (Sigma D8885-500G)) to concentration of 
1mg/ml (for one plate: 2 tablets in 10 mL buffer) 
ii)  Distribute 100 µL to each well. 
iii)  Incubate plate in the darkness for 1h and read the OD at 405 nm with the 
reference at 620 nm. 
F Manipulations of Eukaryote Cells 
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F-I In Vitro Antigen Presentation Assay 
F-I-a Eukaryote Cell Lines 
a) Murine myeloid dendritic cells (mDCs): mDCs used in this study were 
generated from the bone marrow of C57BL/6 mice (502) and were kindly provided 
by Dr Christian Villiers (INSERM-U823, France). 
b) B3Z cells: The B3Z clone is a hybridoma between murine cell lines Z8 and 
B3. Z8 cell line expresses in its genome the β-galactosidase gene under the control 
of the IL2 promoter; B3 cell line is one CD8 + T lymphocyte clone that is specific 
for the ovalbumin peptide SIINFEKL (residues 257–264) in the context of H-2Kb. 
B3Z cells were cultivated in RPMI medium (Gibco. Invitrogen, France) 
supplemented with 10% FBS (Gibco. Invitrogen, France), 1% 
Penicillin-Streptomycin (GIBCO invitrogen, France), 800 µg/mL Geneticin 
(Invitrogen, Carlsbad, CA) and 50 µg/mL β-mercaptoethanol (Invitrogen, Carlsbad, 
CA). 
F-I-b The Principle of Assay 
As B3Z hybridoma cell line is specific for the ovalbumin peptide SIINFEKL, it 
could be activated when dendritic cells correctly received and processed the antigenic 
message (SIINFEKL epitope). Meanwhile, this activation is generally associated with 
the production of IL2. B3Z activation can be assessed by measuring the activity 
β-galactosidase.  
F-I-c Methods 
a) Wash and resuspend mDCs in RPMI medium supplemented with 2X 
glutamine (Gibco.Invitrogen), 20% FBS  
b) Seated mDCs in flat-bottom 96-well plates at the concentration of 1*105 
cells/well.  
c) Prepare bacterial cultures as previously described (see in B-V section). 
d) Resuspend bacteria cells in RPMI and add to plate at multiplicity of infection 
(m.o.i) of 5.  
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e) Incubate bacteria cells with B3Z cell at 37°C, 5% CO2 for 3 hours, 
f) Add 10 µL of 250 µg/mL gentamicin (PAA Laboratories GmbH, Pasching, 
Austria) to each well and incubate plate at 37°C, 5%CO2 for 30 min (step for 
killing bacteria).  
g) Centrifuge the plate at 350 G for 10 min and discard the supernatant. 
h) Add B3Z cells to plate at 1*106 cells/well in RPMI medium supplemented 
with 10% FBS, 1% Penicillin-Streptomycin, 800 µg/mL Geneticin and 50 µg/mL 
β-mercaptoethanol for 16 hours. 
i) Centrifuge the plate at 350 G for 5 min and discard the supernant. 
j) Add 100 µL/well of lysis buffer (CPRG 0.15 mM; MgCl2 9 mM; Triton 
X-100 1%; β-mercaptoethanol 50 µM; PBS ;) and incubate the plate at 37°C for 
several hours. 
k) Read the OD at 570 nm 
F-II Tumor Cell Lines 
Five tumor cell lines were used in this work: three of them, B16OVA, GL26 and 
GL261, were derived from C57BL6 mice; and two others, MC2 and MC2-HER2, 
were derived from human β2m–HLA-A2.1 (α1α2)–H-2Db (α3 transmembrane 
cytoplasmic) (HHD) transgenic mice. 
B16OVA is derived from murine melanoma B16-F0 cell line. It was obtained by 
transfecting B16-F0 cell line with ovalbumin cDNA. B16-OVA cell line used in this 
work was kindly provided by Dr Georges Vassaux (Molecular Oncology Unit, Cancer 
Research UK Clinical Centre, Royaume-Uni). B16OVA cells were cultivated in 
DMEM medium (GIBCO, Invitrogen, France) containing 10% FBS, 1% 
Penicillin-Streptomycin and 800 µg/mL Geneticin G418. 
GL26 and GL261 are two common murine glioma cell lines. These two cell lines 
were grown in DMEM supplemented with 10% FBS, 1% Penicillin-Streptomycin. 
MC-2 cell line relates to the original sarcomas that were induced by the 
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carcinogen methylcholanthrene (MC) in HHD mice; MC-2-HER-2 cell line was 
obtained by transfecting MC-2 cell line with full length HER-2 cDNA. Both cell lines 
were kindly provided by Dr Simona Vertuani (Immune and Gene Therapy Unit, 
Cancer Centrum Karolinska, Karolinska Hospital, Sweden). Cell lines were 
maintained in IMDM (GIBCO, Invitrogen, France) supplemented with 10% FBS, 1% 
Penicillin-Streptomycin. Geneticin G418 was added at 800 µg/mL to the medium for 
the MC-2/HER-2 cell line culture. 
G Manipulations of Animals 
G-I Mice  
Female C57BL/6j mice were purchased from Janvier SA (Le Genest-Saint-Isle, 
France); homozygous HLA-A2.1 transgenic mice (human ß2m-HLA-A2.1 
(α1α2)-H-2dB (α3 cytoplasmic domains of mouse)) were purchased from Charle 
River (France). All animals were experimented at 6-8 weeks of age. They were kept 
under pathogen-free conditions in the animal facility of the University Joseph Fourier 
(Grenoble, France). All animal experiments were approved by the Animal Experiment 
Committee of the Region and were performed in accordance with institutional and 
national guidelines. 
G-II Animal Immunization  
Mice were administered bacteria vaccines through subcutaneous (s.c.) injection. 
With CHA-OST-fusion protein strains, mice were injected in right flank at the dose of 
5*106 bacteria (100 µL)/time/mouse on following prophylactic (D-14/D-7) or various 
therapeutic vaccination schemas. With CHA-OAL-fusion protein strains, mice were 
injected either at the dose of 1*108 bacteria (100 µL)/time/mouse in right frank or 
5*107 bacteria (50 µL)/position/time/mouse at 4 positions in right and left franks on 
following the different vaccination schema. All injections in mice were achieved with 
BD Micro-Fine™+ Insulin Syringes (BD, UK). 
G-III Tumor Challenge 
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Before mice injection, all tumor cells were washed by PBS, pH 7.2 and then 
resuspended in PBS for injection. Immunized (prophylactic groups) or 
non-immunized (therapeutic groups) female C57BL/6j mice were injected s.c. in left 
flank on day 0 with B16OVA cells at the dose of 2*105 cells (100 µL)/ mouse; with 
GL26 or GL261 cells at the dose of 1*105 cells (100 µL)/ mouse. Immunized HHD 
mice were injected s.c. in left flank on day 0 with MC-2 or MC-2-HER-2 cells at the 
dose of 7*104 cells (100 µL)/ mouse. All injections in mice were achieved with BD 
Micro-Fine™+ Insulin Syringes (BD, UK). The emergence and the dynamic growth 
of tumor mass were measured every 48 hours. When the diameter of tumor exceeded 
10 mm, mice were sacrificed and this day corresponded to the period of survival. 
Analysis of data was realized with GraphPad Prism 5 software. 
H Statistics 
Bar graph analyses were evaluated by Student’s t-test. Kaplan-Meyer survival 
curves of animals treated with different protocols were analyzed using the logrank test. 
A p-value below 0.05 between groups was considered to indicate a statistically 
significant difference. 
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Optimization of Bacterial Vaccine Vectors 
 
 
 
 
 
 
 
 
 
Results – Chapter 1 
148 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results – Chapter 1 
149 
Résumé en Français : 
Dans ce chapitre, nous avons tenté d'améliorer la performance de nos vecteurs 
bactériens en suivant différentes stratégies. Avant tout, un épitope (PADRE) 
spécifique des lymphocytes CD4+ Th a été ajouté aux antigènes. D’une part, cette 
addition est à l’origine d’une réponse immunitaire forte médiée par les CD8+ CTL. 
D’autre part, elle réduit la suppression médiée par les cellules Treg pour activer les 
cellules effectrices. Ainsi, une amélioration de la protection anti-tumorale in vivo a été 
obtenue. Par la suite, un modèle d'expression bi-antigénique a été appliqué aux 
vecteurs bactériens. Les vecteurs bi-antigéniques ont montré l’efficacité anti-tumorale 
supérieure que les vecteurs mono-antigéniques ; cependant autant que les vecteurs 
mono-antigéniques combinées. En outre, un vecteur potentiel activant l’immunité 
humorale a été construit par la délétion des deux protéines structurelles du SST3 : 
PopB et PopD. Des IgG spécifiques de l’antigène ont été détectés après des 
vaccinations avec un vecteur muté ΔPopBΔPopD. 
In English: 
A Improvement of Vaccine Efficiency by Adding CD4+ Th Helper 
Epitope (Pan-HLA-DR-binding Epitope (PADRE)) 
CD4+ T cells have been proved to play an important role during the priming and 
development of immune response. PADRE (AKFVAAWTLKAAA) is a widely-used 
MHC II-presented CD4+ T-helper epitope. It has been demonstrated to be a strong 
inducer of T helper cells in a variety of vaccine vector for providing help not only for 
the generation of CTL response, but also for the induction of a humoral immune 
response (503, 504). Particularly, PADRE is a promiscuous CD4+ Th determinant 
capable of binding with high affinity to most of DR alleles so that both human and 
murine MHC II molecules can bind this sequence. So, in this work, we attempted to 
improve the efficacy of our bacterial vaccines by adding PADRE as CD4+-T-cell 
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activator to the antigen delivery system. 
A-I Construction of PADRE Containing Exogenous Antigen-expression Plasmids 
The plasmid pExsAi-S54 (fig. 12-A) permits the cloning of target antigen in 
fusion with the first 54 amino acids of ExoS, which will allow the secretion of target 
antigen via T3SS of P. aeruginosa. pExsAI has been previously constructed by our 
laboratory. Basing on this vector, the PADRE coding sequence was inserted into the 
frame of fusion protein coding region. Since the location of insert might affect the 
transcription, translation, secretion through T3SS by bacteria, as well as the 
degradation of fusion protein by acid proteases in cytoplasm or by proteasome of 
APCs, PADRE coding sequence has been inserted either upstream or downstream of 
antigen cloning site.  
The strategy for constructing PADRE Nter-containing exogenous antigen expression 
vector is presented in figure 12-B. Briefly, PADRE was integrated upstream of 
cloning site. A PADRE insert was synthesized to contain at 5’ end a linker for the 
BamH I site of pEXSAi-S54, a new BamH I restriction site, and a linker for the SpH I 
site in pEXSAi-S54 at 3’ end. Then this insert was ligated to BamH I/SpH I digested 
pEXSAi-S54 vector to form a new circular plasmid. As the pair of bases (marked in 
blue) was changed, the original BamH I restriction site was deleted. Therefore, there 
is only one BamH I/SpH I framing cloning site at 3’ end of PADRE in the new 
plasmid. PADRE (Cter)-cloning vector where PADRE is integrated downstream of 
cloning site was also constructed by the same strategy (Fig. 12-C). 
In order to evaluate T helper efficiency of PADRE in our bacterial vaccines, we 
chose TRP2, one well-known TAA expressed by both murine and human glioma, as 
target antigen. Two different constructions were made for TRP-2 (TRP2L125-376, 
TRP2S291-376). TRP2S included the strongest in silico predicted epitope (TRP2363-372); 
TRP2L contained not only the predicted TRP2363-372 but also one published 
TRP2181-188 epitope (505). We cloned the two TRP2 sequences in our PADRE 
containing antigen expression vector (marked in blue in Fig 12-B&C). 
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Figure 12: Construction of PADRE Containing Exogenous Antigen Expression Plasmids.  
(A) PADRE containing plasmids were constructed from pEXSAi-S54 which comprises 
exoS54–necessary sequence for the secretion and translocation of toxins or toxin-protein fusion 
fragments; and multiple cloning sites (MCS) region containing BamHI/SpHI sites. (B) and (C) 
Strategy for constructing PADRE-containing exogenous antigen repression plasmids. We 
integrated PADRE either upstream or downstream of cloning site. Then, antigen comprising 
BamHI and SpHI sites could be integrated to PADRE-containing vector and form the fusion 
protein coding sequence with exoS54 and PADRE. 
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Both sequences were cloned at BamH I/Sph I restriction sites in protein coding region 
of PADRE-containing vector. The correct integrations of TRP2L and TRP2S were 
confirmed by commercial sequencing.  
A-II In Vitro Evaluation of Protein Secretion Ability of PADRE Containing 
Vectors 
P. aeruginosa can secret at least four effector proteins through its T3SS: ExoS, 
ExoT, ExoY and ExoU. The first 54 amino acids of ExoS is the necessary sequence 
for its secretion and translocation through T3SS. We transformed CHA-OST strain 
with the plasmid which can express the fusion protein beginning with the first 54 
amino acids of ExoS (ExoS54), allowing the fusion protein to be also secreted and 
translocated by CHA-OST strain through T3SS. Besides, it is known that for the 
intracytoplasmic translocation through T3SS, two proteins play an important role: 
PopB and PopD which are also secreted upon T3SS induction and can be visualized 
by SDS-PAGE of cultured bacteria. When bacterial cells contact eukaryotic cells or 
under low calcium condition, T3SS is activated and PopB, PopD could insert into the 
membrane of eukaryotic cells and form the secretion and translocation channel.  
Before vaccination, the secretion abilities of transformed strains – 
CHA-OST-PADRE-TRP2L and CHA-OST-PADRE-TRP2S have been verified in 
vitro through EGTA mediated calcium depletion in the culture medium, and the 
results are shown in figure 13. In this figure, the first lane represents CHA-OST-EI 
strain which was the control strain that contains non-antigen coding sequence. Thus, 
in the first lane we can see the two structural proteins – PopB and PopD (marked with 
arrows), but not target protein secretion. In the following lanes which represent 
CHA-OST-TRP2L, CHA-OST-PADRE(Nter)-TRP2L, 
CHA-OST-TRP2L-PADRE(Cter), CHA-OST-TRP2S, 
CHA-OST-PADRE(Nter)-TRP2S and CHA-OST-TRP2S-PADRE(Cter), besides 
PopB and PopD which indicate the correct activation of T3SS, we can also see the 
bands corresponding to the different target proteins (marked with asterisks). These 
results could not only confirm the T3SS secretion ability in vitro, but also predict the 
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in vivo protein delivery ability of our vaccine strains. 
 
Figure 13: In Vitro Investigation of Fusion Proteins Secretion by PADRE Containing 
Exogenous Antigen Delivery Bacterial Vectors.  
The secretion ability of PADRE containing exogenous antigen delivery strains has been verified 
before vaccination. For each strain, we can see two important structural proteins (marked with 
arrows)–PopB (top) and PopD (bottom) which form cytotoxins translocation channel in eukaryote 
cells membrane. CHA-OST-EI was the control strain which was transformed with pEXSAi-S54 
without antigen, so in this strain, we can only observe PopB and PopD but not target protein. And 
in the other vaccine strains, we see fusion protein corresponding right molecular weight (marked 
with asterisks) as well as PopB and PopD. Thus, we can confirm the secretion ability of 
vaccination strains in vitro and also predict their in vivo antigen translocation abilities. 
A-III Evaluation of Vaccination Efficiency via Immune Response Monitoring 
A-III-a CTLs Cytotoxicity Detection Assay 
CTL cytotoxicity detection assay measures ex vivo immune response activation. 
Here, two groups of vaccine strains were assessed. In the first group, 
CHA-OST-TRP2L, CHA-OST-PADRE(Nter)-TRP2L and 
CHA-OST-TRP2L-PADRE(Cter) strains have been investigated. In the second group, 
CHA-OST-TRP2S, CHA-OST-PADRE(Nter)-TRP2S and 
CHA-OST-TRP2S-PADRE(Cter) strains have been tested. In each group, mice 
injected with PBS were used as a negative control. We estimated the cytotoxicity of 
lymphocytes isolated from the mice by their ability to lyse GL26 cells after 6 days of 
in vitro induction. 
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Figure 14: CTL Cytotoxicity Assessment for Investigating the Immune Response in Mice 
Immunized with TRP2L Delivering Strains. 
Mice were injected with CHA-OST-TRP2L or CHA-OST-PADRE(Nter)-TRP2L or 
CHA-OST-TRP2L-PADRE(Cter) strains or PBS (negative control) two times on 14 days and 7 
days before splenocytes sampling. Isolated lymphocytes were incubated with mitomycin-C-treated 
GL26 cells for 6 days for obtaining effector CTLs. Then, CTL assays were performed through 
measuring the LDH released by GL26 cells (Target, T) which were lysed by effector CTLs 
(Effector, E). The cytotoxicity is estimted by LDH release in % of that of total cell lysis. Data 
represented the mean +/- SD from 6 animals per group in triplicate (cumulative results of 2 
independent experiments conducted using the same methodology). 
Figure 14 presents the results of CTL assay for TRP2L group. We can see that 
with the increase of effector/target ratio, the lysis rate of GL26 cells increased in all 
samples, but the lines corresponding to immunized mice augment more obviously 
than that corresponding to control mice, which indicate the immune response 
activation in vaccinated mice. By comparing the different vaccine strains, we can find 
that CTLs cytotoxicity of mice injected with CHA-OST-PADRE(Nter)-TRP2L strain 
was stronger than that of mice injected with CHA-OST-TRP2L-PADRE(Cter) strain; 
and the later was still stronger than that of mice injected with CHA-OST-TRP2L, 
whereas the difference between strains is not evident. 
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Figure 15: CTL Cytotoxicity Assessment for Investigating the Immune Response in Mice 
Immunized with TRP2S Delivering Strains. 
Mice were injected with CHA-OST-TRP2S or CHA-OST-PADRE(Nter)-TRP2S or 
CHA-OST-TRP2L-PADRE(Cter) strains or PBS (negative control) two times on 14 days and 7 
days before splenocytes sampling. The prinicle for CTL cytotoxicity assay is the same as that 
described in the legend of figure 14. Data represented the mean +/- SD from 6 animals per group 
in triplicate (cumulative results of 2 independent experiments conducted using the same 
methodology). 
Figure 15 shows the results of cytotoxic CTL assay for TRP2S group. Similar to 
TRP2L group, the lysis rate also increased according to the E/T ratios, and we can 
also find the obvious difference between immunized mice and control mice, and the 
cytotoxicity of CTLs from mice injected with CHA-OST-PADRE(Nter)-TRP2S and 
CHA-OST-TRP2S-PADRE(Cter) are also a little stronger than that of mice injected 
with CHA-OST-TRP2S.  
By comparing and combining the results of these two groups, we can confirm the 
anti-tumor immune response stimulated in vivo by bacteria strains, whereas the 
difference between different constructions was not so significant. 
A-III-b Regulatory T (Treg) Cells Detection Assay 
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Treg cells, which are also called suppressor T cells, are a specialized 
subpopulation of T cells that act to suppress T cells responses and maintain the 
homeostasis of immune system. Recent researches proved that regulatory T cells are 
more defined by expression of the forkhead family transcription factor FoxP3. 
Expression of FoxP3 is required for regulatory T cell development and appears to 
control a genetic program specifying this cellular subset. Moreover, the large majority 
of FoxP3-expressing regulatory T cells are found within the MHC II restricted 
CD4-expressing (CD4+) helper T cell population and express high levels of the 
interleukin-2 receptor alpha chain (CD25). Therefore, those that express CD4+, 
CD25+ and Foxp3+ can be defined as regulatory T cells or "Tregs".  
In order to investigate the immune modulating environment after bacterial 
vaccines injections, we also measured the quantity of regulatory T cells after 
vaccinations to estimate their impact to anti-tumor efficiency of our vaccines. In this 
trial, the investigated vaccine strains were also divided into two groups: the first group 
was composed of CHA-OST-TRP2L, CHA-OST-PADRE(Nter)-TRP2L and 
CHA-OST-TRP2L-PADRE(Cter) strains; and the second group contained 
CHA-OST-TRP2S, CHA-OST-PADRE(Nter)-TRP2S and 
CHA-OST-TRP2S-PADRE(Cter) strains. The situation of Treg in immunized mice 
was described by comparing with that in mice injected with PBS. 
Figure 16 shows the results of Treg cells assessment in TRP2L group. We find 
that there was a general decrease of CD4+/CD25+/FoxP3+ regulatory T cells in DLN 
of immunized mice compared to that of negative control mice. The more obvious 
decrease of Treg cells in the lymph node was found in the mice immunized with 
CHA-OST-PADRE (Nter)-TRP2L strain, and the quantity of Treg cells in the lymph 
node of mice injected with CHA-OST-TRP2L strain decreased less. 
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Figure 16: Evaluation of Regulatory T (Treg) Cells in Mice Immunized with TRP2L 
Delivering Strains. 
Mice were injected with CHA-OST-TRP2L or CHA-OST-PADRE(Nter)-TRP2L or 
CHA-OST-TRP2L-PADRE(Cter) strains or PBS (negative control) two times on 14 days and 7 
days before lymph nodes sampling. Lymphocytes isolated from draining lymph node (DLN) of 
mice were stained with fluoresein-conjugated antibodies anti-CD4+, anti CD25+ and anti FoxP3+. 
The CD4+/CD25+/FoxP3+ T cells were considered as regulatory T cells (Tregs) and detected by 
flow cytometry. The situation of Tregs cells in immunized mice were estimated by comparing with 
that in negative control mice. Data represented the mean +/- SD from 6 animals per group in 
triplicate (cumulative results of 2 independent experiments conducted using the same 
methodology). 
Figure 17 shows the results of Treg cells assessment in TRP2S group. We can 
find the similar relation among the three vaccines as that in the TRP2L group: there 
were less Treg cells in lymph node of mice injected with 
CHA-OST-PADRE(Nter)-TRP2S strain and the Tregs in lymph node of mice injected 
with CHA-OST-TRP2S strain were more than that of other mice. 
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Figure 17: Evaluation of Regulatory T (Treg) Cells in Mice Immunized with TRP2S 
Delivering Strains. 
Mice were injected with CHA-OST-TRP2S or CHA-OST-PADRE(Nter)-TRP2S or 
CHA-OST-TRP2S-PADRE(Cter) strains or PBS (negative control) two times on 14 days and 7 
days before lymph nodes sampling. The prinicle Tregs assessment is the same as that described in 
the legend of figure 16. Data represented the mean +/- SD from 6 animals per group in triplicate 
(cumulative results of 2 independent experiments conducted using the same methodology). 
A-IV Evaluation of Vaccination Efficiency via Tumor Challenge 
Through this experiment, we estimated the true anti-tumor efficacy of PADRE 
containing exogenous antigen delivery vectors via their abilities to inhibit the 
formation and the development of tumor. For each vaccine, mice were vaccinated two 
times on 14 days and 7 days before the injection of tumor cells, and mice injected 
with PBS before tumor challenge served as negative control. 1*105 GL26/ mouse 
were s.c. inoculated on day 0. 
Results – Chapter 1 
159 
 
Figure 18: In vivo Evaluation of TRP2L Delivering Vectors. 
Mice were s.c. immunized with different TRP2L delivering strains D-14/D-7 before s.c. GL26 
tumor challenge. Kaplan-Meyer curves displayed survival data from groups of 6 mice. Statistical 
analysis: p = 0.007 for CHA-OST-PADRE(Nter)-TRP2L VS PBS; p= 0.026 for 
CHA-OST-PADRE(Nter)-TRP2L VS CHA-OST-TRP2L; p= 0.022 for 
CHA-OST-PADRE(Nter)-TRP2L VS CHA-OST-TRP2L-PADRE(Cter); p = 0.259 for OST-TRP2L 
VS PBS; p = 0.106 for OST-TRP2L-PADRE(Cter) VS PBS; p = 0.548 for 
OST-TRP2L-PADRE(Cter) VS OST-TRP2L.  
Figure 18 presents the results of survival period for the TRP2L group. We can 
see that, tumor emerged and progressed more rapidly in mice injected with PBS. The 
vaccines CHA-OST-TRP2L, CHA-OST-PADRE(Nter)-TRP2L and 
CHA-OST-TRP2L-PADRE(Cter) delayed tumor formation and tumor growth , but 
only CHA-OST-PADRE(Nter)-TRP2L vector statistically prevented the tumor 
formation. The statistic difference between CHA-OST-PADRE(Nter)-TRP2L strain 
and the other vaccines are significant (p= 0.007 for CHA-OST-PADRE(Nter)-TRP2L 
VS PBS; p= 0.026 for CHA-OST-PADRE(Nter)-TRP2L VS CHA-OST-TRP2L; p= 
0.022 for CHA-OST-PADRE(Nter)-TRP2L VS CHA-OST-TRP2L-PADRE(Cter)). 
However the difference between CHA-OST-TRP2L, CHA-OST-TRP2L-PADRE(Cter) 
and PBS is not statistically significant.  
Figure 19 shows the results for TRP2S group. We can also find the similar 
relation between vaccinated mice and control mice as that in the TRP2L group. In 
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general, tumor formed and developed more rapidly in control group (mice injected 
with PBS), all vaccine strains delayed more or less tumor formation and only 
CHA-OST-PADRE(Nter)-TRP2S statistically inhibited tumor emergence and 
development. The statistic difference between CHA-OST-PADRE(Nter)-TRP2S strain 
and CHA-OST-TRP2S strain is significant (p = 0.047), but not between 
CHA-OST-PADRE(Nter)-TRP2S and CHA-OST-TRP2L-PADRE(Cter) strains. 
 
Figure 19: In vivo Evaluation of TRP2S Delivering Vectors. 
Mice were s.c. immunized with different TRP2S delivering strains D-14/D-7 before s.c. GL26 
tumor challenge. Kaplan-Meyer curves displayed survival data from groups of 6 mice. Statistical 
analysis: p = 0.019 for CHA-OST-PADRE(Nter)-TRP2S VS PBS; p = 0.047 for 
CHA-OST-PADRE(Nter)-TRP2S VS CHA-OST-TRP2S; p= 0.945 for 
CHA-OST-PADRE(Nter)-TRP2S VS CHA-OST-TRP2S-PADRE(Cter); p = 0.683 for 
CHA-OST-TRP2S VS PBS; p = 0.125 for CHA-OST-TRP2S-PADRE(Cter) VS PBS; p = 0.366 for 
CHA-OST-TRP2S-PADRE(Cter) VS CHA-OST-TRP2S.  
B Construction of Bi-antigen Delivery Vectors 
In recent years, multi-epitope or multi-antigen expression pattern has been 
applied to enhance the potency of cancer vaccines. In order to strengthen our vaccine 
vectors, we also tried to apply multi-antigen expression pattern in our bacterial 
exogenous antigen delivery system. 
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B-I Construction of Bi-antigen Expression Plasmid 
  
Figure 20: Construction of Bi-antigen Expressing Plasmid. 
The bi-antigen co-expression vector was constructed basing single antigen expression vector 
(pEAI3 S54) in which the first antigen has been cloned at BamH I/Bgl II sites, the second 
S54-PADRE-antigen fusion protein expression cassette containing RBS site, fusion protein and 
STOP codon was added to single antigen expression plasmid at Bgl II/Sph I sites which located 
downstream to the first antigen. 
Firstly, we constructed bi-antigen expression structure basing on PADRE 
containing single fusion protein expression plasmid. The principle is described in Fig 
20.  
Briefly, the first antigen was cloned at BamH I/Bgl II positions in multiple 
cloning sties (MCS) region in PADRE containing antigen expression plasmid 
(pEAI-S54-PADRE). The second S54-PADRE-antigen2 fusion protein expression 
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sequences containing ribosome binding site (RBS) + fusion protein2 + STOP codon 
were amplified by PCR using mono-antigen expression plasmids as templates. The 
PCR products were cloned as Bgl II/Sph I fragments into Bgl II/Sph I-digested 
pEAI-S54-PADRE-antigen1 at the downstream position of the first fusion protein 
expression cassette. Because each fusion protein expression cassette contains RBS 
and STOP-codon, two fusion proteins each containing Exo54 secretion TAG could be 
individually synthesized. 
For constructing bi-antigen vectors, several antigens were chosen. Besides the 
model antigen ovalbumin, two melanoma associated antigens, TRP2 and GP100, were 
also targeted. Here, the TRP2 cloning sequence was TRP2L125-376 that we have 
discussed in the previous chapter; and the GP100 cloning sequence was GP10021-150 
containing one nature murine GP10025-33 epitope (506). Thereby, based on above 
principle, we constructed several bi-antigen expression plasmids: pEAI 
S54-Padre-OVA248-376 S54-Padre-TRP2L125-376, pEAI S54-Padre-TRP2L125-376 
S54-Padre-OVA248-376 and pEAI S54-Padre- TRP2L125-376 S54-Padre- GP10021-150. 
B-II In vitro Evaluation of Antigen Secretion Ability of Bi-antigen Vectors 
For bi-antigen delivery application, we chose CHA-OST as the experimental 
strain and transformed it with above mentioned bi-antigen expression plasmids. 
In order to evaluate bi-antigen vectors, we first assessed the antigen secretion 
ability of different strains in vitro. The results were shown in figure 21. Here, we used 
always CHA-OST-EI as the negative control and used relative single antigen vectors 
as the positive references. As we previously discussed, PopB and PopD are two 
important indicators of T3SS activation. In the figure 21, the two structure proteins 
(marked with arrows) can be observed in all lanes, which indicate the correct 
activation of T3SS. Besides, we can also see the bands corresponding to the different 
antigens (marked with asterisks) in all lanes except the first lane corresponding to 
CHA-OST-EI. So these results confirm the double antigen secretion ability of 
bi-antigen bacterial vectors. However, even both antigens could be secreted by 
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bi-antigen vectors, we found that when the antigen was cloned at the second position 
in bi-antigen vector, it was less secreted than when cloned alone in single-antigen 
vector. 
 
Figure 21: In Vitro Evaluation of Fusion Protein Secretion Ability of Bi-antigen Vectors.  
T3SS-mediated fusion protein secretion by bi-antigen vectors was assessed by SDS-PAGE. The 
positions of PopB (top) and PopD (bottom) are marked with arrows; the positions of 
S54-PADRE-antigen fusion proteins are marked with asterisks. 
B-III In vitro Evaluation of Antigen Translocation Ability of Bi-antigen Vectors 
In previous work (3), it has been proved that the fusion protein delivery mediated 
by of P. aeruginosa could lead to DC maturation, activation and antigen presentation 
to specific CD8+ T lymphocytes. So, we evaluated in this work if bi-antigen vector 
has the same antigen translocation ability for a given antigen as mono-antigen vector. 
Furthermore, we wondered also if the antigen position could interfere with that 
process. To answer these questions, bi-antigen vector was evaluated through B3Z 
activation assay.  
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Figure 22: In Vitro Evaluation of T3SS-mediated Antigens Translocation by Bi-antigen 
Vectors through B3Z Activation Assay.  
B3Z activation was assessed with a β-galactosidase enzymatic assay (absorbance at 570 nm). The 
bi-antigen vaccines vectors containing S54-PADRE-OVA fusion protein at the different position in 
bi-antigen expression plasmid  (CHA-OST-PADRE-OVA-PADRE-TRP2L & 
CHA-OST-PADRE-TRP2L-PADRE-OVA) delivered the ovalbumin fragment through T3SS and 
was compared with three control vectors: CHA-OST-EI (negative control) and two single antigen 
vectors (CHA-OST-PADRE-OVA & CHA-OST-PADRE-TRP2L). Data represented the mean +/- 
SD from six animals per group in triplicate (cumulative results of two independent experiments 
conducted with the same methodology). 
B3Z hybridoma cell line is specific for the ovalbumin peptide SIINFEKL 
(residues 257–264) in the context of H-2Kb and expresses the β-galactosidase gene 
under the control of the IL-2 promoter. B3Z activation indicates that dendritic cells 
have correctly received and processed the antigenic message. Therefore we chose 
OVA248-376 as the model antigen and cloned it in either the first position or the second 
position in bi-antigen vector with TRP2L125-376 as the second antigen. In figure 22, we 
can see that TCR-mediated B3Z activations were obtained after incubation with DCs 
exposed to CHA-OST-PADRE-OVA, CHA-OST-PADRE-OVA-PADRE-TRP2L and 
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CHA-OST-PADRE-TRP2L-PADRE-OVA strains, but no activation was found after 
incubation with DCs exposed to CHA-OST-EI control strain. These results indicated 
that as for antigen delivery and presentation, bi-antigen vectors appear to contribute 
slightly less to B3Z activation than mono-antigen vector although the difference was 
not statistically significant; nevertheless, no difference was found between 
CHA-OST-PADRE-OVA-PADRE-TRP2L and 
CHA-OST-PADRE-TRP2L-PADRE-OVA strains, which demonstrate that the antigen 
cloning position will not affect its delivery by bi-antigen vector. 
B-IV Evaluation of Bi-antigen Vectors by ex vivo Immune Monitoring through 
IFN-γ ELISpot Assay 
For evaluating the vaccination efficiency of bi-antigen bacterial vector, we 
investigated the antigen specific immune response after two times of injections of 
mice with either mono-antigen strain (CHA-OST-PADRE-TRP2L or 
CHA-OST-PADRE-GP100, 5*106 bacteria / time) or bi-antigen strain 
(CHA-OST-PADRE-TRP2L-PADRE-GP100, 5*106 bacteria / time). The T cell 
responses specific to the two TRP2 epitopes (TRP2363-372 and TRP2181-188) and one 
GP100 epitope (GP10025-33) were monitored through IFN-γ ELISpot assay and this 
test has been repeated two times. 
However, the results of this trial were not satisfying. In all immunized mice, no 
evident T cell responses against TRP2363-372, TRP2181-188 and GP10025-33epitopes were 
detected (data not shown). 
B-V In vivo Evaluation of Bi-antigen Vectors in Murine Tumor Models 
B-V-a In Murine Glioma Model (GL261) 
GL261 glioma cell line is one of the most frequently used murine brain tumor 
models and expresses both melanoma associated antigen TRP2 and GP100. To 
evaluate in vivo tumor protection efficiency induced by bi-antigen vector, we injected 
C57BL/6 mice with either mono-antigen strain (CHA-OAT-PADRE-TRP2L or 
CHA-OST-PADRE-GP100, 4*106 bacteria / time), bi-antigen strain 
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(CHA-OST-PADRE-TRP2L-PADRE-GP100, 4*106 bacteria/time) or combined 
mono-antigen strains (CHA-OST-PADRE-TRP2L+ CHA-OST-PADRE-GP100, 8*106 
bacteria in total/time). Here, we performed both prophylactic and therapeutic 
anti-GL261 assay. In both assays, the group injected with CHA-OST-EI strain was the 
negative control.  
 
Figure 23: In Vivo Evaluation of Bi-antigen Vectors in Prophylactic Vaccination Model (in 
Murine GL261 Tumor Model). 
Mice were s.c. injected with different CHA-OST-fusion protein strains on 14days and 7 days 
before s.c. GL261 tumor challenge. Kaplan-Meyer curves displayed survival data from groups of 
12 mice (cumulative results of two independent experiments conducted with the same 
methodology). Statistical analysis: p < 0.01 for immunized groups VS CHA-OST-EI; p = 0.044 for 
CHA-OST-PADRE-TRP2L-PADRE-GP100 VS CHA-OST-PADRE-GP100; p =0.63 for 
CHA-OST-PADRE-TRP2L-PADRE-GP100 VS CHA-OST-PADRE-TRP2L; and p =0.51 for 
CHA-OST-PADRE-TRP2L-PADRE-GP100 VS combined strains. 
For the prophylactic assay, we injected C57BL/6 mice subcutaneously with the 
different strains at both 14 and 7 days before subcutaneous injection of 1*105 GL261 
cells, the results are shown in figure 23. In this assay, we can see that all mice injected 
with CHA-OST-EI developed rapidly a tumor and were sacrificed within 6 weeks 
after injection of GL261 cells; in all immunized groups, tumor formation has been 
significantly delayed (CHA-OST-PADRE-TRP2L VS CHA-OST-EI, p = 0.0016; 
CHA-OST-PADRE-GP100 VS CHA-OST-EI, p = 0.0094; combined strains VS 
CHA-OST-EI, p = 0.0005; CHA-OST-PADRE-TRP2L-PADRE-GP100 VS 
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CHA-OST-EI, p = 0.0005). The bi-antigen strain injections and combined strains 
injections were more efficient to prevent tumor formation than mono-antigen strains. 
The difference between bi-antigen injected group and CHA-OST-PADRE-GP100 
group was statistically significant (p < 0.05), whereas there was no significant 
difference among CHA-OST-PADRE-TRP2L injected group, bi-antigen strain 
injected group and combined strains injected group. 
 
Figure 24: In Vivo Evaluation of Bi-antigen Vectors in Therapeutic Vaccination Model (in 
Murine GL261 Tumor Model). 
Mice received a s.c. tumor challenge with GL261 tumor cells on day 0 and then were vaccinated 
with different CHA-OST-fusion protein strains on following D1/D5/D9/D13/D17/D21 therapeutic 
schema. Kaplan-Meyer curves displayed survival data from groups of 12 mice (cumulative results 
of two independent experiments conducted with the same methodology). Statistical analysis: p = 
0.022 for CHA-OST-PADRE-TRP2L VS CHA-OST-EI; p = 0.054 for CHA-OST-PADRE-GP100 
VS CHA-OST-EI; p = 0.0018 for combined strains VS CHA-OST-EI; p = 0.0014 for 
CHA-OST-PADRE-TRP2L-PADRE-GP100 VS CHA-OST-EI; p = 0.046 for 
CHA-OST-PADRE-TRP2L-PADRE-GP100 VS CHA-OST-PADRE-GP100; p = 0.50 for 
CHA-OST-PADRE-TRP2L-PADRE-GP100 VS CHA-OST-PADRE-TRP2L; and p=0.84 for 
CHA-OST-PADRE-TRP2L-PADRE-GP100 VS combined strains. 
For the therapeutic assay, we injected C57BL/6 mice subcutaneously with 1*105 
GL261 cells on day 0 and then with the different strains on following the therapeutic 
schema containing six injections with 4 days of interval (described in the next 
chapter). The results are shown in figure 24. We can observe similar results that those 
obtained in prophylactic assay. CHA-OST-PADRE-TRP2L strain injections, 
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combined strains injections and bi-antigen strain injections provided the significant 
tumor protection (CHA-OST-PADRE-TRP2L VS CHA-OST-EI, p = 0.032; combined 
strains VS CHA-OST-EI, p = 0.0018; CHA-OST-PADRE-TRP2L-PADRE-GP100 VS 
CHA-OST-EI, p = 0.0014). The CHA-OST-PADRE-GP100 strain injections slightly 
delayed the tumor formation whereas the difference was not significant 
(CHA-OST-PADRE-GP100 VS CHA-OST-EI, p = 0.055). Combined strains and 
bi-antigen strain were more efficient than mono-antigen strain. Moreover, the 
differences between CHA-OST-PADRE-TRP2L injected group, bi-antigen strain 
injected group and combined strains injected group were not remarkable, while the 
difference between bi-antigen injected group and CHA-OST-PADRE-GP100 group 
was statistically significant (p < 0.05).  
B-V-b In Murine Melanoma Model (B16) 
Transplantable murine melanomas are well-established models for the study of 
experimental cancer therapies. Melanomas express different tumor-associated Ags, 
such as TRP2, GP100, MAGE, etc., which are potential targets for novel designs of 
therapeutic cancer vaccines. Many immunotherapeutic protocols have been tested 
using the murine B16 melanoma cell line that originated in the C57BL/6 (H-2b) 
mouse strain. So, in this study, we have also investigated our bi-antigen vectors in 
murine B16 model. The investigated vaccine strains were same as that assessed in 
GL261 model. 
In the prophylactic assay, C57BL/6 mice were subcutaneously injected with the 
different strains at both 14 and 7 days before subcutaneous injection of 2*105 B16 
cells, the results are shown in figure 25. We can find that immunization with single 
antigen strains slightly delayed the tumor formation, but the difference was not 
significant; moreover, the combined injection mode or administration with bi-antigen 
vector can provide a slight optimization, but the difference between single antigen 
vectors, combined strains and bi-antigen strain was neither statistically significant. 
However, just the slight optimization provided by combined strains or bi-antigen 
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strains leads to the significant differences between immunized groups and 
non-immunized control group. (CHA-OST-PADRE-TRP2L VS CHA-OST-EI, p = 
0.32; CHA-OST-PADRE6GP100 VS CHA-OST-EI, P = 0.17; combined strains VS 
CHA-OST-EI, p = 0.046; CHA-OST-PADRE-TRP2L-PADRE-GP100 VS 
CHA-OST-EI, p = 0.037) 
 
Figure 25: In Vivo Evaluation of Bi-antigen Vectors in Prophylactic Vaccination Model (in 
Murine B16 Tumor Model). 
Mice were s.c. injected with different CHA-OST-fusion protein strains on 14 days and 7 days 
before s.c. B16 tumor challenge. Kaplan-Meyer curves displayed survival data from groups of 6 
mice. Statistical analysis: p =0.32 for CHA-OST-PADRE-TRP2L VS CHA-OST-EI; P =0.17 for 
CHA-OST-PADRE6GP100 VS CHA-OST-EI; p =0.046 for combined strains VS CHA-OST-EI; p 
=0.037 for CHA-OST-PADRE-TRP2L-PADRE-GP100 VS CHA-OST-EI. 
In B16 melanoma model, as the tumor protection provided by bacterial vaccines 
was not so significant in prophylactic assay, we didn’t go on with the therapeutic 
assay. 
In vivo tumor challenge results obtained in both tumor models clearly indicated 
that vaccinations with two antigens are more efficient than vaccinations with one 
antigen and that this bivalence could be obtained with only one strain expressing both 
antigens delivered through T3SS. Moreover, the bi-antigenic strain contributed to the 
injection of fewer amounts of bacteria, 4.106 VS 8.106 for the combination of the both 
single antigen expression strain. 
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C Construction of Humoral Response Activating Vector 
We have previously demonstrated that antigen delivery through the T3SS of P. 
aeruginosa would target at MHC-I-restricted antigen presentation pathway and be 
capable of trigger CD8 + CTL responses (3, 6). Thereby, in order to trigger a broader 
anti-tumor immune response and enhance the vaccination efficacy, we looked for 
elaborating the vectors which target humoral immune response arm of antitumour 
immunity.  
C-I Strategy 
 
Figure 26: Strategy for Humoral Response Activating Bacterial Vector Construction 
(Adapted from Frank DW et al. (446)).  
For the toxin translocation through P. aeruginosa T3SS, tow structure proteins- PopB and PopD 
are crucial. When bacterial cells contact eukaryotic cells or present in low calcium condition, 
T3SS is activated and PopB and PopD could insert into the membrane of eukaryotic cells and 
form the secretion and translocation channel. We supposed that the intra-cytoplasmic translocation 
of toxins should be blocked and the toxins would be secreted to extra-cellar space, which might 
induce an antigen specific humoral immune response. 
As we have previously discussed, the T3SS was the principal factor that 
contributed most to the virulence of P. aeruginosa. Particularly, for the 
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intra-cytoplasmic delivery of toxins, two structure proteins – PopB and PopD are 
needed. Thereby, we supposed that even T3SS is activated, if PopB and PopD are not 
present, the intra-cytoplasmic translocation of proteins should be blocked. In this 
condition, P. aeruginosa acts as a general exogenous pathogen. The 
pathogen-associated proteins might be captured within bacteria by APCs through 
phagocytosis/pinocytosis or be secreted into extra-cellular space. Thereby, antigen 
specific humoral response might be activated. Basing on this hypothesis, we 
suggested that P. aeruginosa ΔPopBΔPopD mutant can be used as antigen delivery 
vectors for humoral immune response activation. This strategy is briefly described by 
figure 26. 
C-II Construction of CHA-OST-ΔPopBΔPopD (ΔBD) Mutant  
The mutagenesis was performed by the method developed by L. Quénée (497). 
The plasmids used for allelic exchange were developed by M. Derouazi in 2005. 
Firstly, we realized the popBpopD gene deletion in the mutant CHA-OST in order to 
obtain the CHA-OST-ΔBD strain. 
 
Figure 27: Verification of CHA-OST-ΔBD Strain by SDS-PAGE. 
PopB (top) and PopD (bottom) were detected in the bacterial culture of CHA-OST strain (marked 
with arrows) but not in that of CHA-OST-ΔBD strain. 
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Then, we verified the CHA-OST-ΔBD strain by PCR technique. However, the 
results of several assays were incredible. In repeated verifications, there were always 
the bands of non-specific amplification. As PopB and PopD can be visualized by 
SDS-PAGE of cultured bacteria, we chose the alternative method to investigate the 
mutant strain. 
In figure 27, we can see in the lane which represents the culture of CHA-OST 
strain, two bands corresponding to PopB and PopD proteins exist, but they are not 
present in the lane which represents the culture of CHA-OST-ΔBD strain. 
C-III T3SS Investigation of CHA-OST-ΔBD Strain 
In order to investigate the T3SS of CHA-OST-ΔBD strain, we transformed it 
with pEAI S54-Padre-OVA248-376. As the T3SS evaluation studies described before, 
we assessed T3SS activation of CHA-OST-ΔBD strain in calcium deleting medium 
and verified the antigen expressing and secretion ability of this strain. Here, 
CHA-OST-EI strain served as the negative control and CHA-OST-OVA strain was 
used as positive reference. We tested the three strains in two conditions, either 
vaccinations condition in which we added only IPTG to induce antigen expression but 
no calcium deletion was realized; or in vitro T3SS activating condition in which 
calcium was depleted by EGTA and magnesium was added to maintain divalent 
cations. 
 In figure 28, we can see that PopB and PopD proteins can be observed in the 
lanes corresponding to CHA-OST-EI and CHA-OST-PADRE-OVA strains in both 
conditions, the bands are more evident in T3SS activating condition than in 
vaccination condition. However, in both conditions, in the lanes corresponding to 
CHA-OST-ΔBD-PADRE-OVA strain, PopB and PopD are not present; meanwhile, 
OVA protein was secreted when T3SS has been activated. These results demonstrate: 
1) the successful deletion of Pop B and Pop D proteins in CHA-OST-ΔBD mutant; 2) 
the fusion protein expression and secretion ability of this strain; and 3) the good 
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carrying of fusion protein by CHA-OST-ΔBD before T3SS activation. 
 
Figure 28: In Vitro Evaluation of Fusion Protein Expression and Secretion Ability of 
CHA-OST-ΔBD Vector.  
T3SS-mediated fusion protein expression and secretion by CHA-OST-ΔBD vector was 
investigated in two conditions: 1) vaccinations condition, in which only IPTG was added to induce 
antigen expression but no calcium depletion was realized; 2) in vitro T3SS activating condition, in 
which calcium was depleted by EGTA and magnesium was added to maintain divalent cations. 
The positions of PopB (top) and PopD (bottom) are marked with arrows; the positions of 
S54-PADRE-antigen fusion proteins are marked with asterisks. 
C-IV Investigation of Humoral Response Induced by CHA-OST-ΔBD Vector 
To investigate humoral response activating ability of CHA-OST-ΔBD vector, we 
used OVA as model antigen. Here, CHA-OST-EI strain served as negative control, 
CHA-OST-PADRE-OVA was used as the reference, and commercially ordered OVA 
protein supplemented with complete/non-complete adjuvant was used as the positive 
reference. In CHA-OST-EI and CHA-OST-PADRE-OVA groups, mice were injected 
with 5*106 bacteria /time; in OVA group, mice were injected with pure protein at 5 
µg/time. For CHA-OST-ΔBD-PADRE-OVA strain, two quantities were assessed: 
5*106 bacteria /time (L) or 1 *107 bacteria /time (H). Moreover, one more group in 
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which mice were injected with combined strains (5*106 CHA-OST-PADRE-OVA + 
5*106 CHA-OST-ΔBD-PADRE-OVA / time) was also added in this assay. In this trial, 
mice were administered 3 injections with 14 days of interval and the antibody 
detection was realized 14 days after the last injection. For each group, six mice were 
experimented. 
 
Figure 29: Evaluation of the Humoral Response Activating Ability of CHA-OST-ΔBD Vector. 
Mice were subcutaniously injected three times at a 14 days of interval with OST-PADRE-OVA 
(5*106/time) or CHA-OST-ΔBD-PADRE-OVA at low (5*106/time) or high (1*107/time) dose or 
combined strains (CHA-OST-PADRE-OVA (5*106/time) + CHA-OST-ΔBD-PADRE-OVA 
(5*106/time)). Antibody detection was realized 14 days after the last injection. Mice injected with 
CHA-OST-EI (5*106/time) were used as negative control and mice injected with pure OVA 
protein (5µg/time) supplemented with complete/non-complete adjuvant were used as positive 
control. Data represented the mean with individual values from six animals per group in duplicate. 
In figure 29, we can see that: 1) no evident antigen specific humoral response 
was activated by CHA-OST-PADRE-OVA injections, which confirm that T3SS 
mediated antigen delivery is MHC I pathway restricted; 2)  some response were 
observed in CHA-OST-ΔBD-PADRE-OVA strain injected groups and the response 
was bacteria dose dependent, which reveals that the humoral response activating 
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potential of this mutant vector; whereas the response was not statistically significant 
(P= 0.08, one way ANOVA); 3) moreover, by comparing 
CHA-OST-ΔBD-PADRE-OVA low dose injected group and combined strains injected 
group, no obvious interference between different strains was observed, which means 
the there was no interference and competition between the different strains. 
D Discussion 
D-I Addition of CD4+ Th Epitope – PADRE 
Several MHC class II restricted peptides have been identified to be potentially 
helpful for the development of vaccines. PADRE was firstly developed by Alexander 
in 1994 (507). We chose PADRE as CD4+-T-cell activator to enhance the vaccine 
performance because this peptide has been demonstrated as a strong inducer of T 
helper cells in a variety of vaccine vectors for not only the generation of CTL 
response, but also the induction of a humoral immune response (251, 504, 508, 509). 
Furthermore, different to other MHC II restricted peptides, PADRE is a promiscuous 
CD4+ Th determinant capable of binding with high affinity to most of DR alleles so 
that both human and murine MHC II molecules can bind this sequence. Thereby, it 
would be not only an ideal CD4+ T cell activator for cancer immunotherapy within 
murine model but also a promising candidate for human anti-tumor vaccines 
development.  
Since the location of insert encoding the target antigen might affect the 
transcription, translation, secretion through T3SS by bacteria, as well as the 
degradation of fusion protein by acid proteases in cytoplasm or by proteasome of 
APCs, PADRE coding sequence has been inserted either upstream or downstream of 
antigen cloning site. We first investigated in vitro fusion proteins expression and 
secretion ability of PADRE containing vector. We found that the insertion of PADRE 
epitope didn’t interfere the fusion protein expression and secretion ability of bacterial 
vectors, neither the position of PADRE did (Fig. 13).  
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Then, we have proved the optimization effect of PADRE in our vaccines, which 
is more significant when PADRE is synthesized upstream of antigen, i.e. in PADRE 
(Nter) – cloning vector. CTL experiments (Fig. 14 and Fig. 15) demonstrated the 
obvious immune responses stimulated by our bacterial vectors. Moreover, through 
tumor challenge experiments, we found that PADRE(Nter)-cloning vector can 
significantly improve the anti-tumoral efficacy of vaccines; the emergence of tumor 
was delayed and the progression of tumor was decreased. All observations are 
consistent in the groups of different constructions of TRP2 antigen (TRP2L, Fig. 18 
and TRP2S, Fig. 19). However, in CTL experiments, although the cytotoxicity curve 
corresponding CHA-OST-PADRE(Nter)-Antigen was slightly higher than that 
representing the other vaccines, the difference was not significant. We think that this 
could be due to the timing of detection. As we know, cell-mediated response to acute 
infection can generally be divided into four phases: 1) CTLs activation/expansion 
phase: this phase lasts generally 7-8 days after the infection, during which naïve CTL 
precursors are primed and exponentially proliferate; 2) CTLs contraction phase: this 
phase lasts about 2-3 weeks after activation/expansion phase, during which 90%-95% 
effector T cells undergo apoptosis ; 3) memory T cell maintenance phase: during this 
phase, memory T cells could be maintained at stable levels throughout the life of the 
mouse and for many years in human; 4) the rapid CTLs-recalling response following 
re-exposure to the pathogen (90, 510). In this study, we detected CTL cytotoxicity two 
weeks after vaccination, which corresponded to the beginning of the contraction phase; 
meanwhile the programming and maintenance of CD8+ cells by CD4+ T cells will be 
more obvious during the maintenance/memory phase. Thus, it is possible that the 
difference between vaccines shown by CTL experiments was not evident at this time 
point. However, through tumor challenge experiments, we can see the obvious 
difference between different vaccine constructions 35-45 days after vaccination, 
which supports our hypothesis to the results of CTL experiments. In order to verify 
PADRE efficiency by CTLs assay, later experiments should be performed at 
prolonged detection time or ELISpot assays should be used. 
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On the other hand, regulatory T cells have been proved to be the suppressor of 
effector T cells. They can not only induce immune tolerance to self-antigen, but also 
suppress the immune response to non-self antigens, such as microbial antigens, tumor 
antigens, etc. (511). Thus, T regulatory cells are considered as a restriction factor for 
anti-tumor immunotherapy and inactivation of T regulatory cells has been suggested 
as an approach to improve immunogenicity of anti-tumor vaccines (512). Therefore, 
in this study, in order to better evaluate the immune response stimulated by bacterial 
vectors and further estimate the impact of Tregs to our vaccines, we have also 
measured the percentage of regulatory T cells in draining lymph node after 
vaccination. Through Tregs detection assay (Fig. 16 and Fig. 17), we can find in both 
groups (TRP2L and TRP2S) that there were a lower level of Tregs in mice injected 
with CHA-OST-PADRE(Nter)-Antigen. So we can think that the suppression effect of 
immune system to activated effector cells was the weakest in mice injected with 
CHA-OST-PADRE(NTer)-Antigen. Thereby, except for the co-stimulation effect of 
CD4+ cells, this result can further confirm and better explain why the immune 
response stimulated by vaccine CHA-OST-PADRE(Nter)-Antigen is the strongest and 
why the anti-tumor action of CHA-OST-PADRE(Nter)-Antigen is the most efficient. 
Moreover, as deletion of T regulatory cells has been suggested as an approach to 
improve immunogenicity of anti-tumor vaccines. It is possible that we construct 
anti-Tregs vaccine and combine it with PADRE-antigen vaccines in later experiment. 
With less impact of Tregs cells, the anti-tumor efficiency of PADRE-Antigen vaccines 
might be more improved. 
Moreover, in this study, we have found that between the two tested TRP2 
constructions, TRP2L always functioned better than TRP2S. Vaccines containing 
TRP2L fragment can stimulate stronger immune response than TRP2S vaccines, 
which was demonstrated by both CTL assay and tumor challenge experiment. 
Comparing antigen sequences, we think the better efficiency of TRP2L might be due 
to the fact that TRP2L contains longer antigen sequence than TRP2S, in which it 
might exist more potential, non-identified CD8+ and CD4+ epitopes. So, in further 
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experimentation, we need to construct the antigen sequences of different length 
between TRP2L and TRP2S and verify their immunogenicity by vaccination, so as to 
identify the potential epitopes and better explain the difference between TRP2L and 
TRP2S. 
D-II Construction of Bi-antigen Delivery Vectors 
In recent years, multi-epitope or multi-antigen expression pattern has been 
applied to enhance the potency of cancer vaccines. Because vaccinations through this 
approach could induce a broader cellular immune response while making cancer cells 
more visible for T cells, it is likely to be more efficacious than immunization with a 
vaccine for a single antigen (513). Numerous studies demonstrated the efficient tumor 
prevention mediated by different types of vaccine vectors based on this pattern, such 
as multi-epitope DNA vaccine (514), dendritic cell (DC)-based vaccine (515), 
multi-peptide vaccine (516), multi-antigen containing virus vector (517). Also, the 
efficiency of this pattern has been applied not only in animal experiments but also in 
human trials (515, 518, 519). But so far, little correspondent results have been gained 
in bacterial vaccines domain. Thereby, we would like to strengthen the immune 
response activating ability of our bacterial vectors by applying the multiple-antigen 
expression pattern. 
In this study, we developed bi-antigen delivering bacterial vector using one P. 
aeruginosa mutant strain - CHA-OST. Bi-antigen cloning vector was constructed 
from the single antigen expression plasmid, each fusion protein expression cassette 
contains RBS and STOP-codon and thus two fusion proteins could be co-transcribed 
and individually translated (Fig. 20). However, we wounded if the position of antigen 
encoding genes on plasmid with interfere with the relative secretion of each protein. 
So, we first investigated in vitro fusion proteins expression and secretion ability of 
bi-antigen vector. The results shown by several bi-antigen strains were identical: both 
fusion proteins could be well expressed and secreted by bi-antigen vectors; however, 
the protein secretion mediated by bi-antigen vectors is position dependent, fusion 
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proteins were slightly less secreted when they were cloned at the second position 
probably due to a lower level of translation (Fig. 21). We think that there might also 
be a competition between these two proteins as for the secretion through T3SS. It is 
possible that the protein encoded by the first fusion protein expression cassette in 
bi-antigen vectors holds the dominant position during T3SS secretion process.  
As we were not sure if the position – dependent protein secretion will further 
affect the antigen delivery processed by bi-antigen vectors and antigen specific 
immune response activation, we used OVA as the model antigen and cloned it at both 
positions in bi-antigen vector to investigate the influence of antigen cloning position 
to antigen delivery and presentation. Trough B3Z activation assay (Fig. 22), we didn’t 
find evident difference evoked by OVA cloning position, which indicated that the DCs 
activation and antigen presentation were not directly antigen position dependent. 
However, bi-antigen vectors provided slightly lower B3Z activation than single 
antigen vector. We hypothesize that because the assay was realized in vitro, the 
quantity of DCs was limited and saturation of MHC I presentation must have occurred, 
which resulted in the competition between the two antigens as for binding to MHC I 
molecules and limited the presentation of individual antigen. But this would not be a 
problem for in vivo assay. For this reason, it needed to further evaluate bi-antigen 
vector through in vivo tumor challenge.  
In the in vivo experiments, we tested bi-antigen vector expressing two self 
antigens TRP2 and GP100 in two natural tumor model (Glioblastoma (GL261) and 
melanoma B16) and the results were encouraging. In GL261 model, both in 
prophylactic and in therapeutic assay (Fig. 23 and Fig. 24), bi-antigen strains provided 
a more efficient protection. Tumor onset was more effectively delayed and tumor 
growth progression was more evidently reduced in bi-antigen strain vaccinated group 
than in single-antigen strain vaccinated groups. And, bi-antigen strain demonstrated a 
similar performance as combined single-antigen strains. In B16 model (Fig. 25), 
similar results were obtained; bi-antigen strains provided a more efficient tumor 
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protection than each signal antigen delivery strain and demonstrated the similar 
performance to combined single-antigen strains. More interesting, both single antigen 
delivery vector haven’t provide significant tumor protection, but bi-antigen delivery 
vector did. 
Here, we also found that the anti-tumor protection contributed by our bacterial 
vectors is weaker in B16 model than in GL216. We hypothesized that this result might 
be related to the intrinsic characters of B16 tumor. It is well known that B16 is a 
poorly immunogenic cell line and express very low class I levels and hence low levels 
of antigens, which is an important mechanism for B16 to escape from T-cell killing 
and also might be one potential explanation for the weaker B16 protection obtained 
with our bacterial vaccines. Even then, strengthened antitumor effect provided by 
bi-antigen expression pattern has been demonstrated even in this poorly immunogenic 
tumor model.   
All above results reveal the advantages of bi-antigen strains. The first advantage 
is a better efficiency: vaccinations with bi-antigen vector containing GP100 and 
TRP2L provided a better tumor protection than both single-antigen immunizations. 
The second advantage is simplicity: in contrast to the individual preparation for two 
vaccines, bi-antigen vector is processed in one time. Furthermore, through this study, 
the feasibility and the efficacy of multiple antigen delivery via our bacterial vectors 
have been confirmed. Here, we have only investigated bi-antigen delivery pattern, it is 
possible that, in future studies, more than two antigens could be combined in our 
bacterial vaccines to induce a broader immune response; and more significant tumor 
protection might be obtained. 
However, in ex vivo immune monitoring essay, no evident responses to two 
TRP2 epitopes and one GP100 epitope have been detected. Our hypothesis for this 
phenomenon is that the peptide specific immune response activation is dependent on 
protein processing machinery of APCs as well as tumor cells. Indeed, different studies 
reported that several CTL raised against high-affinity binding peptides did not 
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recognize tumor cells expressing the targeted antigen, mainly because their protein 
processing machinery did not display the peptides (520, 521). Thereby, in our 
experiment, both the processing of translocated antigen by APCs and the processing 
of TAAs by tumor cells might affect the immune response to certain peptides. 
Whatever, the performance of our bacterial vectors has been proved by in vivo tumor 
challenge, which reveals the distinct advantage of our immunogenic platform: our 
bacterial vector can deliver whole protein and its application as cancer vaccine would 
not be restricted by CD8+ T peptides identification and hence to MHC I. 
D-III Construction of Humoral Response Activating Vectors 
To date, most of anti-tumor vaccination strategies have aimed to trigger CD8+ 
CTLs responses, as CTLs recognize tumor cells presenting peptides from TAAs 
through MHC-I molecules and the immune response stimulated by this way is more 
specific and more efficient. In fact, both in animal and clinical studies, the strageties 
that focused on the use of MHC class I-restricted tumor Ags and CD8+-directed 
immunization could truly activate antigen specific CTL responses, but the overall cell 
mediated responses were weak and not so efficient to eliminate cancer cells and 
control tumor growth. The limited outcome is mainly due to the immune-escape 
mechanisms established by advanced tumors that inhibit effector T cells or prevent 
full T cell activation (22, 522). In recent studies, interest has been directed to target at 
multiple arms of immunity to generate a strong, broad and long-lasting antitumor 
immunity; incorporation of humoral and cellular immunity may represent further 
improvement of current T cell-based cancer immunotherapy. 
As it has been proved that the immune response activated by P. aeruginosa T3SS 
based vectors is the MHC-I-restricted CD8+ T cells mediated response, we would like 
to elaborate bacterial vectors that could target at anti-tumor humoral immunity. This 
idea has been realized through the structural and functional knowledge of P. 
aeruginosa T3SS. As PopB and PopD are two indispensible T3SS structure proteins 
that insert to the mammalian cells membrane and form the channel allowing toxin 
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translocation, we suggested that the intra-cytoplasmic translocation of protein should 
be terminated when these two proteins were deleted. Bacteria can be captured by 
APCs through phagocytosis or pinocytosis and the pathogen-associated proteins 
would be targeted to MHC II pathway or secreted in extracellular environment; and 
antigen specific humoral response might be activated through Th2 pathway (Fig. 26).  
However, we were not sure if the structural change of T3SS will affect the 
antigen expression and carrying ability of P. aeruginosa ΔPopBΔPopD mutant, 
thereby we first evaluated this mutant strain in vitro in two conditions: vaccine 
preparation condition and T3SS activation condition (Fig. 28). The protein of interest 
has only been detected in T3SS activation condition, which reveals the good antigen 
carrying ability of P. aeruginosa ΔPopBΔPopD mutant.  
Then, the humoral response activating ability of ΔPopBΔPopD mutant was 
assessed by antigen specific IgG titration (Fig. 29). We found that OVA specific IgG 
can be detected in CHA-OST-ΔBD-PADRE-OVA strain injected groups but not in 
CHA-OST-PADRE-OVA strain injected group and the intensity of this response was 
bacteria dose dependent. These results on one hand demonstrated that the response 
activated by P. aeruginosa T3SS delivery mechanism is cellular component mediated 
response; on the other hand affirmed our hypothesis that P. aeruginosa ΔPopBΔPopD 
mutant is powerful to activate the antigen specific humoral response. However, the 
humoral response detected in this experiment is moderate. For the weak humoral 
response, our hypothesis is that the quantity of antigen delivered by 
CHA-OST-ΔBD-PADRE-OVA strain is not sufficient to activate significant humoral 
response. It has been previously detected in our laboratory that 5*108 of P. aeruginosa 
vaccine vector can express and secret about 1 µg interest protein, in this trial, we 
injected 5*106 CHA-OST-ΔBD-PADRE-OVA per mice each time, which means mice 
were immunized with OVA at the level of about 0.01 µg/time. This immunization 
quantity is much weak than that administered in positive control group 
(5µg/mouse/time). As the humoral response was bacteria dose dependent, the 
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significant humoral response might be occurred when the quantity of delivered 
protein is augmented. This can be achieved by using one avirulent strain which can be 
administered at high dose. 
Furthermore, in order to validate the efficacy of this mutant, some supplementary 
experiments need to be realized. For example, as we discussed above, the humoral 
response activated by P. aeruginosa ΔPopBΔPopD mutant is possibly Th2 pathway 
mediated, the activation of antigen specific CD4+ Th cells should be evaluated. 
Moreover, the potential improvement of CD8+ T-cell mediated responses should be 
investigated. Finally, the anti-tumor efficiency of this mutant should be validated by 
tumor challenge in animal model. 
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Résumé en Français: 
Dans nos travaux précédents, l'efficacité anti-tumorale prophylactique des 
vecteurs de P. aeruginosa a été prouvée. Dans l’objectif d’aller vers des applications 
chez l’homme, leurs performances anti-tumorales doivent être évaluées en mode 
thérapeutique. Plusieurs schémas thérapeutiques contenant deux injections ont été 
testés en modèle B16OVA murin. Bien que la protection existe, ces protocoles de 
vaccination doivent être optimisés. Ainsi, dans ce chapitre, afin d'optimiser l’efficacité 
thérapeutique de nos vaccins et de déterminer un schéma plus idéal pour la 
vaccination thérapeutique, nous avons essayé de moduler la fréquence et l'intervalle 
d'injection. Les résultats in vivo et in vitro ont montré qu’une fréquence et un 
intervalle appropriés d’immunisation sont importants pour programmer la réponse 
immune primaire contre l’antigène. 
In English: 
In our previous work, the prophylactic anti-tumor efficiency of P. aeruginosa 
vectors has been proved (3, 6). For clinical application purpose, their anti-tumor 
protection performance should be confirmed in therapeutic vaccination mode. 
A Optimization of Therapeutic Vaccination Scheme 
A-I Previously Tested Therapeutic Vaccination Schema 
Previously, several two-injection therapeutic schedules in murine B16OVA 
model have been tested (10). Although protection occurred, these vaccination 
protocols should be optimized. Among these therapeutic vaccination schemas, 
D+0/D+7 schema demonstrated the better anti-tumor protection. So at the beginning 
of this work, we assessed one more time this scheme through the tumor challenge in 
B16OVA tumor model. Here, CHA-OST-PADRE-OVA strain (5*106/time) was used 
as vaccine vector.  
Results – Chapter 2 
188 
 
Figure 30: Evaluation of the Therapeutic Anti-tumor Efficiency of P. aeruginosa Vector on 
Following D+0/D+7 Schema. 
Mice were inoculated with B16OVA cells on day 0 and subcutaneously injected with 
CHA-OST-PADRE-OVA strain (5*106/time) on day 0 and day 7. CHA-OST-EI was used as 
negative control. Kaplan-Meyer curves displayed survival data from groups of 6 mice. Statistical 
analysis: p=0.03 for CHA-OST-PADRE-OVA (D+0/D+7) VS CHA-OST-EI. 
In accordance with previous experiments, tumor protection was provided by two 
times of therapeutic vaccinations this time (p=0.03) (Fig. 30). These survival data 
were saved as the reference for further optimization. 
A-II Optimization Strategy 
Some recent anti-tumor researches based on different vaccine vectors 
demonstrated encouraging therapeutic results using OVA as model antigen and their 
vaccination schedules contained more vaccination times or shorten vaccination 
interval (523-526). Thus, in order to optimize the therapeutic potency of our vaccines 
and determine an ideal therapeutic vaccination schema, we tried to increase 
vaccination times or reduce vaccination interval. In this trial, 
CHA-OST-PADRE-OVA strain was used as vaccination strain. 
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Figure 31: Optimization of the Therapeutic Anti-tumor Efficiency of P. aeruginosa vector by 
Increasing Vaccination Frequency. 
Mice were inoculated with B16OVA cells on day 0 and subcutaneously injected with 
CHA-OST-PADRE-OVA strain (5*106/time) on day+0, day+7 and day+14. CHA-OST-EI was 
used as negative control. Kaplan-Meyer curves displayed survival data from groups of 6 mice. 
Statistical analysis: p=0.03 for schema D+0/D+7/D+14 VS schema D+0/D+7. 
Firstly, we increased the vaccination frequency without changing vaccination 
interval. Mice were first challenged with B16OVA tumor cells on day 0 and then 
injected three times with CHA-OST-PADRE-OVA strain on day 0, +7 and +14. The 
results were shown in figure 31. Here, we can see that increasing the number of 
vaccination can slightly delay the tumor formation, but the difference was not 
significant (p=0.3) 
Then, we tried to reduce the vaccination interval but not changing the 
vaccination numbers. That means mice were first challenged with B16OVA tumor 
cells on day 0 and then injected three times with CHA-OST-PADRE-OVA strain on 
day 1 and +5. Tumor protection provided by this schema was shown in figure 32. 
Similar to preceding experiment, reducing the interval of vaccination can slightly 
delay the tumor formation, but no significant difference was not observed (p=0.59) 
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Figure 32: Optimization of the Therapeutic Anti-tumor Efficiency of P. aeruginosa Vector by 
Reducing Vaccination Interval. 
Mice were inoculated with B16OVA cells on day 0 and subcutaneously injected with 
CHA-OST-PADRE-OVA strain (5*106/time) on day+1 and day+5. CHA-OST-EI was used as 
negative control. Kaplan-Meyer curves displayed survival data from groups of 6 mice. Statistical 
analysis: p=0.59 for schema D+1/D+5 VS schema D+0/D+7. 
Thereby, for obtaining a significant optimization, we attempted to change the 
vaccination schedule in both parameters – vaccination number and vaccination 
interval. In this condition, mice were always first challenged with B16OVA tumor 
cells on day 0 and then injected with CHA-OST-PADRE-OVA strain on day 
+1/+5/+9/+13 or +1/+5/+9/+13/+17/+21. This time, encouraging results were 
obtained. In figure 33, we can see that by augmenting vaccination number and 
reducing vaccination interval at the same time, tumor protection was improved and 
the optimization was vaccination related; the statistically significant change was 
observed in the mice injected six times with 4 days interval. Here, it has to be noticed 
that we vaccinated the mice 6 times because before the 7th vaccination, there were 
already some mice were sacrificed with the tumor exceeded 10mm of diameter. 
Moreover, thinking about the toxicity of CHA-OST strain and possible immunity 
impairment caused by the bacteria administration, we didn’t try much shorter interval.   
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Figure 33: Optimization of the Therapeutic Anti-tumor Efficiency of P. aeruginosa Vector by 
Increasing Vaccination Frequency and Reducing Vaccination Interval. 
Mice were inoculated with B16OVA cells on day 0 and subcutaneously injected with 
CHA-OST-PADRE-OVA strain (5*106/time) on following D+1/D+5/D+9/D+13 or 
D+1/D+5/D+9/D+13/D+17/D+21 schema. CHA-OST-EI was used as negative control. 
Kaplan-Meyer curves displayed survival data from groups of 6 mice. Statistical analysis: p=0.13 
for schema D+1/D+5/D+9/D+13 VS schema D+0/D+7; p=0.04 for schema 
D+1/D+5/D+9/D+13/D+17/D+21 VS schema D+0/D+7. 
B Confirmation of the Optimization Strategy through Immune 
Response Monitoring 
As we published before (3, 6), the immune response activated by T3SS delivery 
is CD8+ cytotoxic T lymphocytes (CTLs) mediated immune response. Therefore, in 
order to confirm the in vivo findings and our optimization strategy, we have also 
assessed the dynamic evolution of acute CD8+ T cell response activated by different 
vaccination protocols through ELISpot assay.  
In this trial, we used always CHA-OST-PADRE-OVA as vaccination strain. In 
each group, there were 3 mice and the experiment was repeated twice. Each time, we 
quantified antigen specific CD8+ T cells at three time points. The first measurement 
was realized just before the injections. The second time point was 4 days after the last 
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injection of each group, a lag corresponding to the peak values of activated CD8+ T 
cell responses. On day25, when we measured the peak value of T cell response in 
D1/D5/D9/D13/D17/D21 group, we would also like to know remaining T cell 
response in D1/D5 group. As this day corresponded to a lag of 20 days after the last 
injection in D1/D5 group, we chose 20 days after the last injection as the third 
measurement time point for all groups. By combining results measured at different 
time points, we can evaluate the dynamic change of acute T cell response for each 
group. In figure 34, we can see the typical two phases of T cell response in all groups: 
an expansion phase followed by a contraction phase. Moreover, through increasing 
injection frequency and reducing injection interval, the immune response expansion 
phase was prolonged, the peak value of T cell response was increased and the T cell 
response contraction phase was delayed. These results confirmed that more frequent 
and continuous injection could reinforce adapted T cell response. 
 
Figure 34: Dynamic Change of CD8+ T Cells Mediated Responses Activated by Different 
Immunization Protocols. 
The CD8+ immune response was assessed through ELISpot at three time points: 1) before the first 
injection; 2) 4 days after the last injection; 3) 20 days after the last injection. CHA-OST-EI was 
used as negative control. Data represented the mean +/- SD from six animals per group 
(cumulative results of two independent experiments conducted with the same methodology). 
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C Further Evaluation of Therapeutic Vaccination Schemas through 
Function Evaluation of Memory CTLs 
The ultimate purpose of cancer vaccine administration is to generate long lasting 
immune memory to prevent tumor recurrence. To prevent tumor cells from becoming 
established tumor, it is critical that the vaccine-induced tumor-specific memory T 
cells can immediately sense tumor cells emergence and be rapidly reactivated and 
expanded to kill the malignant cells in initial stage. Thereby, in order to further 
evaluate the efficiency of our bacterial vector, we have also investigated memory T 
cell mediated response after immunizations and its potential to prevent tumor 
recurrence. 
First, we examined whether the memory T cells can sense the inoculation of 
B16OVA tumor cells and be reactivated. Three months after the last vaccination, we 
inoculated mice with B16OVA tumor cells and quantified recalled CTLs' response. 
Generally, 1 month after pathogen infection, pathogen related CD8+ T cell response 
should enter memory T cells dominating phase and little effector CTLs could be 
detected (89). Thereby, we believe that the CTLs quantified here could demonstrate 
the reactivation and expansion ability of memory T cells. In figure 35, we 
demonstrated by ELISpot analysis that 3 months after the last vaccination, only few 
CTLs were remaining in all groups and there was no evident CTLs amount difference 
among the different groups; but 7 days after the inoculation of B16OVA cells which 
express the specific antigen, there were significant CTLs increasing in all immunized 
groups but not in negative control group and the most significant change was found in 
D1/D5/D9/D13/D17/D21group. 
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Figure 35: Function Evaluation of Memory CTLs Induced by Different Immunization 
Protocols through Effector CTLs Recalling Assessment Realized by ELISpot. 
Mice (n=3 per group) were vaccinated with the different immunization protocols. B16OVA tumor 
cells were s.c. injected 3 months after the last injection. The CTLs recalling response was assessed 
by ELISpot at two time points: 1) one day before B16OVA cells inoculation; 2) 7 days after 
B16OVA cells inoculation. CHA-OST-EI was used as negative control. Data represented the 
mean+/- SD. * p<0.05; ** p<0.01. 
To confirm these findings, we also verified long term protection against tumor 
after bacterial vector immunization in animal model. The results in figure 36 showed 
that by comparing to negative control group, there is a significant long term tumor 
rejection in all groups (schema D1/D5 VS CHA-OST-EI, p=0.0029; schema 
D0/D7/D14 VS CHA-OST-EI, p=0.0014; schema D1/D5/D9/D13/D17/D21 VS 
CHA-OST-EI, p=0.0006). The tumor rejection was more significant in the group 
which has been vaccinated 6 times with 4 days of interval (schema 
D1/D5/D9/D13/D17/D21 VS schema D1/D5, p=0.004; schema 
D1/D5/D9/D13/D17/D21 VS schema D0/D7/D14, p=0.1917). These results suggest 
that bacterial vector induced long lasting T cells able to sense the B16OVA tumor cell 
challenge and immediately expand to a significantly higher level and execute a strong 
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effector function. We hypothesize that this phenomenon corresponds to a good 
induction of memory T cells by our vaccination; the best vaccination scheme for that 
purpose is D1/D5/D9/D13/D17/D21 vaccination schedule. 
 
Figure 36: Function Evaluation of Memory CTLs Induced by different immunization 
Protocols through Tumor Challenge. 
Kaplan-Meyer curves displayed survival data of mice (n=6) vaccinated with various immunization 
protocols and challenged with B16 OVA tumor cells three months after the last vaccination. 
CHA-OST-EI was used as negative control. Kaplan-Meyer curves displayed survival data from 
groups of 6 mice. Statistical analysis: p<0.01 for immunized groups VS CHA-OST-EI; p=0,004 
for schema D1/D5/D9/D13/D17/D21 VS schema D1/D5; p=0.1917 for schema 
D1/D5/D9/D13/D17/D21 VS schema D0/D7/D14. 
The data presented in this chapter lead to the conclusion that our bacterial vector 
could provide efficiently therapeutic anti-tumor protection and that the 
D1/D5/D9/D13/D17/D21 schedule is more efficient in both short term and long term 
response than the other schema.  
D Discussion 
In our previous work, the potential use of P. aeruginosa attenuated strains as 
carriers for antitumor vaccination purposes has been only reported in prophylactic 
experiments (3, 6, 10). As the ultimate objective of our bacterial vaccines 
development is clinical application, their tumor protection efficiency should be 
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evaluated and confirmed in therapeutic mode.  
We have tested the therapeutic vaccination schema with two injections at 7-days 
of interval, although tumor protection occurred, the results were not satisfying. So, in 
order to verify the therapeutic efficiency of our vaccines, we need to establish one 
efficient vaccination strategy at first.  
It has been well accepted that the CD8+ T-cell response is a dynamic process and 
acute CTLs response contains expansion and contract phase (90). Recently, one 
progressive-differentiation model has been proposed for the sustained expansion 
during the primary response to antigen. According to the progressive-differentiation 
model , accumulated stimulation of CD8+ T cells by antigen may induce successive 
rounds of division/differentiation (527). As we have discussed in previous paragraphs, 
that the immune response activated by P. aeruginosa T3SS based vectors is the 
MHC-I-restricted CD8+ T cells mediated response, we hypothesized that the change 
in vaccination frequency or injection interval could modify CD8+ immune response. 
The results of in vivo tumor challenge assays obtained with OVA antigen 
demonstrated that altering only the vaccination frequency or the injection interval 
couldn’t carry expected results; significant improvement of therapeutic vaccination 
efficiency has been realized by changing both parameters (Fig. 31-33). In fact, 
continuous and more frequent immunizations could more effectively prime the 
immune response (Fig. 34). With the increase of vaccination frequency and the 
reduction of vaccination interval, the expansion phase has been obviously prolonged, 
the peak value of specific anti OVA CD8+ T cells amount was enhanced and CD8+ T 
response persisted for longer time. Both in vitro and in vivo results demonstrated that 
appropriate immunization frequency and interval are both important for programming 
primary immune response to antigen. 
Furthermore, in the fight of the immune system against cancer, a long lasting and 
effective CD8+ T cell memory is also crucial, because this T cell population can sense 
the emergence of tumor cells and control tumor recurrence. Therefore, in this work we 
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also estimated the long term efficacy of our bacterial vectors by inoculation of 
B16OVA tumor cells three months after bacterial vectors immunization. The results 
obtained from both ex-vivo immune monitoring (Fig. 35) and in vivo tumor challenge 
(Fig. 36) demonstrated that the T cell response induced by our bacterial vector was 
able to sense the residual tumor cells and effectively inhibiting the tumor recurrence. 
Our bacterial vectors demonstrate the therapeutic efficiency not only in artificial 
B16OVA model, but also in natural tumor model (GL261 and B16) of which the 
results are presented and discussed in result-chapter 1.  
Based on these preliminary results, we can conclude that through modulating the 
frequency and the interval of injections, the anti-tumor therapeutic efficiency of our P. 
aeruginosa vaccines could be successfully optimized. As the bacterial vector used in 
this experiment was CHA-OST which is not totally avirulent, the toxicity of this 
bacteria strain and the possible immunity impairment caused by the bacteria 
administration were indeed the considerations for us. Therefore, we haven’t tried the 
vaccination schedule with the interval less than 4 days. In future experiments using 
other more attenuated strains, as well as different antigens, the therapeutic vaccination 
strategies containing different immunization frequencies and variable intervals should 
be individually evaluated. It is possible that vaccination efficiency could be more 
enhanced. 
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Résumé en Français: 
L'objectif ultime de toutes les recherches du cancer est que les résultats de ces 
recherches puissent être appliqués dans le traitement du cancer humain. De façon 
similaire, le développement de nos vaccins anti-tumoraux basés sur des bactéries 
vivantes est également orienté vers les applications cliniques. Dans ce chapitre, avant 
tout, un candidat (CHA-CLIN1) qui pourrait être appliqué en clinique a été généré par 
l'adaptation dans un milieu chimiquement défini d'un mutant (CHA-OAL) de P. 
aeruginosa totalement avirulent. Ensuite, la très faible infectiosité de cette nouvelle 
souche a été surmontée par l’injection des souris à de multiples emplacements. Les 
résultats in vivo et in vitro ont montré qu’une injection à de multiples emplacements 
est plus performante qu’une injection dans un emplacement unique. L’immunisation 
dans des emplacements multiples avec le vecteur CHA-CLIN1 pourrait donner des 
efficacités prophylactique et thérapeutique proches de celles du vecteur CHA-OST. 
In English:  
The ultimate objective of all cancer researches is that the results of these 
researches can be applied in human cancer treatment. In a similar way, the 
development of our bacteria based cancer vaccines should also be oriented towards 
clinical applications. For this purpose, one ideal bacterial vaccine should represent the 
best compromise between virulence attenuation and efficiency. Moreover, for good 
manufacturing practices reason, bacterial vectors should be produced in chemically 
define medium with constant growth performance to ensure the quality of the product.  
That is the reason why we initiated the work presented in this chapter.  
A Adaptation of CHA-OAL Mutant in One Chemically Defined Medium 
A-I Definition of Bacteria Culture Medium 
M9 medium (Miller, et al. 1972) is one of the standard minimal medium for the 
cultivation of bacteria. DeBell RM et al compounded one chemically defined medium 
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which has been proved to be ideal for Exotoxin A production by P. aeruginosa (501). 
So, the initial culture medium for CHA-OAL strain adaptation was prepared based on 
these media. However, the growth rate of bacteria was not high enough (Fig. 37).  
 
Figure 37: Adaptation of CHA-OAL Strain in One Chemically Defined Medium.  
The initial culture medium for CHA-OAL adaptation was prepared basing on M9 medium and 
DeBell RM prepared chemically defined medium in which Mg2+ and Ca2+ were of low level. 
The growth rate of bacteria was not high enough. CHA-OAL strain was later adapted in the 
medium supplemented with 1 mmol/L Mg2+ and Ca2+ and growth rate of bacteria was optimized. 
After adaptation by progressive medium replacement, the growth of CHA-OAL strain in 
M9-TheREx medium was constant. (A) Adaptation of CHA-OAL strain in Mg2+ and Ca2+ poor 
(left) and abundant (right) medium was described by mean doubling time during exponential 
growth (min) in terms of LB percentage in culture medium; (B) Adaptation of CHA-OAL strain in 
Mg2+ and Ca2+ poor (left) and abundant (right) medium was described by mean overnight OD (600 
nm) in terms of LB percentage in culture medium. 
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Some studies revealed that elevated levels of Mg2+ and Ca2+ could help P. 
aeruginosa growth and proteins production (528, 529). Hence, we further modified 
the adaptation medium by supplementing it with Mg2+ and Ca2+ and the composition 
of the modified M9 medium (M9-TheREx) is shown in table 7. In figure 37, we can 
see that, when CHA-OAL strain was being adapted in the medium with low level of 
Mg2+ and Ca2+, with the decreasing of LB proportion in culture medium, the 
amplification speed of bacteria also decreased: overnight OD value was reduced and 
doubling time during exponential growth was prolonged. However, when CHA-OAL 
strain was being adapted in M9-TheREx medium, both parameters were optimized. 
After adaptation by progressive medium replacement, the growth of CHA-OAL strain 
in M9-TheREx medium was constant and even faster than in LB broth (mean 
doubling time during exponential growth: 43 min in M9-TheREx and 68 min in LB). 
In order to distinguish with original CHA-OAL strain, we renamed the adapted strain 
as CHA-CLIN1. 
A-II Investigation of Micro-biological Characters of CHA-CLIN1 Strain as 
Antigen Delivery Vector 
A-II-a Toxicity Detection 
Table 9: In Vivo Toxicity Test of CHA-OST and CHA-CLIN1 Mutants 
 
In order to verify if the adaption and the new growth condition have modified the 
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virulence of CHA-CLIN1 strain, we assessed the in vivo toxicity of strains either 
cultivated in LB or M9-TheREx medium by observing mortality after one s.c. 
injection of 107, 108, or 109 bacteria to 6-week-old female C57BL/6 mice. The 
toxicity of the new CHA-CLIN1 strain was also compared with the toxicity of 
CHA-OST strain (table 9). It can be observed that the toxicity of CHA-CLIN1strain in 
M9-TheREx is very low compared to the toxicity of CHA-OST strain and is at the 
same level of the previously published CHA-OAL strain. 
A-II-b T3SS Analysis in CHA-CLIN1 Strain 
After that, we also investigated if T3SS characters of CHA-CLIN1 strain were 
modified by both adaptation and growth in M9-TheREx medium.  
 
Figure 38: T3SS Evaluation of CHA-CLIN1 Strain. 
M9-TheREx medium cultivated CHA-CLIN1 strain was transformed with 
pEAI-S54-Padre-OVA248-376 and its antigen expression and secretion ability was assessed by 
SDS-PAGRE. The positions of PopB (top arrow) and PopD (bottom arrow) are marked with 
arrows; the positions of S54-PADRE-antigen fusion proteins are marked with asterisks. 
In this assay, we used OVA as model antigen. Thus, we transformed 
CHA-CLIN1 strain with pEAI-S54-Padre-OVA248-376 and verified the fusion protein 
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secretion in both LB and M9-TheREx medium. The results are presented in figure 38. 
Compared to CHA-OAL strain, CHA-CLIN1 strain grown in M9-TheREx conserved 
well its antigen expression and secretion ability. Moreover, the presence of PopB and 
PopD which indicates the activation of T3SS was correct. 
B Optimization of the Vaccination Efficiency of CHA-CLIN1 Strain  
In our previous work, we used CHA-OAL strain as vaccination vector in vivo for 
tumor protection in the B16OVA melanoma murine model (10), but the results 
indicated that CHA-OAL strain with two injections was less efficient than CHA-OST 
strain. So, we tried to optimize the efficiency of CHA-CLIN1 strain in this work. 
B-I Definition of an Ideal Vaccination Dose 
To define an ideal vaccination dose, we immunized mice with different doses of 
CHA-CLIN1-PADRE-OVA bacteria (107, 108, or 109 bacteria/time) on day -14 and 
day -7. And, CD8+ T cells activation was assessed through ELISpot assay on day 0. 
In this assay, immunization with the CHA-OST-PADRE-OVA strain (5*106 bacteria 
/time on D-14 and D-7) served as positive reference.  
In figure 39, we can see that 108 CHA-CLIN1-PADRE-OVA/time primed the 
strongest CD8+ T response among the three doses, but the vaccination efficiency of 
CHA-CLIN1 strain was always significantly weaker than that of CHA-OST. 
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Figure 39: Definition of the Most Efficient Dose of CHA-CLIN1 Strain through ELISpot 
Assay.  
C57BL/6 mice were injected in right flank with CHA-CLIN1-PADRE-OVA strain at the dose of 
107 or 108 or 109 cells/time or with CHA-OST-PADRE-OVA strain at the dose of 5*106 cells/time 
D-14/D-7 days before ELISpot assay. Data represented the mean +/- SD from three animals per 
group, *p<0.05, **p<0.01. 
B-II Definition of an Efficient Vaccination Mode 
In recent studies, mutations in the aroA gene have been applied to pathogens, 
such as Salmonella typhi (530), Aeromonas hydrophila (531) and P. aeruginosa (532), 
for the live, attenuated vaccine strains production. Because aroA gene encodes an 
enzyme essential for the synthesis of aromatic amino acids which are generally not 
available in host tissues, the deletion of aroA gene both restrains the bacterial growth 
and inhibits the pathogenic dissemination in mammalians, which could also limit the 
immunogenicity and efficiency of vaccine (533).  
So, we tried to optimize CHA-CLIN1 strain efficiency through two approaches: 
1) vaccination of mice at multiple loci (four s.c. injections in right and left flanks, 
5*107 bacteria/position/time, on D-14/D-7) and 2) vaccination with more injections 
and reduced time between two injections (1*108 bacteria/time, on 
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D-16/D-12/D-8/D-4). For the two vaccination protocols, the amount of injected 
bacteria was identical. The effects of the different optimization strategies were firstly 
estimated by ELISpot mediated CD8+ T cell response quantification on day 0 and the 
results were shown in figure 40. 
 
Figure 40: Strategy for Optimizing the Vaccination Efficiency of CHA-CLIN1 Strain.  
Protocol 1: C57BL/6 mice were injected twice at four positions in right and left flanks with 
CHA-CLIN1-PADRE-OVA strain of 5*107 cells/position/time 14 days and 7 days before ELISpot 
assay; Protocol 2: C57BL/6 mice were injected four times with four days of interval at single 
position in right flank with CHA-CLIN1-PADRE-OVA strain at the dose of 108cells/time before 
ELISpot assay. The immune responses primed following the different protocols were compared 
with that activated by standard CHA-OST-PADRE-OVA injections. Data represented the mean+/- 
SD from three animals per group **p<0.01. 
We observed that there were no remarkable optimization through increasing 
injection frequency and reducing injection interval. However the multi-position 
injection with CHA-CLIN1-PADRE-OVA strain significantly optimized the 
vaccination efficiency and primed a nearly identical CD8+ response as 
CHA-OST-PADRE-OVA strain. 
B-III In vivo Evaluation of the Vaccination Efficiency of CHA-CLIN1 Strain  
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In order to confirm the optimization strategy, we further assessed in vivo 
B16OVA tumor protection mediated by CHA-CLIN1-PADRE-OVA vaccinations at 
either uni-position or multi-positions. Here, both prophylactic and therapeutic 
anti-B16OVA assay were performed. CHA-OST-EI strain was used as negative 
control and CHA-OST-PADRE-OVA strain was used as positive reference. 
 
Figure 41: In Vivo Evaluation of the Optimized Vaccination Protocol for CHA-CLIN1 Strain 
in Prophylactic Vaccination Mode. 
C57BL/6 mice were injected twice at uni-position with CHA-CLIN1-PADRE-OVA strain at the 
dose of 2*108 cells/time or at four positions in right and left flanks at the dose of 5*107 cells 
/position /time on 14 days and 7 days before B16OVA tumor challenge. CHA-OST-EI is the 
negative control. CHA-OST-PADRE-OVA is the positive control. Kaplan-Meyer curves displayed 
survival data from groups of 6 mice. Statistical analysis: p<0.01 for immunized groups VS EI, no 
statistically significant difference between immunized groups. 
Figure 41 presents the results of prophylactic assay. In contrast to CHA-OST-EI 
strain injected group, all immunized groups demonstrated efficient anti-tumor 
protections, no mouse developed tumor in all groups. CHA-CLIN1-PADRE-OVA 
vaccinations based on different protocols demonstrated the same efficacy as 
CHA-OST-PADRE-OVA strain. 
Figure 42 shows the results of therapeutic assay. All immunized groups presented 
tumor rejections with slight differences between the three immunized group, 
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CHA-CLIN1-PADRE-OVA vaccinations at four positions were slightly more efficient 
than CHA-OST-PADRE-OVA vaccinations which were still better than 
CHA-CLIN1-PADRE-OVA vaccinations at one position, whereas the differences 
between the three groups there were not statistically significant 
 
Figure 42: In Vivo Evaluation of the Optimized Vaccination Protocol for CHA-CLIN1 Strain 
in Therapeutic Vaccination Mode. 
C57BL/6 mice received a s.c. tumor challenge with GL261 tumor cells on day 0 and then were 
vaccinated with at uni-position with CHA-CLIN1-PADRE-OVA strain at the dose of 2*108 
cells/time or at four positions in right and left flanks with CHA-CLIN1-PADRE-OVA strain at the 
dose of 5*107 cells/position/time on following D1/D5/D9/D13/D17/D21 therapeutic schema. 
CHA-OST-EI is the negative control. CHA-OST-PADRE-OVA is the positive control. 
Kaplan-Meyer curves displayed survival data from groups of 6 mice. Statistical analysis: p<0.01 
for immunized groups VS EI; no statistically significant difference between immunized groups. 
C Discussion 
In clinical trials, for bacteria based vaccines, safety (virulence attenuation), 
efficacy, and the production process of bacterial vector complying with current good 
manufacturing practices grade are indispensible. In our previous work (10), 
CHA-OAL strain, one P. aeruginosa-attenuated mutant, was constructed and 
characterized with greatly reduced toxicity. Hence, it could be an ideal candidate for 
clinical trials. However, all the encouraging results of the CHA-OAL strain were 
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obtained in a complex not chemically defined LB broth. Moreover, the CHA-OAL 
strain demonstrated uncontrollable growth defects in this medium (data not shown). 
Moreover, its efficiency at high doses has not yet been assessed. All these preliminary 
results emphasize the need to: i) develop a new chemically defined medium; ii) adapt 
the CHA-OAL strain to that medium; and iii) define an appropriate vaccination mode 
to validate its vaccination efficiency.  
C-I Adaptation of CHA-OAL Strain in One Chemically Defined Medium 
M9 is one of the standard minimal medium for bacterial culture. In recent 
fundamental studies, M9 medium has been applied in different bacterial species 
culture, such as Escherichia coli B, Salmonella Typhimurium, and Pseudomonas 
putida (534-536). On the other hand, DeBell RM et al. compounded one chemically 
defined medium in which L-amino acids, basal and trace salts, glucose and glycerol 
are important compositions; and this chemically defined medium has been proved to 
be ideal for exotoxin A production by P. aeruginosa (501). Thus, we attempted to 
adapt CHA-OAL vector basing on these media. However, the preliminary results were 
not satisfactory; the growth rates of bacterial cells were low and the overall bacteria 
proliferation was poor (Fig. 37).  
Several studies have shown that elevated levels of Mg2+ and Ca2+ may promote P. 
aeruginosa growth (528, 529). However, in the initial adaptation medium, Mg2+ and 
Ca2+ were not abundant. Thereby, we added 1mM MgSO4 and 1mM CaSO4 and also 
chemically defined synthetic yeast extracts to M9 medium, yielding modified M9 
(M9-TheREx) media (Table 7). After adaptation by progressive medium replacement, 
the growth of CHA-OAL strain in M9-TheREx medium was greatly increased and 
even better than in LB broth (Fig. 37). These results revealed the influrence of 
divalent cations to P. aeruginosa proliferation. 
On the other hand, in vitro T3SS evaluation demonstrated that the adaptation and 
culture in M9-TheREx medium did not affect 2 important phenotypes of bacteria: 
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toxicity (Table 9) and protein expression and secretion capacities (Fig. 38).  
As the adaptation process was long and led to faster growth of the bacteria, we 
decided to rename this strain—CHA-CLIN1.  
C-II Optimization of the Vaccination Efficiency of CHA-CLIN1 Strain  
Recently, auxotrophic strains (notably auxotrophic for aromatic amino acids) 
have been generated to obtain safer attenuated vaccines in immunotherapy studies. 
Because the aroA gene encodes an enzyme essential for the synthesis of aromatic 
amino acids that are generally not available in host tissues, the deletion of aroA could 
limit the pathogenic growth and dissemination in mammalians (533). Indeed, we 
previously verified the dissemination of the CHA-OAL strain after an SC injection, no 
bacteria were found in the organs such as blood, liver, spleen, and kidney (10). We 
suggest that this absence of dissemination could restrain the immunogenicity and 
efficiency of vaccine. 
Thereby, in this experiment, we used different vaccination modes to improve the 
efficiency of the CHA-CLIN1 strain: vaccination at shorten interval in order to 
modulate immune response; or vaccination at multiple loci in order to mimic bacteria 
dissemination. The results of immune monitoring assay (Fig. 40) demonstrated that a 
simple increase in vaccination frequency did not significantly change the 
experimental results, whereas the vaccinations at multiple loci could artificially mimic 
the dissemination of bacteria and led to a reinforced immune response. And this 
finding is in accordance with that of in vivo tumor challenge: multiple loci injections 
demonstrated a better performance than uni-position injections and executed nearly 
the same prophylactic and therapeutic efficiencies as the CHA-OST strain (Fig. 41 
and 42). Here, the difference was not statistically significant, for this point, our 
hypothesis is that OVA is one of the most powerful rejection antigens; the immune 
response is so strong to cover up the difference provoked by the different protocols. 
Therefore, we should continue to investigate our optimization strategy using 
self-antigen.
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Résumé en Français: 
Dans ce chapitre, dans le but d’évaluer le potentiel de notre vecteur bactérien 
dans l'immunothérapie humaine, nous avons utilisé le vecteur CHA-OST pour 
délivrer un antigène basé sur les séquences humaines d’HER-2 dans un premier 
modèle de souris humanisées (human ß2m-HLA-A2.1 (α1α2)-H-2dB (α3 
transmembranaire cytoplasmique), HHD). La protection anti-tumorale a été obtenue 
après une immunisation par une double injection de la souche 
CHA-OST-PADRE-HER-2. 
In English: 
In order to estimate the potential of our bacterial vector for human 
immunotherapy, we would like to apply the vector to deliver antigen based on human 
sequences in one first level humanized mice model.  
The human β2m–HLA-A2.1 (α1α2)–H-2Db (α3 transmembrane cytoplasmic) 
(HHD) transgenic mice are H-2Db-/- β2m-/- double knockout and could express only 
HLA class I molecules to force the mouse CD8T cell repertoire to make use of the 
transgenic HLA class I molecules both at the thymic and peripheral levels. Phenotypic 
and functional analyses of their peripheral CD8+ T cell repertoire indicate that HHD 
monochains support thymic positive selection of CD8+ CTL and activate 
virus-specific HLA-A2.1–restricted CTL in the periphery (537). So, we try to estimate 
the anti-tumor response activating efficiency of our bacterial vector in this animal 
model.  
In this trial, we choose human HER-2 (ErbB-2) as the model antigen. HER-2 is a 
185-kDa glycoprotein member of the epidermal growth factor receptor family of 
tyrosine kinases which is over-expressed in 25–40% of all breast cancers and in a 
variety of other tumors such as ovarian, gastric and colorectal carcinomas.  
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A Construction of HER-2 Expression Vector 
The sequence encoding the positions 340-507 of human HER-2 protein was 
cloned at BamH I/Sph I sites in our PADRE containing single antigen expression 
plasmid. The sequence that we chose contains two published HLA-A2 restricted 
HER-2 epitopes: HER-2369-377 and HER-2435-443 (538, 539). The correct cloning was 
confirmed by commercial sequencing.  
In this assay, we used CHA-OST strain as the vaccination vector and transformed 
it with pEAI-S54-Padre-HER-2340-507 plasmid. As usual, before the animal 
experimentations, we first verified in vitro the protein expression and secretion state 
of HER-2 containing vector. The results were as we expected and were shown in 
figure 43. T3SS was well activated and HER-2 fusion protein was well expressed and 
secreted. 
 
Figure 43: In Vitro Evaluation of Fusion Protein Secretion Ability of 
CHA-OST-PADRE-HER2 Strain.  
The fusion protein expression and secretion ability of CHA-OST-PADRE-HER-2 strain was 
assessed by SDS-PAGE. The positions of PopB (top) and PopD (bottom) are marked with arrows; 
the position of S54-PADRE-HER2 fusion protein is marked with asterisk. 
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B Ex Vivo Monitoring the Immune Response Activated by HER-2 
Expressing Vector 
For evaluating the immunization efficiency of our bacterial vector in humanized 
murine model, we investigated the antigen specific immune response after two times 
of CHA-OST-PADRE-HER-2 strain injections. The T cell responses specific to the 
two published HER-2 epitopes (HER-2369-377 and HER-2435-443) were monitored 
through IFN-γ ELISpot assay and this test has been repeated two times. 
However, the results of this trial were not satisfying, no evident T cell responses 
against HER-2369-377 and HER-2435-443 epitopes were detected (fig. 44).  
 
Figure 44: Evaluation of the Vaccination Efficiency of Bacterial Vector in Humanized 
Murine Model through Ex Vivo Immune Monitoring Assessed by IFN-γ ELISpot Assay. 
HHD mice were injected with CHA-OST-PADRE-HER-2 strain at 5*106 bacteria/ time on day-14 
and day-7. The T cell responses specific to the two HER-2 epitopes (HER-2369-377 and 
HER-2435-443) were assessed on day 0 through IFN-γ ELISpot assay. CHA-OST-EI was used as 
negative control. Data represented the mean +/- SD from six animals per group (cumulative results 
of two independent experiments conducted with the same methodology). 
C In Vivo Evaluation of HER-2 Expressing Vector in HHD Transgenic 
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Mice 
CHA-OST-PADRE-HER-2 strain was further evaluated in humanized murine 
model through tumor challenge experiment. HHD mice were s.c. injected with 
CHA-OST-PADRE-HER-2 strain two times on day -14 and day -7, then s.c. 
inoculated with 7*104 MC-2-HER-2 cells on day 0. Here, mice administered with 
CHA-OST-EI strain were used as negative control. For each group, 6 mice were 
experimented. 
In figure 45, we can see that in contrast to ex vivo immune response monitoring 
test, the results of this trial were positive. Immunizations with 
CHA-OST-PADRE-HER-2 strain significantly delayed the tumor formation (p=0.05 
for CHA-OST-PADRE-HER-2 versus CHA-OST-EI), which demonstrate that our 
bacterial vector are also efficacious in this humanized murine model. 
 
Figure 45: In Vivo Evaluation of the Vaccination Efficiency of Bacterial Vector in HHD 
Murine Model. 
HHD mice were s.c. injected with CHA-OST-PADRE-HER-2 on D-14/D-7 before s.c. 
MC2-HER2 tumor challenge. Kaplan-Meyer curves displayed survival data from groups of 6 mice. 
Statistical analysis: p=0.05 for CHA-OST-PADRE-HER-2 VS CHA-OST-EI. 
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D Discussion 
The experiments realized in HHD mice permitted the investigation of our 
bacterial vector in one first level humanized animal model. 
The anti-tumor performance of our bacterial vaccine vector was revealed by in 
vivo tumor challenge. The tumor formation was significantly delayed in immunized 
HHD mice (Fig. 45).  
However, in immune monitoring assay, no evident immune response has been 
detected to two published HER-2 epitopes (Fig. 44). There are two possible 
explanations for these results. First, as we have previously discussed in bi-antigen 
vector chapter, the peptide specific immune response activation depends on protein 
processing machinery of APCs as well as tumor cells. Both the processing of 
translocated antigen by APCs and the processing of TAAs by tumor cells might affect 
the immune response to certain peptides. Thereby, the good epitopes might be not the 
predicted ones. Second, some studies reported that HER-2 can induce multiple defects 
in antigen presentation, such as inefficient antigen processing, down regulation of 
MHC class I expression, so that HER-2 expressing carcinomas are poorly recognized 
by CTLs and the protection in MC2-HER-2 model is independent of cellular 
component but humoral component depended (540-542). In this case, the anti-tumor 
effect observed in above tumor challenge assay is possible provide by humoral 
immunity. There might be HER-2 Ags released from lysed bacteria to the extracellular 
space, pinocytosed by APCs and presented through MHC II pathway.  
Thereby, in order to find out the true mechanism, more experiments need to be 
realized: 1) to investigate the humoral response activation after immunization; 2) to 
apply humoral immunity activating vector (CHA-OST-ΔBD) in this model to verify if 
the protection in MC2-HER-2 model is indeed humoral component dependent; 3) to 
combine CHA-OST and CHA-OST-ΔBD vectors and verify if strengthened efficiency 
will occur.
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Résumé en Français: 
Une immunité anti-vecteur préexistante représente un obstacle pour la plus part 
des vaccins basés sur les bactéries ou les virus. Dans ce chapitre, nous avons étudié ce 
problème potentiel pour notre vecteur bactérien. L’essai du challenge tumoral a 
montré qu’une administration répétée du vecteur bactérien ne fait pas diminuer 
l'efficacité de la vaccination. 
In English: 
Even attenuated bacteria has been widely proposed as a vaccine carrier, one of 
the major issue for the use of bacterial vaccine vector is that pre-existing anti-bacteria 
immunity might affect its ability of eliciting effective immune responses against 
heterologous passenger antigens through different manners, like faster elimination of 
the vaccine carrier, induction of regulatory T cells, etc. 
Thereby, in the experiment presented in this chapter, we have addressed this 
consideration with repeated immunization utilizing CHA-OST strain that should not 
specifically stimulate peptide-specific CTL responses. And then, we investigated the 
influence of pre-existing anti-vector immunity to vaccine efficacy through tumor 
challenge assessment. 
A Investigation of the Influence of Pre-existing Anti-vector Immunity to 
Vaccination Efficacy 
The strategy of investigation is described in figure 46. Briefly, the 
experimentation timing was as following: 1) anti-vector immunity priming: 3 months 
before the tumor challenge, mice were administered with 2 injections with the interval 
of 7 days; 2) anti-vector immunity boosting time point: 2 months before the tumor 
challenge, mice were administered 4 injections with the interval of 4 days; 3) 
anti-tumor prophylactic vaccination: mice were administered with two injections on 
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14 days and 7 days before the tumor challenge; 4) Tumor challenge: mice were s.c. 
inoculated with 2*105 B16OVA cells/mice. 
Four groups were involved in this trial: 1) Group 1: mice injected with 100µl 
PBS/time on following the experimental schedule described above. 2) Group 2: mice 
injected with 5*106 CHA-OST/time on following the experimental schedule described 
above. 3) Group 3: mice injected with 5*106 CHA-OST/time for anti-vector immunity 
priming and boosting; and immunized with 5*106 CHA-OST-PADRE-OVA/time for 
the induction of antitumor immunity. 4) Group 4: mice injected with 5*106 
CHA-OST-PADRE-OVA/time on day -14 and day -7 before tumor challenge, which 
served as the positive control. Here, the group 1 and group 2 on one hand acted as the 
negative control for immunized groups; on the other hand served to verify if the 
repeated injections of P. aeruginosa strains would interfere the dynamic formation of 
B16OVA tumor. In each group, 6 mice were experimented.  
 
 
Figure 46: Strategy for Investigating the Influence of Pre-existing Anti-vector Immunity to 
Bacteria Vaccine Efficiency. 
The figure 47 presents the results of tumor challenge. We can see that, there is no 
difference between the group 3 in which mice have been repeatedly administered with 
CHA-OST-PADRE-OVA strain before tumor challenge and the positive control group 
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(group 4), in both groups tumor has been completely rejected and all mice were 
always survival, which indicates that pre-existing anti- P. aeruginosa immunity has 
not affect its ability of eliciting effective immune responses against heterologous 
passenger antigens. On the other hand, there was also no difference between PBS 
injected group and CHA-OST injected group, which means that the repeated 
injections of P. aeruginosa strain will not interfere the dynamic formation of tumor. 
Thereby, these results support the use of P. aeruginosa as a candidate vaccine vector. 
 
Figure 47: In Vivo Investigation of the Influence of Pre-existing Anti-vector Immunity to the 
Anti-tumor Efficiency of Bacterial Vector. 
This experiment was designed for investigating the influence of pre-existing anti-vector immunity 
to vaccination efficiency. Four groups of mice were involved and the experimentation timing is 
described in figure 46. Mice in Group 3 were repeatedly injected with 5*106 CHA-OST/time for 
induction of anti-vector immunity and with 5*106 CHA-OST-PADRE-OVA/time for prophylactic 
vaccination before tumor challenge. Mice only injected with 100µL PBS/time (Group 1) or 5*106 
CHA-OST/time (Group 2) before tumor challenge were used as negative control. And, mice 
administered with 5*106 CHA-OST-PADRE-OVA / time only on 14 days and 7 days before the 
tumor challenge were used as positive control. Kaplan-Meyer curves displayed survival data from 
groups of 6 mice. Statistical analysis: p<0.0001 for groups 3&4 VS groups 1&2; no difference was 
found between group 3 and group 4. 
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The pre-existing anti-vector immunity is one major obstacle for the most bacteria 
or virus based vaccines, because it might accelerate the elimination of the vaccine 
carriers and limit the activation of effective immune responses against heterologous 
passenger antigens. 
Directly through tumor challenge assay (Fig. 47), no evident impairment of 
vaccination efficiency has been detected after repeated bacterial vector administration. 
For this finding, there are several possible explanations: 1) P. aeruginosa is one acute 
infectious pathogen, the immune response to pathogen related Ags could be activated 
in short term and before the bacteria are eliminated, thereby the influence of 
pre-existing anti- P. aeruginosa immunity is not so evident; 2) the strain used in this 
experiment is one attenuated mutant strain, the immune defense to this vector may not 
be so strong; 3) the antigen used in this experiment is OVA which is a one of the most 
powerful rejection antigens and the immune response to OVA is strong so that the 
immune impairment to the bacterial vector has been covered up; 4) the vaccination 
efficiency has been verified in prophylactic mode in which the protection is generally 
more evident than in therapeutic mode, particularly using OVA. 
Thereby, in order to confirm the influence of pre-existing anti-P. aeruginosa 
immunity to vaccination efficacy, more experiments need to be realized: 1) to quantify 
pre-existing anti-vector humoral and cellular immune response; 2) to verify the 
vaccination efficiency using self antigen; 3) to verify the vaccination efficiency 
through immune monitoring assay; 4) to verify the vaccination efficiency in 
therapeutic vaccination mode.   
Conclusion and Percpectives 
227 
 
 
 
 
 
 
CONCLUSION AND PERSPECTIVES 
 
 
 
 
 
 
 
 
 
 
Conclusion and Percpectives 
228 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion and Percpectives 
229 
En Français: 
En raison de l’efficacité pour délivrer des antigènes directement dans le 
cytoplasme des CPAs in vivo, les vecteurs bactériens atténués tels que Yersinia, 
Salmonella, Shigella, et qui sont basés sur les propriétés du système de sécrétion de 
type 3 (SSTT) ont attiré de plus en plus d’attention grâce à leur potentiel dans le 
développement des vaccins contre le cancer. P. aeruginosa utilise cet appareil pour 
délivrer ses effecteurs toxiques au cours d’une infection. Auparavant, plusieurs 
souches atténuées de P. aeruginosa ont été obtenues dans notre laboratoire et leur 
utilisation potentielle comme vecteur de vaccination anti-tumorale a été démontrée 
dans des modèles murins (3, 10, 11). 
L’objectif du travail de cette thèse est de renforcer le vecteur vaccinal basé sur le 
SST3 de P. aeruginosa et d’essayer de développer des vecteurs bactériens vaccinaux 
pour des applications cliniques. Pour se faire, nous avons effectué plusieurs séries 
d'expériences afin : d'améliorer l'efficacité de vaccination du vecteur bactérien, de 
proposer un processus de préparation du vecteur conformément aux bonnes pratiques 
de fabrication actuelles et d’évaluer le potentiel de ce vecteur pour l'immunothérapie 
humaine dans un modèle animal humanisé. 
Dans un premier temps, la performance de notre vecteur bactérien a été améliorée 
en utilisant différents modèles de tumeurs murines et en suivant différentes stratégies. 
Avant tout, un épitope (PADRE) spécifique des lymphocytes CD4+ Th a été ajouté 
aux vecteurs. D’une part, cette addition est à l’origine d’une réponse immunitaire 
forte médiée par les CD8+ CTL. D’autre part, elle réduit la suppression médiée par les 
cellules Treg pour activer les cellules effectrices. Ainsi, une amélioration de la 
protection anti-tumorale in vivo a été obtenue. Par la suite, un modèle d'expression 
bi-antigénique a été appliqué au vecteur bactérien. La délivrance du vecteur 
bi-antigénique a révélée plusieurs avantages par rapport a un vecteur d’un antigène 
singulier. Parmi ces avantages l’efficacité et la simplicité. Le vecteur bi-antigénique 
peut atteindre une efficacité de vaccination équivalente à celle obtenue pour les deux 
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vecteurs combinés de chaque antigène, mais administré en une seule dose qui est sûre. 
En outre, un vecteur potentiel activant l’immunité humorale a été construit par la 
délétion des deux protéines structurelles du SSTT: PopB et PopD. Des IgG 
spécifiques de l’antigène ont été détectés après des vaccinations avec un vecteur muté 
ΔPopBΔPopD. Cette réponse humorale est dépendante de la dose des bactéries. 
Dans un deuxième temps, la performance thérapeutique du vecteur bactérien a été 
optimisée par la modulation de la fréquence des injections et l'intervalle qui les sépare. 
Les résultats in vivo et in vitro ont montré qu’une fréquence et un intervalle 
appropriés d’immunisation  sont importants pour programmer la réponse immune 
primaire contre l’antigène. Grâce à cela, la performance thérapeutique de notre 
vecteur bactérien a été confirmée dans des modèles naturels de tumeurs. En outre, 
l'efficacité à long terme de notre vecteur bactérien a été évaluée pour la première fois. 
Nos résultats démontrent que la réponse médiée par les cellules T mémoires et induite 
par le vecteur bactérien est capable de détecter les cellules tumorales résiduelles et 
inhibe efficacement la récurrence de la tumeur. La modulation de la fréquence et 
l'intervalle d'injection pourrait conduire à une efficacité variable à long terme. 
Dans un troisième temps, un candidat qui pourrait être appliqué en clinique a été 
généré par l'adaptation dans un milieu chimiquement défini d'un mutant (CHA-OAL) 
de P. aeruginosa totalement avirulent. Nous avons constaté que les cations divalents 
(Mg2 + et Ca2+) joue un rôle crucial dans la prolifération de P. aeruginosa. Comme la 
délétion du gène aroA dans la souche CHA-CLIN1 pourrait limiter sa dissémination 
et ainsi limiter l’immunogénicité et l'efficacité de ce vecteur, nous avons essayé 
d'injecter des souris avec cette souche à de multiples emplacements pour reproduire 
artificiellement la dissémination des bactéries. Grâce à cela, la très faible infectieusité 
de cette nouvelle souche a été surmontée. Les résultats in vivo et in vitro ont montré 
qu’une injection à de multiples emplacements est plus performante qu’une injection 
dans un emplacement unique. Une immunisation dans des emplacements multiples 
avec le vecteur CHA-CLIN1 pourrait donner des efficacités  prophylactique et 
thérapeutique proches par rapport au vecteur CHA-OST. 
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Dans un quatrième temps, et dans le but d’évaluer le potentiel de notre vecteur 
bactérien dans l'immunothérapie humaine, nous avons utilisé le vecteur CHA-OST 
pour délivrer un antigène basé sur les séquences humaines d’HER2 dans un premier 
modèle de souris humanisées (HHD). Les résultats du challenge tumoral sont 
encourageants. Ils ont permis de mettre en évidence la possibilité d’utiliser nos 
vecteurs bactériens afin d’évaluer, d'optimiser et de définir des séquences d'antigènes 
humains pour des essais cliniques ultérieurs. 
Enfin, une immunité anti-vecteur préexistante représente un obstacle pour la plus 
part des vaccins basés sur les bactéries ou les virus. Nous avons étudié ce problème 
potentiel dans ce travail et des résultats intéressants ont été obtenus. Les essaies du 
challenge tumoral ont montré qu’une administration répétée du vecteur bactérien ne 
fait pas diminuer l'efficacité de la vaccination. 
Par ailleurs, il est sûr que certaines de ces expériences doivent être refaites et 
certains de ces résultats ont besoin d’être reproduits. 
En outre, certaines de ces stratégies devraient être optimisées comme la 
construction d'un vecteur contenant plus d'antigènes pour induire une réponse 
immunitaire plus forte et plus large et assure un rejet plus efficace de la tumeur. La 
performance d’activation de l’immunité humorale devrait également être améliorée en 
utilisant une autre souche atténuée pouvant délivrer une grande quantité d'antigènes. 
Pour simuler une réponse immunitaire plus semblable à celle de l'homme, nous 
pouvons vérifier ces concepts dans certains modèles avancés d’animaux humanisés, 
tel que la ligné murine NSG (ou NOD scid gamma) (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) 
qui est parmi les les souches les plus immunodéprimés des souris du laboratoire 
consanguinées décrite à ce jour. Les souris NSG sont dépourvus des cellules T 
matures, des cellules B et des cellules NK. Elles sont également déficientes dans de 
multiples voies de signalisation de cytokines et ont de nombreux défauts dans 
l'immunité innée (542). Ces immunodéficiences des souris NSG permettent la greffe 
d'un large éventail de cellules humaines primaires afin de reconstituer un répertoire 
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immunitaire humain. Dans ce modèle animal, nous pourrons obtenir des preuves plus 
convaincantes pour des futures applications cliniques. 
De plus, les stratégies d'administration des antigènes doivent être combinées. Le 
concept actuel de l'immunothérapie contre le cancer consiste à ce que les vaccins 
efficaces contre le cancer devraient être capables de cibler : i) les cellules T CD4+ et 
CD8+ pour générer une immunité anti-tumorale forte et de longue durée, ii) des 
moyens multiples de l'immunité qui pourrait être important pour lutter contre le fait de 
contourner la réponse immunitaire à différents niveaux par la tumeur. À cet égard, 
nous devrions étudier les stratégies de vaccination hétérologues et combinées. 
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In English: 
Due to the endowed effective ability to deliver antigen to cytoplasm of APCs in 
vivo, T3SS based attenuated bacterial vectors, such as Yersinia, Salmonella, Shigella, 
attracted more and more attention for their potential interest in cancer vaccine 
development. P. aeruginosa exploits also this endowed apparatus to deliver its 
effector toxins during infection of mammalian. Previously, several attenuated P. 
aeruginosa strains have been established in our laboratory and their potential as the 
carriers for anti-tumor vaccination purpose has been reported in murine models (3, 10, 
11).  
The objective of the work presented in this manuscript is to strengthen P. 
aeruginosa T3SS based vaccine vectors and direct the development of bacterial 
vaccine vectors toward clinical applications. For this purpose, we carried out several 
series of experiments to improve the vaccination efficiency of bacterial vectors; to 
realize the production process of bacterial vectors complying with current good 
manufacturing practices grade; and to evaluate the potential of bacterial vectors for 
human immunotherapy in one humanized animal model. 
First, the performance of our bacterial vector has been improved in different 
murine cancer models by several strategies. First of all, one CD4+ Th epitope - 
PADRE has been added to bacterial vectors. The addition of PADRE has been 
observed to on one hand induce stronger CD8+ CTL mediated immune responses and 
on the other hand attenuate Treg cells mediated suppression to activated effector cells. 
Thereby, improved in vivo anti-tumor protections have been obtained. Second, 
bi-antigen expression pattern has been applied to bacterial vectors. Bi-antigen 
delivery vectors demonstrate several advantages than single-antigen delivery vectors, 
including: efficiency and simplicity. Meanwhile, bi-antigen delivery vectors can 
achieve the equal vaccination efficiency as combined single-antigen delivery vectors, 
but be administered at the safer dose. Moreover, one potential humoral immunity 
activating vector has been constructed through the deletion of two T3SS structural 
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proteins - PopB and PopD. Antigen specific IgG has been detected after the 
immunizations with one ΔPopBΔPopD mutant vector and this humoral response was 
bacteria dose dependent. 
Second, the therapeutic performance of bacterial vector has been optimized by 
modulating injection frequency and interval. Both in vitro and in vivo results 
demonstrated that appropriate immunization frequency and interval are equally 
important for programming primary immune response to antigen. Through this way, 
the therapeutic performance of our bacterial vector has been confirmed in natural 
tumor models. Besides, in this work, the long term efficacy of our bacterial vector has 
been evaluated for the first time. Our results demonstrate that the memory T cell 
response induced by bacterial vector was capable of sensing the residual tumor cells 
and effectively inhibiting the tumor recurrence. The modulation of injection frequency 
and interval might lead to variable long term efficiency.  
Third, one clinically applicable candidate has been generated by adapting one 
totally avirulent P. aeruginosa mutant (CHA-OAL) in a chemically defined medium. 
Through this experiment, we found that divalent cations (Mg2+ and Ca2+) make a 
crucial role for P. aeruginosa proliferation. Furthermore, as the deletion of aroA gene 
in CHA-CLIN1 strain could limit its dissemination and thereby restrain the 
immunogenicity and efficiency of this vector, we tried to inject mice with this strain at 
multiple loci to artificially mimic the dissemination of bacteria. Through this way, the 
poor infectivity of this new strain has been overcome. Both in vitro and in vivo results 
demonstrated that multiple loci injections demonstrated a better performance than 
uni-position injections; and multiple loci immunizations with CHA-CLIN1 vector 
executed nearly the same prophylactic and therapeutic efficiencies as CHA-OST 
vector. 
Fourth, in order to estimate the potential of our bacterial vector for human 
immunotherapy, we use the CHA-OST vector to deliver antigen based on human 
HER-2 sequences in one first level humanized murine model (HHD mice). These 
results from this experimental model show the possibility to apply our bacterial 
Conclusion and Percpectives 
235 
vectors for further investigation, optimization and definition of human antigen 
sequences in relative clinical trials.  
Finally, as the pre-existing anti-vector immunity is one major obstacle for the 
most bacteria or virus based vaccines, we have also investigated the potential issue in 
this work. Attractive results have been obtained. Through tumor challenge assay, no 
evident impairment of vaccination efficiency has been detected after repeated 
bacterial vector administration. 
Next, certainly, some of these experiments need to be repeated and some of these 
results require to be reproduced. 
Moreover, some of these strategies should be more optimized, such as the 
construction of a delivery vector containing more antigens to induce a strong and 
broad immune response and provide more efficient tumor rejection. The humoral 
immunity activation performance should also be enhanced by using one more 
attenuated strain which can deliver a large quantity of antigens.  
And then, for simulating the immune response more similar to humans’, we can 
verify these concepts in some advanced humanized animal models, for example, 
NSG(or NOD scid gamma) (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) murine line which is 
among the most immunodeficient strains of inbred laboratory mice described to date. 
NSG mice lack mature T cells, B cells, and natural killer (NK) cells. They are also 
deficient in multiple cytokine signaling pathways and have many defects in innate 
immunity (543). The compound immunodeficiency in NSG mice permit the 
engraftment of a wide range of primary human cells and thereby the reconstitution of 
a human immune repertoire. In this animal model, we can obtain more convincing 
proofs for future clinical applications.  
Furthermore, antigen delivery strategies should be combined. The current concept 
of cancer immunotherapy is that effective cancer vaccines should be capable of 
targeting both CD4+ and CD8+ T cells to generate a strong and long-lasting antitumor 
immunity and targeting multiple arms of immunity may be important to counteract 
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tumor immune-escape at different levels. In this respect, we should investigate 
combined heterologous vaccination strategies. 
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Publications: 
Derouazi M, Wang Y, Marlu R, Epaulard O, Mayol JF, Pasqual N, Le Gouellec A, 
Polack B, Toussaint B. « Optimal epitope composition after antigen screening using a 
live bacterial delivery vector: application to TRP-2 ». Bioeng Bugs 2010 Jan-Feb; 
1(1):51-60. 
Abstract: 
Immunotherapeutic approaches, based on the generation of tumor-specific cytotoxic 
T-lymphocytes (CTL), are currently emerging as promising strategies of anti-tumor 
therapy. The potential use of attenuated bacteria as engineered vectors for vaccine 
development offers several advantages, including the stimulation of innate immunity. 
We developed an attenuated live bacterial vector using the type III secretion system 
(TTSS) of Pseudomonas aeruginosa to deliver in vivo tumor antigens. Using an 
inducible and rapid expression plasmid, vaccination with several antigens of different 
length and epitope composition, including TRp-2, gp100 and MUC18, was evaluated 
against glioma tumor cells. We observed similar CTL immunity and T-cell receptor 
(TCR) repertoire diversity with the vaccines, TRP2(125-243), TRP2L(125-376) and 
TRP2S(291-376). However, only immunization with TRP2L(125-376) induced 
significant anti-tumor immunity. Taken together, our data indicate the importance of 
the epitopes composition and/or peptide length of these peptides for inducing 
cytotoxic T-lymphocyte (CTL) mediated immunity. Characteristics that consistently 
improved anti-tumor immunity include: long peptides with immunodominant and 
cryptic CD8(+) epitopes, and strong CD4(+) Th epitopes. Our bacterial vector is 
versatile, easy-to-use and quick to produce. This vector is suitable for rapid screening 
and evaluation of antigens of varying length and epitope composition. 
 
Yan Wang, Audrey Le Goue¨llec, Hichem Chaker, Hoda Asrih, Benoit Polack, and 
Bertrand Toussaint. « Optimization of Antitumor Immunotherapy Mediated by Type 
III Secretion System-based Live Attenuated Bacterial Vectors ». Accepted by Journal 
of Immunotherapy on Dec 19, 2011. 
Abstract: 
Recently, due to their effective ability to deliver antigen to antigen-presenting cells in 
vivo, type III secretion system-based attenuated bacterial vectors have increasingly 
attracted attention for their potential interest in cancer vaccine development. We have 
previously developed live attenuated Pseudomonas aeruginosa type III secretion 
system-based vectors to deliver in vivo tumor antigens. In this work, we improved the 
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performance of these bacterial vectors through several approaches in different murine 
cancer models involving non–self-antigens or self-antigens. First, by modulating 
injection frequency and interval, bacterial vaccination activated immune response 
could be enhanced and the in vivo therapeutic efficacy of bacterial vaccines could be 
improved. The optimized vaccination scheme induced long-lasting CD8+ T cells’ 
response. Second, a dual antigen delivery pattern was successfully applied in our 
bacterial vectors. Compared with a single antigen delivery vector, biantigen delivery 
vectors demonstrated several advantages including better tumor rejection efficiency, 
simplicity of use, and safety. Third, 1 more attenuated mutant-CHA-OAL strain that is 
totally avirulent in mice was further adapted to grow in a chemically defined medium 
to comply with current good manufacturing processes. The poor infectivity of this 
new strain could be overcome by vaccinations at multiple loci, yielding an efficiently 
improved vaccination performance. Taken together, our results highlight the potential 
of our live attenuated P. aeruginosa vectors for applications in relevant clinical trials. 
 
Conference: 
Y. Wang, M. Derouazi, R. Marlu, O. Epaulard, Nicolas Pasqual, B. Polack and B. 
Toussaint. « Optimal epitope composition after antigen screening using a live 
bacterial delivery vector- Application to TRP2 » (poster). The 2nd European Congress 
of Immunology, Berlin, Germany, 2009-09.
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Résumé en Français 
En raison de l’efficacité pour délivrer des antigènes directement dans le cytoplasme des 
CAPs in vivo, les vecteurs bactériens atténués et basés sur les propriétés du système de 
sécrétion de type 3 (SST3) attirent de plus en plus l’attention grâce à leur potentiel dans le 
développement des vaccins contre le cancer. Pseudomonas aeruginosa est un pathogène 
opportuniste responsable d’infections graves chez les personnes immunodéprimées, les grands 
brûlés et les patients atteints de la mucoviscidose. Cette pathogénicité repose sur de nombreux 
facteurs de virulence dont le SST3. Dans nos travaux précédents, le potentiel de souches 
atténuées de P. aeruginosa dans le domaine de la vaccination anti-tumorale a été démontré. 
Dans ce travail, nous avons optimisé des vecteurs vaccinaux basés sur le SST3 de P. 
aeruginosa pour des applications cliniques. 
Dans un premier temps, la performance de ces vecteurs bactériens a été améliorée en 
utilisant différents modèles de tumeurs murines. Ceci par : 1) l'ajout d'un épitope spécifique 
des lymphocytes CD4+ Th aux vecteurs; 2) l’application d’un modèle d'expression 
bi-antigénique aux vecteurs; 3) la construction de vecteurs induisant une réponse humorale. 
Dans un deuxième temps, la performance thérapeutique du vecteur bactérien a été optimisée 
par la modulation de la fréquence des injections et l'intervalle qui les sépare. Cette 
performance a été confirmée dans des modèles différents de tumeurs murines. Dans un 
troisième temps, un candidat qui pourrait être appliqué en clinique a été généré par 
l'adaptation d'un mutant  (CHA-OAL) de P. aeruginosa totalement avirulent dans un milieu 
chimiquement défini. La très faible infectiosité de cette souche a été surmontée par en 
vaccinant à des emplacements multiples. Par la suite, le potentiel du vecteur bactérien dans 
l'immunothérapie humaine a été également évalué- dans un premiers temps-dans un modèle 
de souris humanisées (HHD). Enfin, nous avons observé qu’une immunité anti-vecteur 
pré-existante n’a pas d’effet sur l'efficacité de la vaccination par le vecteur bactérien. 
L’ensemble de nos résultats a mis en évidence le potentiel de nos vecteurs vivants et 
atténués de P. aeruginosa pour des applications dans des essais cliniques pertinents. 
 
Mots clés : L’immunothérapie du cancer, Vaccin bactérien vivant atténué, Système de 
Sécrétion de Type III, Pseudomonas aeruginosa. 
 
